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Abstract 
 
This study examined how SpyCEP impaired the neutrophil response to Group A 
Streptococcus (GAS). It was known prior to this study that SpyCEP cleaved some of the 
neutrophil specific chemokines (Kurupati, et al. 2010, Zinkernagel, et al. 2008). These 
chemokines are known to have a variety of effects on neutrophil function, and the impact of 
SpyCEP on two specific effects, neutrophil homing to infection foci and NETosis, has been 
reported (Edwards, et al. 2005, Zinkernagel, et al. 2008). 
 This study identified that the substrate range of SpyCEP included all known 
neutrophil specific chemokines. No other substrates were found. Furthermore, the relative 
cleavage rate of these chemokines by SpyCEP was determined, with the most potent, CXCL8, 
being the optimum substrate (Mukaida, et al. 1998). It was hypothesised that other effects of 
chemokines on neutrophils, not just neutrophil homing and NETosis, would also be ablated. 
 Neutrophil release from the bone marrow stores is potentiated by chemokines. It was 
found that neutrophil release from the bone marrow was lower when mice were infected with 
SpyCEP-positive compared to SpyCEP-negative bacteria. Furthermore, lower levels of 
circulating chemokines were also found in mice infected with SpyCEP-positive GAS. 
 Chemokines also play a role in the activation of neutrophils, and the upregulation of 
receptors involved in this process (Detmers, et al. 1990). This study identified that neutrophil 
phagocytosis of SpyCEP-positive bacteria was impaired compared to SpyCEP-negative 
bacteria. The neutrophils incubated with SpyCEP-positive bacteria were found to have less 
chemokine at their surface, and lower surface expression of a phagocytosis receptor, CR3. 
This receptor is known to be important for GAS phagocytosis (DeMaster, et al. 2002) 
providing a mechanism for this effect.  
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 This work has found several novel effects of SpyCEP on neutrophil function. These 
impairments take place throughout the neutrophil response to GAS infection.  
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Chapter 1 - Introduction 
 
1.1 Group A Streptococcus biology 
 
Group A Streptococcus (GAS) is a Gram positive human pathogen that is capable of 
causing a broad spectrum of disease, ranging from mild, self-limiting non-invasive conditions 
to severe and potentially life-threatening invasive disease. Non-invasive diseases caused by 
GAS are very common, yet rarely quantified as they are typically unreported. Invasive 
disease, whilst uncommon, can often have a high mortality rate and be difficult to treat. 
Furthermore GAS is also able to cause auto-immune sequelae, linked to a range of conditions 
(Cunningham 2000). 
 
1.1.1 Non-invasive GAS disease and burden 
 
The most common disease associated with GAS is tonsillo-pharyngitis. This is 
especially frequent amongst the young, in whom GAS colonises the throat and tonsils of the 
affected individual, resulting in a productive supprative infection. Disease rate follows 
seasonal fluctuations, being most prevalent in autumn and winter months (Cunningham 2000). 
Tonsillo-pharyngitis, whilst mild, causes considerable disruption, especially to schooling. 
Such disease receives little epidemiological attention, however one such study examining an 
economically developed population revealed a disease rate of 0.14 cases per child per year, 
with 71% of such cases receiving antibiotic treatment, and 46% missing some time from 
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school, with an average of 14 hours per child (Danchin, et al. 2004). Whilst being more 
common in children, GAS still causes considerable numbers of tonsillo-pharyngitis cases 
amongst adults, and is thought to be responsible for between 4 and 10% of adult sore throats 
(Bisno 1996, Komaroff, et al. 1986). Cases of tonsillo-pharyngitis may be associated with 
scarlet fever, a complication of GAS infection most typically linked to tonsillo-pharyngitis 
and most typically seen in children. This is characterised by a rash, strawberry tongue and 
desquamation of the skin. Scarlet fever is caused by superantigen expression by these non-
invasive strains (Bohach, et al. 1990). 
GAS is also responsible for pyoderma and impetigo infections, especially in less 
economically developed nations. These diseases involve an infection limited in depth to the 
epidermis, which, once established, is highly contagious (Bisno and Stevens 1996). 
Prevalence of such disease is highly variable, but seems to typically range between 1 and 20% 
in less economically developed countries, and is most common in summer months (Carapetis, 
et al. 2005).  
Although these non-invasive diseases cause a disease burden directly, the major 
burden of non-invasive disease results from post-infection autoimmune sequelae, such as 
rheumatic fever. As such, the prevalence of rheumatic fever is higher in regions where non-
invasive disease is more prevalent, such as in the Pacific Islands (Carapetis, et al. 2005). 
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1.1.2 Autoimmune sequelae 
 
1.1.2.1 Rheumatic Fever 
 
Rheumatic fever is characterised by fever, inflammation in the joints, heart, central 
nervous system and skin (Cunningham 2000). Rheumatic fever is the leading cause of 
juvenile heart disease world-wide, and is especially prevalent in developing countries where 
it has an incidence of over 0.8 cases per 100 children (Guilherme and Kalil 2010). Indeed, 
this type of GAS disease is the leading cause of mortality of all GAS-associated conditions 
worldwide, and is responsible for approximately 250,000 deaths annually (Carapetis, et al. 
2005). 
Rheumatic fever is classically associated with GAS pharyngitis, and as such its 
prevalence is seasonal, following the trends of pharyngitis (Cunningham 2000). It is thought 
that such infections occasionally trigger an autoimmune attack due to cross-reacting 
antibodies, raised against GAS antigens such as surface M protein. Although the mechanisms 
which trigger autoimmunity are still unclear, it is hypothesised that these antibodies then 
damage endothelial and epithelial surfaces, exposing immunogenic material below, allowing 
a heightened immune response to proceed (Cunningham 2003). It is also thought that a 
variety of host factors are involved in determining susceptibility to disease, such as HLA type, 
but this too is poorly understood (Guilherme and Kalil 2010).  
The prevalence of rheumatic fever has declined in wealthier countries due to a 
reduction in prevalence of pharyngitis among children and the introduction of antibiotic 
treatment regimes in cases of GAS pharyngitis (Bisno, et al. 2002). Such treatments are not 
used worldwide, which contributes to the continuing high incidence in developing countries. 
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Furthermore, with a recurrence rate of over 40%, and the cumulative nature of the damage 
caused by such attacks leading to valvular heart disease, a more effective method of tackling 
rheumatic fever worldwide is clearly required (Seckeler, et al. 2010). Indeed a broad 
spectrum vaccine against the numerous serotypes of GAS, using either conserved epitopes or 
a pan-serotype approach is a focus of GAS research. 
 
1.1.2.2 Acute Post-streptococcal Glomerulonephritis  
 
Acute post-streptococcal glomerulonephritis is primarily a disease of children and 
young adults, and is at its most prevalent in summer months, mirroring the epidemiology of 
pyoderma-type GAS infections (Bisno, et al. 1970). Not all serotypes of GAS are equally 
capable of causing acute post-streptococcal glomerulonephritis, and the prevalence of this 
disease has been in steady decline (Carapetis, et al. 2005).  
As with rheumatic heart disease, the aetiology of this post-infection sequela of GAS 
disease is unclear. Hypotheses include the deposition of immune complexes of antibody and 
GAS antigen in the kidney and the generation of cross-reactive antibodies following the GAS 
infection (Cunningham 2000). Regardless of the cause, the disease causes extensive 
morbidity and mortality. Characteristic symptoms of such disease include oedema, 
hypertension, haematuria, and other complications associated with reduced kidney function. 
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1.1.2.3 Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal 
Infections 
 
An increasing body of research is accumulating linking GAS infections to compulsive 
tic-like disorders, categorised together as Paediatric Autoimmune Neuropsychiatric Disorders 
Associated with Streptococcal Infections (PANDAS). The evidence linking these disorders to 
GAS is variable, and the most certain correlation is found in Sydenham’s Chorea (Shulman 
2009), characterised by severe involuntary movements and emotional disturbances (Swedo, et 
al. 1993). More controversially, it has been suggested that obsessive compulsive disorder and 
Tourette’s syndrome in children are also related to GAS infection, by virtue of cross-reactive 
antibodies against streptococcal antigens and components of the central nervous system 
(Swedo, et al. 1997). Whilst work has confirmed that some patients suffering acute attacks of 
such disease do indeed have circulating antibodies against surface components of GAS 
(Kirvan, et al. 2003, Kirvan, et al. 2006), any causal link is hard to prove, due to the very 
high rate of GAS infection amongst children (Kurlan, et al. 2008). 
 
1.1.3 Invasive disease 
 
Typical GAS invasive disease results in skin and soft tissue infections as described 
below. However, GAS may also cause pneumonia, or post-partum sepsis, a serious disease 
afflicting mothers immediately after childbirth. Bacteraemia, without an obvious focus of 
infection is frequently observed. 
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1.1.3.1 Cellulitis and erysipelas 
 
By far the most common form of invasive streptococcal disease, cellulitis is a soft 
tissue disease, with a diffuse inflammatory response which extends into subcutaneous fat 
layers, without a clear demarcating line (Lopez and Lartchenko 2006). This disease is not 
considered as serious as the other listed invasive manifestations of GAS disease, however it is 
still a significant medical event. An epidemiological study of GAS infection in the UK found 
that such infections had a mortality rate of 16% within seven days of admission to a hospital 
setting, and could also act as a precursor for more severe complications of invasive GAS 
infection such as toxic shock syndrome or kidney damage (Lamagni, et al. 2008b). Erysipelas 
is similar to cellulitis, however features a distinct demarcation defining the infected area, and 
does not infiltrate so deeply into the tissues. Hospitalisation may not be required in all cases, 
and indeed many patients may be treated in the community with oral antibiotics (Lopez and 
Lartchenko 2006). 
 
1.1.3.2 Necrotizing fasciitis  
 
Necrotizing fasciitis (NF) is perhaps the most severe condition caused by GAS, 
featuring alarming clinical symptoms which are difficult to treat and a high mortality rate of 
approximately 32%, but is however an uncommon form of streptococcal disease. The disease 
causes severe pain, fever, and shock (Carapetis, et al. 2005) (Lamagni, et al. 2008b), 
primarily affecting adults between 16 and 60 (Lamagni, et al. 2008a).  
The disease features GAS multiplying to very high bacterial titres and spreading 
rapidly along fascial planes, causing extensive necrotic destruction of subcutaneous tissue, 
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and often deeper connective and muscle tissue, as it progresses due to the release of toxins 
and disruption of normal tissue architecture.  
NF typically arises following a trauma to an extremity of the body, however such 
trauma does not need to break the skin, and the infection may at first be unapparent, 
hindering initial diagnosis (Stevens 1995). Occasionally, NF may develop as a consequence 
of localised skin lesions, for example following varicella (chicken pox) or surgery. One must 
assume that the skin lesion acts as a portal of entry in such cases (Vijaykumar, et al. 2003). 
 
1.1.3.3 Streptococcal Toxic Shock Syndrome 
 
Streptococcal toxic shock syndrome (STSS) is a complication which may arise 
following an invasive infection by GAS. Whilst only being present in 8% of patients 
suffering from invasive GAS, it is a more common feature of NF, occurring in 40% of 
patients with this particular condition, and is also positively associated with the prior use of 
non-steroidal anti-inflammatory drugs (Lamagni, et al. 2008b). Different GAS strains 
produce components which are immunogenic and also express various superantigen toxins. 
The combined effect of such components is that the immune system becomes highly 
activated, releasing an arsenal of immune mediators, in turn leading to septic shock. 
Development of this complication is strongly linked to a fatal outcome, with 45% of patients 
dying when this complication is present (Lamagni, et al. 2008b). 
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1.1.4 Classification of GAS isolates 
 
GAS isolates are normally typed by examination of a variable surface antigen, M 
protein, either serologically (M typing) or using DNA sequence analysis of the M protein 
gene, emm (emm typing). The most common invasive M-types currently found in Europe 
comprising just under 75% of all cases are, in descending order, M1, M28, M3, M89, M87, 
M12, M4, M83, M81 and M5 (Figure 1-1). The distribution of M-types throughout the world 
not only varies by region, but also area to area, indeed a list of most common M-types from 
the developing world would differ from this profoundly (Luca-Harari, et al. 2009). Different 
M-types of GAS are loosely associated with different types of disease, with M1 and M3 
associated with invasive type disease, and M3 especially associated with TSS (Lamagni, et al. 
2008b), M28 and M89 being associated with post-partum sepsis, M81 strains being 
associated with those suffering with pre-existing diabetes, and M12 being associated with 
pharyngitis (Luca-Harari, et al. 2009). As well as disease manifestation, there is also 
correlation between the expression of certain virulence factors and M-type, such as 
superantigens, and with M18 strains producing strikingly more protective capsule (Alberti, et 
al. 1998). As well as these correlations, the different M protein types may also represent 
differing M protein structures (Miller, et al. 1988), with differing effects on virulence (Dale, 
et al. 1996).  
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Figure 1-1 – M-type distribution in Europe 
Distribution of invasive M-types in Europe, between 2003 and 2004, data taken from Luca-
Harari et al. 2009. 
Another serotypic method of typing GAS is T-typing, based on variable sequences 
within the bacterial pilus (Falugi, et al. 2008). T types correlate well with M-types, but with 
reduced specificity, as there are fewer T serotypes than M serotypes, and furthermore a 
particular strain may express several T antigens simultaneously, leading to T patterns rather 
than distinct types (Johnson and Kaplan 1993).  Currently there is a resurgence in invasive 
GAS infections worldwide, associated with a hypervirulent M1T1 strain (Luca-Harari, et al. 
2009). 
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1.1.5 Treatment of GAS 
 
1.1.5.1 Intervention 
 
The first line treatment used in streptococcal infections is penicillin and its derivatives, 
to which GAS has remained sensitive. Alarmingly, reports from Canada seem to show the 
emergence of penicillin resistant strains via an unknown mechanism in patients who have 
received treatment for repeated episodes of pharyngitis (Ogawa, et al. 2011). The use of 
penicillin-type drugs to treat GAS infections while common is not universal due to allergies 
against β-lactam-type antibiotics. In such cases, macrolides are used, such as erythromycin. 
Clindamycin is also used in addition to the β-lactams when treating deep tissue infections 
caused by GAS (Mulla 2004). Unfortunately, the sensitivity seen using β-lactams is not seen 
with macrolides, with resistance being noted around the world, and being especially prevalent 
in some countries (Lynskey, et al. 2011). Of particular note is a 95% resistance rate against 
macrolides reported in China (Chang, et al. 2010). 
Macrolide resistance is mediated by two distinct mechanisms. The M-phenotype 
refers to one such method that elicits low level protection against a narrow range of drugs, 
including erythromycin, but not drugs such as clindamycin, other lincosamides or 
streptogramin B. Such resistance is mediated by expression of a drug efflux pump (Clancy, et 
al. 1996). GAS may also use a broader specificity, high level protection method, known as 
the MLSB. This method depends upon methylase modification of the ribosome target site of 
these drugs. 
The efficacy of pooled human intravenous immunoglobulin (IVIg) has been a matter 
of debate with initial work in a mouse model of invasive GAS infection showing little 
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protective effect (Patel, et al. 2000). However, more recent work examining human trials and 
information from the clinic suggest IVIg is a useful treatment for severe GAS infections 
(Darenberg, et al. 2003, Norrby-Teglund, et al. 2003). The mode of action for IVIg is thought 
to include neutralising toxins including superantigens and opsonising bacteria with specific 
anti M-protein antibodies (Norrby-Teglund, et al. 2003). 
In cases of NF however, such interventions are often insufficient to clear the infection, 
and invasive surgical debridement, and some cases, amputation is required to halt the spread 
of the disease (McHenry, et al. 1995). Such interventions add considerably to the morbidity 
of this particular type of invasive GAS disease.  
 
1.1.5.2 Prevention of GAS disease using a vaccine 
 
Much effort has been expended searching for a vaccine against GAS. The main focus 
of development has been on the variable surface M-protein, the basis for M typing. However, 
its variability has hampered such attempts, making the production of a broad spectrum 
vaccine challenging. Various reports have suggested the protective coverage of a 26-valent 
vaccine which reached human trials would be as low as 20% in some parts of the world 
(Richardson, et al. 2010). Furthermore, due to fears that antibodies against the M protein are 
the aetiological agent responsible for rheumatic fever, work examining such a vaccine type is 
making only slow progress (Lynskey, et al. 2011). 
The other main tool in serotyping GAS, the pilus or T antigen is also being investigated 
as a vaccine candidate, as it is known there are fewer T serotypes than M serotypes (Johnson 
and Kaplan 1993). A 12-valent vaccine has been suggested to have the potential to provide 
protection against 90% of strains worldwide (Falugi, et al. 2008, Mora, et al. 2005). Other 
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vaccine candidates have been suggested, including SpyCEP, which are conserved virulence 
proteins found on the surface of GAS, and will be discussed in more detail elsewhere (Steer, 
et al. 2009).   
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1.2 The Immune Response 
 
1.2.1 Barrier defences 
 
The initial defence the host has against infection by GAS are the physical barriers 
provided by the skin, with its multiple layers of epidermis, and epithelial surfaces which 
express tight junctions. The surface of skin not only prevents GAS invasion into deeper 
tissues, its low pH of between 3 and 5 acts to inhibit bacterial growth on its surface. The 
epithelial layers are protected by mucus which acts to capture microorganisms, which are 
then swept out of the body by cilia (Chaplin 2010). Such defences are not breached when 
GAS establishes a non-invasive infection, with GAS instead colonising these surfaces. As 
these represent the majority of GAS infections, the efficacy of such barriers at preventing 
GAS invasion is evident (Cunningham 2000). 
GAS enters sterile sites of the body through adhering to and then traversing epithelial 
cells. The initial adhesion and colonisation of these cells involves a wide variety of GAS 
proteins binding to host proteins fibronectin and collagen (Kreikemeyer, et al. 2004). GAS is 
then able to internalise and persist within these epithelial cells (LaPenta, et al. 1994).  One 
hypothesis is that GAS will periodically invade across the epithelial layer, and establish a 
transient bacteraemia within the patient (Johansson, et al. 2010). Such events may be 
responsible for the less serious GAS invasive diseases cellulitis and erysipelas. Of note, 
necrotizing fasciitis is epidemiologically associated with blunt trauma to the afflicted area of 
the body (Kaul, et al. 1997, Stevens, et al. 1989). A possible explanation for this is that such 
muscular injuries cause increased cellular expression of vimentin, and this localised increase 
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may encourage the binding of GAS to these muscular sites, assuming a transient bacteraemia 
happens to coincide with such a trauma (Bryant, et al. 2006). 
 
1.2.2 Antimicrobial peptides 
 
Antimicrobial peptides are small, highly charged peptides, which exert microbicidal 
activity against bacteria, but also against fungi. Due to their small size, they can penetrate the 
cell wall of GAS, and interact with its membrane. They have amphiphilic structures, allowing 
them to interact with membranes and then cause disruption using their charge. They can be 
subdivided into several groups on the basis of conserved structural features (Schneider, et al. 
2005). Two of these subgroups, the cathelicidins and the β-defensins have been demonstrated 
to be important in the containment of GAS infections and the prevention of invasive disease 
(Morrison, et al. 2002, Nizet, et al. 2001). GAS evades the activity of antimicrobial peptides 
in a variety of ways, including preventing their binding, and proteolytic degradation. 
GAS also acts to increase the charge of its cell membrane, which so acts to repel these 
cationic peptides. The mechanism of this activity is to modify the teichoic acid component of 
the cell wall (Kristian, et al. 2005). Furthermore, a broad spectrum cysteine protease 
produced by GAS, SpeB, is capable of cleaving the potent cathelicidin, LL-37 (Nyberg, et al. 
2004). A further virulence factor produced by GAS, streptococcal inhibitor of complement 
(SIC) produced exclusively by M1 strains, can inactivate LL-37 as well as other antimicrobial 
peptides by binding rather than by cleavage (Fernie-King, et al. 2004, Frick, et al. 2003). 
Interestingly, LL-37 has been shown to influence a two-component regulator of GAS, 
CovR/S, enhancing the expression of virulence factors regulated by this system (Gryllos, et al. 
2008). 
SpyCEP interferes with the neutrophil response against Group A Streptococcus 
30 
 
1.2.3 Complement 
 
The complement system consists of a cascade of inactive serine proteases and other 
proteins. Upon interaction with various danger signals, protease members of this family 
activate, and subsequently activate further proteases and other proteins further down the 
cascade. A summary of the pathways is shown below (Figure 1-2) 
 
 
 
Figure 1-2– Complement pathway 
Figure depicting the three complement pathways, classical, alternative and lectin. The main 
effector components of the complement pathway are highlighted orange. Other important 
immune regulating proteins are highlighted purple. 
 
Whilst the classical pathway must be specifically activated by antibody, the 
alternative pathway features C3b being continuously deposited on the surface of both human 
and foreign cells (Zipfel and Skerka 2009). This potentially unwanted complement activation 
SpyCEP interferes with the neutrophil response against Group A Streptococcus 
31 
 
is prevented by soluble factors such as Factor H, which detect self and deactivate 
complement, whilst leaving that deposited on bacteria intact (Atkinson, et al. 1991). 
Regardless of how it is activated and the intermediary steps followed, the complement 
cascade converges in a common set of end products which have powerful and broad spectrum 
antibacterial activity (Zipfel and Skerka 2009). C3b binds to the bacterial cell surface, and is 
a powerful opsonin, being bound by a variety of complement receptors, such as complement 
receptor 1 (CR1) and complement receptor 3 (CR3), which are expressed on the surface of 
phagocytes. CR1 is formed from a molecule of CD35, whereas CR3 is a heterodimer of 
CD11b and CD18; both are expressed strongly by neutrophils (Hynes 1992), and are both 
upregulated upon infection by the binding of the neutrophil activating chemokine CXCL8 to 
its receptor on the neutrophil surface (Detmers, et al. 1990, Paccaud, et al. 1990). The 
importance of C3b is highlighted the arsenal of virulence factors that GAS brings to bear 
upon it (1.3.2).  
The steps passed through before activating C3 into C3b also have immune system 
functionality. C3a, C4a and C5a are soluble anaphlatoxins. These are pro-inflammatory 
molecules, which activate and recruit immune cells to sites of infection (Gasque 2004). C5a 
is an especially potent chemoattractant for neutrophils, cells which are known to be of vital 
importance in the clearance of GAS (Peveri, et al. 1988, Wexler, et al. 1983). It is hence 
unsurprising that GAS has virulence factors directed against such anaphlatoxins (Laarman, et 
al. 2010, Wexler, et al. 1985). 
Additional to its function as an opsonin, C3b is also recruited to form C5 convertase, 
which liberates C5a and C5b. C5b interacts with other proteins of the complement cascade to 
form the membrane attack complex. The role of the membrane attack complex in controlling 
GAS is unclear. It is thought not to play a role as the thick cell wall of GAS and other Gram 
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positive bacteria protect them from its effects. However, GAS does express proteins which 
disrupt its formation (Fernie-King, et al. 2002).  
 
1.2.4 Cellular recognition of pathogens 
 
Phagocytes express pathogen recognition receptors (PRRs) which are capable of 
binding a broad range of ligands which are expressed by pathogens but not by the host, such 
as components of the bacterial cell wall, or double stranded viral RNA (Gordon 2002). Upon 
binding such pathogen associated molecular patterns (PAMPs), signalling cascades trigger a 
wide range of immune activity. One such class of PRRs are the Toll-like receptors (TLRs), 
which detect a variety of different PAMPs. Of importance for GAS infections are TLR1, 2, 
and 9, which recognise lipopeptides, lipoteichoic acid and unmethylated CpG DNA 
respectively, all hallmarks of bacterial infection. Interestingly, TLR4 also recognises short 
fragments of hyaluronic acid (Taylor, et al. 2004), which forms the anti-phagocytic capsule 
of GAS (Wessels, et al. 1991).  
Upon binding their ligands, the TLRs recruit a barrage of adapter proteins including 
MyD88, activating an array of signalling cascades through the signalling kinases MAPK, 
PI3K and IKK onto the transcription regulator NFκB. Amongst the effects of such signalling 
pathways is the upregulation of CR3 (Lynam, et al. 1994). 
 
1.2.5 Chemical mediators of inflammation 
 
Chemokines are small molecule inducers of cell motility. Chemokines can be 
subdivided into a variety of families, and act on a variety of different cell types. All 
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chemokines with neutrophil activity belong to the CXC family, so named due to the 
characteristic arrangement of cysteine residues proximal to their amino termini (cysteine-X-
cysteine) (Murdoch and Finn 2000). The 17 mammalian chemokines which belong to the 
CXC family can be further subdivided into two groups by virtue of the presence or absence of 
a glutamic acid-leucine-arginine (ELR) tripeptide motif, immediately before the first cysteine 
of the CXC motif. The presence of this motif is a canonical feature of neutrophil specific 
chemokines; all chemokines with such a motif act on neutrophils, whereas those without this 
motif act on other cells of the immune system (Clark-Lewis, et al. 1991, Hebert, et al. 1991) ( 
Systematic 
Name 
Functional 
Name 
ELR 
Motif 
Responding Cell 
Type 
Known 
Receptors 
CXCL1 GROα + Neutrophil CXCR2>CXCR1 
CXCL2 GROβ + Neutrophil CXCR2 
CXCL3 GROγ + Neutrophil CXCR2 
CXCL4 PF-4 - Fibroblast Unknown 
CXCL5 ENA-78 + Neutrophil CXCR2 
CXCL6 GCP-2 + Neutrophil CXCR1, CXCR2 
CXCL7 NAP-2 + Neutrophil CXCR1, CXCR2 
CXCL8 IL-8 + Neutrophil CXCR1, CXCR2 
CXCL9 MIG - TH1/NK cell CXCR3 
CXCL10 IP-10 - TH1/NK cell CXCR3 
CXCL11 I-TAC - TH1/NK cell CXCR3, CXCR7 
CXCL12 SDF-1α - All leukocytes CXCR4, CXCR7 
CXCL13 BCA-1 - B cell CXCR5 
CXCL14 BRAK - Monocyte Unknown 
CXCL15 Lungkine - Neutrophil Unknown 
CXCL16 SCYB16 - T cell CXCR6 
CXCL17 VCC-1 - Dendritic cell Unknown 
 
Figure 1-3). These chemokines have common structural characteristics; their N 
termini are globular and bind the chemokine receptors, whereas their C-termini are alpha 
helical, and bind glycosaminoglycans. The binding of the N-termini of such chemokines to 
their cognate receptors, CXCR1 and CXCR2, promotes extravasation of neutrophils as the 
chemokine C-termini bind endothelial surfaces. After extravasation, the chemokines enable 
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chemotactic trafficking to infection sites and the activation of neutrophils, including the 
upregulation of receptors such as CR3 (Detmers, et al. 1990). 
 
 
 
 
 
 
 
 
 
Systematic 
Name 
Functional 
Name 
ELR 
Motif 
Responding Cell 
Type 
Known 
Receptors 
CXCL1 GROα + Neutrophil CXCR2>CXCR1 
CXCL2 GROβ + Neutrophil CXCR2 
CXCL3 GROγ + Neutrophil CXCR2 
CXCL4 PF-4 - Fibroblast Unknown 
CXCL5 ENA-78 + Neutrophil CXCR2 
CXCL6 GCP-2 + Neutrophil CXCR1, CXCR2 
CXCL7 NAP-2 + Neutrophil CXCR1, CXCR2 
CXCL8 IL-8 + Neutrophil CXCR1, CXCR2 
CXCL9 MIG - TH1/NK cell CXCR3 
CXCL10 IP-10 - TH1/NK cell CXCR3 
CXCL11 I-TAC - TH1/NK cell CXCR3, CXCR7 
CXCL12 SDF-1α - All leukocytes CXCR4, CXCR7 
CXCL13 BCA-1 - B cell CXCR5 
CXCL14 BRAK - Monocyte Unknown 
CXCL15 Lungkine - Neutrophil Unknown 
CXCL16 SCYB16 - T cell CXCR6 
CXCL17 VCC-1 - Dendritic cell Unknown 
 
Figure 1-3 – Table of CXC chemokines and their properties 
Adapted from (Pease 2011) 
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CXCR1 and 2, which, although expressed at low levels on other immune cell lineages 
such as monocytes and natural killer (NK) cells, are predominantly found on the surface of 
neutrophils (Morohashi, et al. 1995). Circulating neutrophils express approximately 75000 of 
these receptors per cell, compared to 7500 by HL60 cells and 5000 by primary human 
monocytes (Grob, et al. 1990, Zahn, et al. 1997). HL60 are a leukocytic cell line which can 
be differentiated to resemble neutrophils. HL60 cells express phagocyctic receptors, but only 
low levels of chemokine receptors (Collins, et al. 1979). Monocytes are also phagocytic cells, 
but respond to a distinct range of chemokines and express accordingly different chemokine 
receptors (Shi and Pamer 2011). 
Chemokine receptors are G-protein coupled receptors, which are themselves 
upregulated in number as the neutrophil progresses towards an infection site by both de novo 
expression (Manna, et al. 1995, Manna and Samanta 1995) and from intracellular stores 
(Manna and Samanta 1995). As the neutrophil response continues, CXCRs are later 
downregulated primarily by desensitisation and subsequent internalisation (Samanta, et al. 
1990).  
In addition to these chemotactic mediators, other soluble mediators of inflammation, 
cytokines, play a vital role in orchestrating the immune response. These mediators are 
typically thought to derive primarily from cells of the monocyte lineage. However, it must be 
remembered that neutrophils are a potent cytokine source and express pro-inflammatory 
tumour necrosis factor alpha (TNFα), interferon-1-beta (IL-1β), interferon-12 (IFN-12) and 
vascular endothelial growth factor (VEGF) (Scapini, et al. 2000).  
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1.2.6 Neutrophils and other cellular responders 
 
1.2.6.1 Neutrophils 
 
Neutrophils form part of the earliest immune response to bacterial infections, acting as rapid 
response bactericidal cells. These are potent antimicrobial cells, equipped with an arsenal of 
toxic chemicals to destroy pathogens. 
 
 
 
1.2.6.1.1 Neutrophils and the bone marrow 
 
The potent anti-microbial arsenal possessed by neutrophils means however that they are 
tightly regulated, and typically 1-2% of total neutrophil numbers circulate in the blood under 
normal circumstances, with the remainder being held in the bone marrow until required 
(Delano, et al. 2011, Semerad, et al. 2002) (Figure 1-4). Furthermore, neutrophils have an 
extremely short half-life of six hours (Furze and Rankin 2008a), which some have suggested 
is to ensure that proper membrane integrity is maintained, preventing unwanted leakage of 
toxic compounds (Amulic, et al. 2012). 
 
Comment [RL1]:  
Comment [RL2]:  
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Figure 1-4 – Architecture of bone marrow  
Neutrophils (blue round) and held in the bone marrow bound to stromal (green cells). Upon 
activation, they migrate across the sinusoidal endothelium into the circulation. 
 Neutrophils are held in the bone marrow bound to the stromal cells. Here they are 
isolated from the circulation by the sinusoidal endothelial cells, the integrity of which is 
critical to prevent unregulated leukocyte leakage (Burdon, et al. 2008). Neutrophils exit the 
bone marrow by crossing the sinusoidal endothelium, migrating directly through the cells, 
rather than the junctions between them, maintaining the integrity of the endothelium (Burdon, 
et al. 2008). Neutrophil release from the bone marrow is critically dependent on three 
signalling pathways. Neutrophils in the bone marrow express low levels of CXCR4, the 
receptor for CXCL12. It is known that ablation of CXCR4 signalling leads to neutrophils 
being released from the bone marrow (Eash, et al. 2009, Ma, et al. 1999). CXCL12 is 
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constitutively expressed at high concentrations by the bone marrow stromal cells, providing 
the default retention signalling (Shirozu, et al. 1995). 
 Counteracting the retention signals provided by constitutive CXCL12 expression is 
granulocyte colony-stimulating factor (G-CSF). G-CSF acts to reduce expression of CXCL12 
by stromal cells, thus reducing the retention signals (Noursadeghi, et al. 2002). It is known 
that direct perfusion of canulated bone marrow with G-CSF leads to release of neutrophils 
from the bone marrow (Martin, et al. 2003). However, this effect is not seen using CXCR2 
knock-out mice, indicating that CXCR2 signalling is also necessary for bone marrow release 
of neutrophils (Eash, et al. 2010, Kohler, et al. 2011). Interestingly, CXCR4 CXCR2 double 
knock-out mice demonstrate high levels of neutrophil circulation (Eash, et al. 2010), although 
whether this is due to enhanced release from the bone marrow, or a failure to clear old 
neutrophils from the blood stream, the mechanism for which also uses CXCR4 signalling, is 
unclear (Weisel, et al. 2009).  
 KC and MIP2, the murine chemokines which bind CXCR2, and are functional 
orthologues of human CXCL8, are expressed constitutively at low levels by the bone marrow 
endothelial cells and the osteoblasts (Eash, et al. 2010) balanced against the retention signals 
of CXCL12. These signals mutually antagonise each other such that an increase in either 
chemokine can exert large effects on neutrophil release (Furze and Rankin 2008b). The 
expression of KC and MIP-2 by the endothelial cells is enhanced in bone marrow by rising 
concentrations of G-CSF (Eash, et al. 2010). Furthermore, perfusion of either KC or MIP-2 
into canulated bone marrow (Martin, et al. 2003); injected intravenously (Martin, et al. 2003) 
or injected intraperitoneally (Wengner, et al. 2008) leads to the release of neutrophils from 
the bone marrow. The precise mechanism of action of KC and MIP-2 is unclear, but is likely 
to involve provision of a concentration gradient that allows the trafficking of unbound 
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neutrophils out of the bone marrow (Furze and Rankin 2008b). This is summarised in Figure 
1-5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
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Figure 1-5 – Signalling interplay controlling neutrophil release from bone marrow 
(A) – resting state. Stromal cells (green) express high levels of CXCL12 (green circles), 
which antagonise the KC and MIP2 (red circles) released from the endothelial cells and 
osteoblasts. The dominant signal is retention. (B) – infection state. KC, MIP2 (red circles) 
and G-CSF (blue squares) enter the blood stream. These diffuse across the sinusoidal 
endothelium. G-CSF reduces expression of CXCL12 and upregulates production of further 
KC and MIP2, leading to detachment of neutrophils from the stromal cells. KC and MIP2 
form a chemokine gradient into the blood promoting neutrophil egress across the sinusoidal 
endothelium. 
B 
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1.2.6.1.2 Neutrophil activation 
 
After leaving the bone marrow, neutrophils begin to activate. Neutrophil activation 
involves the progressive release of granules from within the neutrophil and other cellular 
changes including increased actin mobilisation. Granules have been grouped as primary, 
secondary, tertiary and secretory vesicles, classically based on their staining with dyes, but 
are actually highly heterogeneous, in both their contents, and the timing of their release 
(Amulic, et al. 2012, Borregaard and Cowland 1997). Neutrophil activation is a progressive 
process, which is triggered by an array of stimuli, rather than being dependent on a single 
signal being received. It is driven by a variety of inflammatory mediators produced by cells 
local to the infection site, such as TNFα, chemokines, and directly by bacterial products such 
as LPS.  
Granules are released from the neutrophil at varying threshold concentrations of 
intracellular calcium, the concentration of which is dependent on the various signalling 
sources neutrophils receive. As such, different granules are released throughout activation. As 
these granules contain a variety of surface proteins, the progressive degranulation process 
alters the surface expression of a variety of receptors, allowing neutrophils to egress from the 
bone marrow, through the peripheral blood, across the endothelial barrier and into the 
infection site. At the site of infection, chemokines are at much higher concentration than in 
the serum, and signalling from chemokine receptors via MAPK/ERK signalling pathways 
leads to the commencement of the oxidative burst, part of the final stages of neutrophil 
activation (Selvatici, et al. 2006).  
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Neutrophil granules also contain a variety of other molecules, including CXCL8. This 
is primarily stored in secretory vesicles, a class of vesicle released easily from the neutrophil. 
Accordingly, CXCL8 can be rapidly released at high concentrations upon stimulation, 
providing a feed forward mechanism for further neutrophil recruitment and activation 
(Cassatella, et al. 1992). 
Neutrophils were once considered to be of limited productive capacity, however work 
has found they are able to secrete a variety of cytokines and chemokines. Many important 
cytokines, such as TNF-α, IL-1β and IL-12 along with chemokines CXCL10, CXCL11, MIP-
1α and MIP-1β are now known to be produced by neutrophils. Whilst a detailed description 
of these cytokines is beyond the range of this study, the cytokines produced act to enhance 
various stages of the immune response. TNF-α has a broad range of functions including 
activation of various intracellular signalling cascades associated with an anti-pathogen state, 
IL-1β upregulates various adhesins on endothelial cells, assisting in the infiltration of other 
leukocytes, and IL-12 drives differentiation of the adaptive immune response to a TH1 
reaction, appropriate for antiviral and anti-bacterial responses. CXCL10 and 11 are 
chemoattractants of monocytes and MIP-1α and MIP-1β chemoattract monocytes, natural 
killer cells and T cells (Scapini, et al. 2000).  
Upon infection, following their liberation from the bone marrow, neutrophils traffic to 
infected or damaged tissues by migrating down CXCR1 and/or 2 specific chemokine 
gradients (Baggiolini 1995). The importance of these two receptors in neutrophil trafficking 
and activation is unclear. There is some evidence to suggest that CXCR2 is involved 
primarily in early stages of activation, which is superseded by CXCR1 signalling as the 
neutrophils near the focus of the infection (Amulic et al. 2012). These chemokines are 
produced by cells at the site of infection in response to a variety of danger signals, including 
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pathogen associated molecular patterns (PAMPs), and are detected by neutrophil CXCR1 and 
2 arranged on the cell surface in a polarized distribution (Amulic, et al. 2012). 
After migrating to the infection site, neutrophils phagocytose opsonised particles by 
binding opsonins using phagocytosis receptors expressed on their surface. Degranulation 
upregulates the numbers of receptors involved in bacterial phagocytosis on the neutrophil 
surface – the neutrophils have become primed to kill bacteria or other pathogens (Thelen, et 
al. 1993). These receptors include complement receptors 1 and 3 (CR1 and 3) which bind 
C3b deposited on the surface of the pathogen, and receptors such as CD16 which bind 
opsonising antibodies. These are all upregulated during neutrophil activation by 
degranulation (Borregaard, et al. 1994, Detmers, et al. 1990, Elghetany 2002, Paccaud, et al. 
1990). Receptor components are found pre-formed in a wide variety of neutrophil granules, 
and thus CR3 is upregulated continuously throughout neutrophil activation as neutrophils 
progressively degranulate (Amulic, et al. 2012). CR1 and FcγRIII are primarily found in 
early released secretory granules (Amulic, et al. 2012, Sengelov, et al. 1994).  CR3 has been 
shown to be of critical importance in the phagocytosis of GAS. Antibody blockade of Fc 
receptors or CR1 have been shown to have limited impact on the phagocytosis of GAS by 
neutrophils, whereas blockade of CR3 caused ablation of phagocytosis (DeMaster, et al. 2002, 
Nilsson, et al. 2005, Weineisen, et al. 2004).  
Neutrophils are relatively poorly studied as phagocytes, as they are difficult to study, 
being short lived cells and refractory to genetic manipulation (Lee, et al. 2003). Furthermore, 
the HL60 cell line which has been used as a neutrophil like immortalised cell differs from the 
neutrophil in several key ways, including in the expression of CXCR receptors (Collins, et al. 
1979, Grob, et al. 1990, Zahn, et al. 1997). As described above, neutrophils have receptors 
able to phagocytose particles opsonised by complement or antibody. Upon binding an 
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opsonised particle, the specific receptors on the surface of the neutrophil cluster beneath the 
particle. These clustered receptors then initiate a signalling cascade leading to the recruitment 
and activation of actin remodelling machinery within the neutrophil. Phagocytosis by 
macrophages mediated by antibody opsonisation is mediated by the extension of pseudopods 
from the macrophage around the particle, whereas complement mediated phagocytosis 
appears as particles sinking into the macrophage (Allen and Aderem 1996). The subsequent 
phagosomes are then gradually made more antibacterial by fusion with granules filled with 
antibacterial agents such as myeloperoxidase and lysozyme  (Nordenfelt and Tapper 2011). 
 
 
 
 
 
 
Figure 1-6 – Diagram of neutrophil trafficking 
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Diagram of neutrophil trafficking. Neutrophils (N) travelling in blood vessels (far right) 
extravasate and migrate down chemokine (green polygons) gradients towards the site of 
infection. At the site of infection, local cells (C) detect bacteria (purple circles) using 
receptors (blue) and release chemokines and other inflammatory mediators. 
An activated neutrophil, as part of a unique type of cell death (NETosis), may expel 
neutrophil extracellular traps (NETs), consisting of chromatin studded with antimicrobial 
proteins (Brinkmann, et al. 2004). These structures have antimicrobial activity, thought to be 
mediated by bacteria sticking in the extended DNA, then being exposed to high 
concentrations of antimicrobial peptides (Papayannopoulos and Zychlinsky 2009).  The 
importance of neutrophils in controlling GAS virulence is great, and is demonstrated by the 
range of virulence factors expressed by GAS to try to evade their killing (Cunningham 2000). 
 
1.2.6.2 Macrophages and others 
 
The other principle phagocytes of the innate immune response are macrophages. 
These cells derive from circulating monocytes, differentiating into cells primed to kill 
pathogens upon interaction with cytokines or directly with microbial products. These cells 
express a similar range of receptors involved in phagocytosis, and indeed much of what is 
known about neutrophil phagocytosis has been extrapolated from research on macrophages 
(Lee, et al. 2003, Verschoor, et al. 2012). Macrophages however phagocytose more slowly 
than neutrophils and have lower capacity to produce antimicrobial molecules than neutrophils 
(Nordenfelt and Tapper 2011). The phagosomes produced are made antibacterial using a 
different mechanism to that used by neutrophils. Rather than fusion with granules, the 
membrane of the phagosome modifies and eventually acidifies by fusion with the lysozome, 
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delivering toxic products onto the bacteria (Janeway Jr, et al. 2001). Macrophages are 
capable of a wider range of cytokine expression and furthermore can present antigens to the 
cells of the acquired immune response driving their expansion and activation (Verschoor, et 
al. 2012). They hence have a critical role bridging the early innate and later acquired immune 
response (Janeway Jr, et al. 2001).  
Monocytes and macrophages express a different set of chemokine receptors to 
neutrophils, and are thus responsive to different chemokines. Whereas neutrophils express 
CXCR1 and 2 at very high levels, these are found at only low concentrations on the surface 
of monocytes (Zahn, et al. 1997). Instead, they express chemokine receptors CCR2 or 
CX3CR1 (Geissmann, et al. 2003). This causes these two different phagocytes to have 
different chemotactic responses. 
Monocytes are known to play an important role in GAS virulence. Monocyte depleted 
mice had much more severe infections than wild type infected mice. A non-lethal dose of 
GAS in wild type mice was sufficient to cause a mortality rate of 100% in mice which were 
monocyte depleted (Goldmann, et al. 2004). M1 GAS strains have also been reported to 
survive and replicate within macrophages by impairing fusion of the lysozome to the 
phagosome. These cells have been reported to provide a protective niche allowing GAS 
persistence (Hertzen, et al. 2010). GAS has not been reported to survive within neutrophils. 
Other cellular mediators of the innate immune response include eosinophils, mast 
cells and basophils. These are also granulocytes, but are otherwise very different from 
neutrophils. They primarily function against large extracellular pathogens by the release of 
toxic compounds within their granules into the extracellular milieu. They are not phagocytes, 
and express different chemokine receptors from neutrophils. All these cell types are relatively 
minor components of the white blood cell population, but are contaminants of neutrophil 
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preparations. Natural killer cells are of lymphoid lineage, and target cells infected with 
intracellular pathogens, especially viruses. They will also not be considered further in this 
study (Janeway Jr, et al. 2001). 
 
 
1.2.7 The acquired immune response 
 
While the innate immune is responding rapidly to the onset of infection, and is 
normally capable of clearing the infection, a specific acquired immune response is 
developing against the infection. A complete description of the development of such a 
response is beyond the scope of this work, and has been described variously elsewhere 
(Janeway Jr, et al. 2001).  
Briefly, antigen is captured by professional antigen presenting cells such as dendritic 
cells or macrophages, which then traffic to lymph nodes where the antigen is presented to T 
cells. Upon their arrival, T cells equipped with receptors specific for such antigen clonally 
expand and mature their receptors, enhancing their specificity. These can then in turn 
promote the clonal expansion and maturation of antigen specific B cells into plasma cells. 
These release large quantities of antibody which may also opsonise the target, or neutralise 
the antigen they target, by blocking the active site or effecting a conformational change 
(Janeway Jr, et al. 2001). Such responses linger in the body after the resolution of infection, 
conferring protection against re-infection, hence eliciting such responses is the aim of 
vaccination. 
Opsonising antibody bound to their target antigen is bound by Fc receptors on 
phagocytes, which recognise the conserved, antigen independent domain of the antibody. 
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Opsonisation by antibody is also accompanied by driving complement deposition on the 
particle surface via the classical pathway of complement deposition (Zipfel and Skerka 2009). 
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1.3 GAS virulence mechanisms 
 
1.3.1 Regulation of virulence 
 
GAS tightly regulates its protein expression, including virulence factors, using a wide 
range of regulatory mechanisms, of which CovR/S (control of virulence) is the best 
characterised, and seems to be the most pluripotent, influencing expression of approximately 
15% of the coding sequence (Graham, et al. 2006). CovR/S is a two component regulator. 
Such regulators consist of a sensor kinase protein (CovS), which upon sensing its stimulus 
phosphorylates a response regulator, and in turn acts to modulate transcription by binding 
DNA (CovR) (Churchward 2007). The expression profile controlled by CovR/S is complex 
and interacts extensively with the other regulatory mechanisms of GAS. However it can be 
generalised that when CovR is phosphorylated and active, it represses the expression of 
virulence factors involved in invasion and upregulates the expression of factors involved in 
persistence and colonisation. Indeed, it has been shown that invasive isolates often have a 
variety of mutations in covRS resulting in the deactivation of its regulatory system and thus 
allowing increased expression of invasive virulence factors. Furthermore, it has been shown 
to be acquired in the course of an experimental infection, in covRS, deactivating the 
regulatory system, (Sumby, et al. 2006, Walker, et al. 2007), (Cole, et al. 2010). Virulence 
factors known to be down-regulated by CovR/S include SpyCEP (Turner, et al. 2009a), 
proteins involved in capsule synthesis (Sumby, et al. 2006), and Sda1 (Walker, et al. 2007), 
whereas SpeB is known to be upregulated by CovR/S (Sumby, et al. 2006).  
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Mga was the first described regulatory system of GAS. It is highly conserved across 
GAS strains and activates expression of a wide range of virulence genes, including those 
encoding M protein, C5a peptidase and SIC (Kreikemeyer, et al. 2003), which all lie 
downstream of mga. Mga is autoregulatory, such that signalling by Mga leads to increased 
expression of further Mga, and it is opposed by transcription suppressors such as Rgg 
(Chaussee, et al. 2002, McIver, et al. 1999). The stimuli of Mga are relatively well 
characterised, and include elevated CO2, iron limitation or increased temperature, common 
factors faced by GAS upon infecting a human host (Caparon, et al. 1992, McIver, et al. 1995, 
Podbielski, et al. 1992). 
 
1.3.2 Defence against opsonisation 
 
The complement system is known to be important in the phagocytosis of GAS 
(DeMaster, et al. 2002). It is hence unsurprising that GAS has mechanisms by which 
complement deposition is impeded. The broad specificity cysteine protease SpeB is able to 
directly cleave C3 and IgG, and has been shown to have a direct negative impact on 
phagocytosis (Lukomski, et al. 1998). Its specificity is sufficiently broad such that its known 
substrates includes some chemokines (Egesten, et al. 2009) and important GAS virulence 
factors including Sda1 (Walker, et al. 2007). Its importance in virulence is undermined by 
observations that many invasive strains express only low levels of SpeB due to mutation in 
CovR/S (Sumby, et al. 2006).   
M protein has multifarious impacts on complement deposition, with variation in 
mechanism between M-types. The different M protein types have been shown to bind various 
complement-interacting factors: factor H, factor H like-1 (FHL1), C4b-binding protein and 
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CD46 complement regulatory protein (Horstmann, et al. 1988, Johnsson, et al. 1998, 
Kotarsky, et al. 1998). Factor H and FHL1 inhibit the alternative complement cascade, being 
present on host cells. They prevent the spontaneous breakdown of C3 into C3a and C3b and 
act to enhance the breakdown of the alternative C3 convertase, preventing further C3b 
deposition (Pangburn, et al. 1977, Weiler, et al. 1976, Whaley and Ruddy 1976). C4b-
binding protein primarily inhibits the classical pathway of complement activation, by binding 
C4, preventing its inclusion into the classical C3 convertase, but does also have some activity 
in increasing the decay of the alternative C3 convertase (Carlsson, et al. 2003). CD46 directly 
interacts with C3b and C4b, allowing for their cleavage from the cell surface (Liszewski, et al. 
1996). Furthermore, specific types of M protein bind to fibrinogen, which further prevents 
complement deposition via the classical pathway (Carlsson, et al. 2005, Whitnack and 
Beachey 1982). Considering these effects, it is not surprising that many studies have 
demonstrated its anti-phagocytic properties, which have been known for many years (Morris 
and Seastone 1955). 
 The polysaccharide capsule of GAS is a further anti-phagocytic factor that has been 
studied since the early days of GAS research (Ward and Lyons 1935). However, more 
modern genetic manipulation has allowed more exacting study of this virulence mechanism. 
The capsule comprises repeating units of N-acetylglucosamine and glucuronic acid 
(Stoolmiller and Dorfman 1969) forming hyaluronic acid. Hyaluronic acid is only weakly 
immunogenic, due to its similarity to hyaluronic acid in the connective tissue of the host, 
which is thought to explain some of its anti-phagocytosis properties (Cunningham 2000). 
Interestingly however, the mechanism by which capsule reduces phagocytosis does not seem 
to involve inhibiting complement deposition, and may instead act as a physical barrier, 
keeping the deposited complement on the bacterial surface from being bound by complement 
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receptors (Dale, et al. 1996).  Its role in virulence has been demonstrated using acapsular 
mutants, which show increased phagocytosis and drastically reduced virulence in the mouse 
model (Wessels, et al. 1991). 
 Streptococcal inhibitor of complement (SIC) is a highly variable protein, produced by 
M1 type GAS strains (Akesson, et al. 1996). This protein binds to the C5b-C7 complex of the 
nascent membrane attack complex, preventing its formation (Fernie-King, et al. 2001).  The 
known function of the membrane attack complex is to disrupt the outer membranes of Gram 
negative bacteria, hence GAS is naturally resistant. The role of SIC in GAS infection is hence 
unclear, however, it has also been found to bind and inactivate anti-microbial defensins, 
which may be the primary virulence function of this protein (Frick, et al. 2003). 
 Whilst the role of opsonisation by antibody is thought to be less important than that of 
complement, GAS expresses a variety of proteases which are able to cleave immunoglobulin 
directly. EndoS, IdeS and SpeB are all able to cleave IgG, with SpeB having cleavage activity 
against various subtypes of immunoglobulin (Collin and Olsen 2001a, Collin and Olsen 
2001b, von Pawel-Rammingen, et al. 2002).  
 
1.3.3 Defence against cellular immunity 
 
As well as preventing opsonisation, GAS has a considerable arsenal of virulence 
factors to disrupt cellular immune effectors. GAS encodes a highly conserved C5a peptidase, 
whose expression is regulated by mga (La Penta, et al. 1994), which cleaves and inactivates 
the chemotactic C5a fragment produced by the complement cascade (Wexler, et al. 1985). 
This is chemotactic for neutrophils, and has been shown to impair neutrophil recruitment to 
the site of infection (Ji, et al. 1996). Its role in virulence in the mouse model has also been 
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demonstrated, with C5a peptidase mutants being less able to colonise the nasopharynx, and 
being cleared more efficiently from a sub-dermal model of infection (Ji, et al. 1996, Ji, et al. 
1997). This enzyme is conserved between GAS and Streptococcus agalactiae, and it has been 
found that vaccination using C5a peptidase is protective in the mouse model against both 
organisms (Cleary, et al. 2004). A further enzyme, SpyCEP, that specifically cleaves and 
inactivates neutrophil chemokines plays a major role in prevention of chemotaxis and is 
discussed in detail in the next section.  
Macrophages and neutrophils which successfully migrate to the infection site to 
phagocytose bacteria are subject to assault by streptolysins. Streptolysin S (SLS) is a broad 
spectrum cytolysin, of unknown mechanism. It is believed to accumulate in cell membranes, 
and form pores, causing irreversible loss of osmotic integrity. SLS has been shown to have 
activity against leukocytes, erythrocytes, platelets, but importantly not GAS membranes 
(Bernheimer and Schwartz 1965, Bernheimer 1966, Hryniewicz and Pryjma 1977). Such 
effects mediate the β haemolytic nature of GAS. SLS mutants are known to be less virulent in 
the mouse model of infection, and indeed SLS is known to lyse neutrophils (Miyoshi-
Akiyama, et al. 2005). 
Streptolysin O (SLO) is a further cytolytic toxin of GAS and has been shown to kill 
neutrophils and macrophages by inducing apoptosis. Its mechanism is somewhat more 
specific than SLS however, requiring the bacteria to be inside the cell to mediate its effect 
intracellularly (Timmer, et al. 2009). SLO forms a pore in the phagosome and allows the 
translocation of NAD+ glycohydrolase into the cell cytosol (Madden, et al. 2001), where it 
cleaves NAD and creates cADP ribose (Karasawa, et al. 1995). SLO mutants have also been 
found to show reduced virulence in vivo (Timmer, et al. 2009). 
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 The final assault of neutrophils on bacteria, NETosis, is also disrupted by GAS. GAS 
expresses a potent DNAse, Sda1 (Aziz, et al. 2004), which degrades the NET, allowing the 
bacteria to escape (Buchanan, et al. 2006). This protein is repressed by an active CovR/S 
system, and hence is upregulated in many invasive isolates where this regulator is lost 
(Sumby, et al. 2006, Walker, et al. 2007). The importance of this virulence factor has been 
demonstrated by experiments showing it provides the driving force for the CovR/S mutation 
in vivo. It was observed that Sda1 mutants seldom acquire CovR/S mutations during in vivo 
passage compared to wild type strains (Walker, et al. 2007). This is unlikely to be an 
observation which could be applied to all GAS strains – GAS expresses many virulence 
factors, with large inter-strain variation in the expression of each (Turner, et al. 2009a). 
 Further work has found an additional role for Sda1 in preventing activation of 
neutrophils, by interfering with TLR9 signalling. This receptor recognises bacterial DNA by 
its characteristic high proportion of C and G residues compared to mammalian DNA, and its 
ligation leads to the release of proinflammatory cytokines. Sda1 has been shown to cleave 
extracellular bacterial DNA. Furthermore, in vivo studies have found that infection foci have 
reduced TNFα and IFNγ following infection with Sda1 positive strains compared to Sda1 
mutants. Indeed, macrophages, which do not kill bacteria using DNA traps, are impaired in 
bacterial killing due to expression of Sda1 (Uchiyama, et al. 2012). 
 It has also been shown that M1 strains of GAS are able to survive within macrophages. 
This is reported to be mediated by the M1 protein itself interfering with fusion of the 
lysosome with the GAS containing phagosome. Survival within the macrophage by GAS is 
reported to potentially provide a reservoir for reactivation of infection (Hertzen, et al. 2010).  
 Of note, as a Gram positive bacterium, the classical secretion mechanisms whereby 
proteins are translocated across a double membrane are not applicable to GAS. For GAS and 
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other Gram positive bacteria, a different mechanism is required. Many GAS extracellular 
virulence factors are secreted out of the cell via the ExPortal (Rosch and Caparon 2005). This 
microdomain is found in the cell membrane of GAS, and is rich in proteins involved in 
translocation. Furthermore, the ExPortal plays a role in the correct folding and maturation of 
secreted proteins. A particular accessory factor HtrA, has been found to be vital in the SpeB 
proper maturation of SpeB (Rosch and Caparon 2005). 
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1.4 Background on SpyCEP 
 
1.4.1 SpyCEP history and specificity of activity 
 
The focus of this thesis are the actions of the GAS chemokine protease SpyCEP. The 
discovery of Streptococcus pyogenes cell envelope proteinase (SpyCEP) arose from 
observations made on clinical features of GAS disease. Patients with invasive GAS diseases 
were noted to have low white cell counts (Stevens, et al. 1989, Taylor, et al. 1999). 
Histological sections taken from patients suffering from NF showed a striking paucity of 
neutrophils, despite the presence of Gram positive cocci and extensive necrosis (Edwards, et 
al. 2005). The chemokine CXCL8 was initially implicated due to the vital role it plays in 
neutrophil chemotaxis. Whilst certain purified GAS products such as superantigens induced 
high CXCL8 expression from human leukocytes in vitro, streptococcal supernatants elicited 
very low levels of CXCL8. It was later found that GAS supernatants cleaved and inactivated 
CXCL8. The enzyme responsible was identified as SpyCEP by mass spectroscopy (Edwards, 
et al. 2005).  
The SpyCEP gene was originally annotated as prtS due to homology to PrtS, a 
caseinase expressed by Streptococcus thermophilus. Since discovery of its activity, the gene 
has been variously annotated cepA, scpC and SpyCEP. Use of scpC was based on 
nomenclature used for the streptococcal C5a peptidases (Scp, A and B) with which SpyCEP 
shares homology, although not substrate specificity (Hidalgo-Grass, et al. 2006). As the 
protease has no activity against C5a peptidase, the term SpyCEP has become the preferred 
term.  
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SpyCEP is a subtilisin-like extracellular serine proteinase that cleaves and inactivates 
certain neutrophil chemokines in a highly specific manner. The diseases caused by GAS stem 
from its ability to produce an astonishing array of virulence factors, targeting a broad swathe 
of the immune response which the bacteria might face. Particular focus is given to 
neutrophils, being part of the earliest immune response to bacterial infections (Edwards, et al. 
2005). Interestingly, several reports have indicated that NF lesions are profoundly neutrophil 
poor, highlighting the impact of such mechanisms on disease pathogenesis (Edwards, et al. 
2005, Hidalgo-Grass, et al. 2006). 
Prior to the start of this work, the substrate list of SpyCEP had not been fully resolved, 
However, consensus has now been reached that SpyCEP can cleave CXCL1, 2, 3, 5, 6, 7 and 
8 (Zingaretti, et al. 2010). This set of substrates comprises the entire human neutrophil 
specific chemokine family. No other substrates, including other chemokines, cytokines, 
immunoglobulin or blood proteins have been found. Such observations indicate that SpyCEP 
is highly specific, targeting solely but completely the neutrophil specific chemokines 
(Edwards, et al. 2005, Hidalgo-Grass, et al. 2006). This activity was abrogated upon addition 
of Pefabloc, a stable and specific serine protease inhibitor, but not by other protease inhibitors 
(Edwards, et al. 2005). 
The SpyCEP cleavage site of CXCL1, 2 and 8 has been determined by mass 
spectroscopy. The cleavage site of CXCL8 is between Q59 and R60, resulting in a 59 amino 
acid and 13 amino acid fragment. The smaller cleavage product of CXCL8 corresponded to 
its C-terminal α-helix. (Figure 1-7). CXCL1 and 2 are cleaved at sites with different amino 
acid sequences, but analogous structural sites, with the C-terminal alpha helix being liberated 
in both cases (Edwards, et al. 2005). 
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Figure 1-7 – SpyCEP cleavage site of CXCL8 
Cleavage activity of SpyCEP on its substrate CXCL8. Mature SpyCEP (scissors) cleaves 
CXCL8 close to its C-terminus in its α-helix, liberating a 13aa helical peptide (red). Such 
cleavage abrogates the biological activity of the chemokine. (Goldblatt, personal 
communication) (Edwards et al. 2005) 
 
1.4.2 Enzyme Kinetics 
 
Enzymes such as SpyCEP classically follow Michaelis-Menten type kinetics. This 
model predicts that the rate of enzyme activity on a substrate is dependent on the 
concentration of a substrate, but at very high concentrations of substrate, the enzyme 
becomes saturated, breaking this link to substrate concentration. The dependence of rate of 
reaction on substrate concentration is illustrated in Figure 1-8. 
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Figure 1-8 – Relationship of rate of reaction and substrate concentration. 
  
Such kinetics are described by the Michaelis-Menten equation, where v is rate of 
reaction, vmax the maximum rate of reaction at excess substrate, S is the substrate and Km is 
the Michaelis-Menten constant of the enzyme – the concentration of substrate required to 
achieve a rate of reaction which is 50% of vmax: 
v = 
    [ ]
    [ ]
 
These constants may be calculated by performing a series of experiments using different 
concentrations of substrate and measuring rate of reaction over a very brief period. Under 
such conditions, it can be assumed that the concentration of substrate has remained constant. 
By plotting these results on a graph (A Scatchard Plot) with y and x axes of 1/v and 1/[S] 
respectively, the y intercept provides a value for 1/vmax and the x intercept a value for -1/Km. 
 
 
1.4.3 Structure of SpyCEP 
 
The immature form of SpyCEP is approximately 180kDa, one of the largest proteins 
expressed by GAS (Edwards, et al. 2005). The protein can be subdivided into functional 
domains (Figure 1-9), based on the annotation of PrtP, a protease produced by L. lactis and 
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sharing considerable homology with SpyCEP. It is the archetype for cell envelope proteases 
expressed by lactic acid bacteria (Hidalgo-Grass, et al. 2006, Siezen 1999). These domains, 
despite their definition, remain poorly characterised. Being 180kDa, SpyCEP has proved 
difficult to express recombinantly or clone in Escherichia coli, hampering its structural 
characterisation, but also preventing complementation of mutant experiments from being 
performed. (Edwards, et al. 2005, Fritzer, et al. 2009, Kurupati, et al. 2010, Zinkernagel, et al. 
2008). The N-terminal-most section of SpyCEP is a signal sequence, which is removed from 
the mature protein, and is responsible for trafficking the protein to the cytoplasmic membrane, 
potentiating its export (Hidalgo-Grass, et al. 2006).  
 
 
Figure 1-9 – Schematic illustration of the structure of SpyCEP 
From left (N terminus) to right (C terminus), SS – signal sequence, required for protein 
export, cleaved from mature enzyme, P – protease domain including catalytic triad residues 
(stars), PA – protease associated domain, A – A domain, B/H – B/H domain, LPXTG – 
sortase enzyme pentapeptide motif, required for attachment of the protein to the bacterial cell 
wall. The functions of the A, B and or H domain are not known (Siezen 1999). 
 
The protease domain of the enzyme is found towards the N-terminus of SpyCEP, and 
is split into two separate sections by a protease-associated domain whose function is unclear 
(Figure 1-9). Each section of the protease domain contains some of the residues of the 
catalytic triad, such that either section of the protease domain alone has no activity.  
The C terminal region of SpyCEP is poorly characterised. It is split into two 
characteristic domains, an A domain and a putative B/H domain (Hidalgo-Grass, et al. 2006). 
N C 
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This nomenclature is again based upon that which has been used for PrtP, as indeed are the 
putative functions assigned to these domains (Siezen 1999). The A domain is next to the 
protease domain, and is thought to be involved in substrate binding or specificity. 
Interestingly, this section of SpyCEP has been observed to be required for chemokine 
cleavage (Kaur, et al. 2010). The region between the A domain and the C terminus shares no 
significant homology to PrtP, hence its identity is only putatively annotated. It has no role in 
chemokine cleavage by recombinant SpyCEP, but may be involved in acting as a stalk, lifting 
the catalytic domains away from the bacterial surface above the capsule (Kaur, et al. 2010). 
The C terminus of the protein features a further component involved in the final 
localisation of SpyCEP; a sortase A enzyme pentapeptide recognition motif: leucine-proline-
X-threonine-glycine (LPXTG) (Navarre and Schneewind 1994). This pentapeptide is bound 
and cleaved by sortase A between the T and G residues whilst the enzyme also binds to, and 
brings into proximity, specific cell wall precursor molecules, pentaglycine bridges. Sortase A 
catalyses the formation of covalent bonds between the cleaved sortase motif and these 
pentaglycine bridges (Navarre and Schneewind 1999). Upon the integration of these 
SpyCEP-bound precursors into the mature GAS cell wall, SpyCEP is presented 
extracellularly. SpyCEP has been detected in GAS cell wall extracts using specific antibody 
(Turner, et al. 2009a). However, antibody can also be used to detect SpyCEP in the 
supernatant of GAS cultures implying this surface anchoring is imperfect or that SpyCEP is 
being liberated from the cell wall following anchoring (Edwards, et al. 2005). No evidence 
for active release of SpyCEP from the cell surface either through autocatalysis or a process 
involving any other GAS proteases has been found.  
Antibodies raised against SpyCEP have provided evidence about its post-translational 
modifications. Antibodies against a C-terminal fragment of SpyCEP detected bands of 
SpyCEP interferes with the neutrophil response against Group A Streptococcus 
62 
 
180kDa and 150kDa in GAS supernatants using immunoblotting in denaturing conditions. 
Similar antibodies raised against the N terminus of SpyCEP however detected bands of 
180kDa and 30kDa (Edwards, et al. 2005). This has subsequently been proven to be a result 
of autocatalytic processing whereby SpyCEP cleaves itself between Q244 and S245, liberating a 
30kDa N terminus and a 150kDa C-terminus (Zingaretti, et al. 2010) (Figure 1-10). These 
bands appeared separate in the denaturing conditions of the immunoblot, proving that the two 
fragments were not covalently attached (Zingaretti, et al. 2010).  
 
Figure 1-10 – Autocatalytic processing of SpyCEP 
Autocatalytic processing of SpyCEP. Domains labelled as per Figure 1-9. Autocatalytic 
cleavage takes place in the protease domain splitting the catalytic triad residues between the 
two fragments. These domains are thought to then loosely associate. It is known that both are 
essential for catalytic activity 
The autocatalytic nature of this modification is proven by the failure of active site 
mutants to cleave themselves. Furthermore, recombinant wild type SpyCEP is unable to 
catalytically process neighbouring active site mutants of SpyCEP, indicating that the reaction 
occurs internally only. The cleavage of SpyCEP into two fragments is unusual in that the 
N C 
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catalytic residues themselves are separated in the process. Despite this, the enzymatic mixture 
retains activity. It may be that SpyCEP which has not undergone autocatalytic cleavage has 
substrate specificity only for cleaving itself, whereas processed SpyCEP has substrate 
specificity for chemokines only  (Zingaretti, et al. 2010). 
 
1.4.4 Activity of SpyCEP in vivo 
 
SpyCEP has been the subject of extensive study to determine its impact on virulence. 
A majority of studies have demonstrated a clear role for SpyCEP in virulence, although some 
have shown SpyCEP has a protective effect. Using a dermonecrotic model of GAS infection 
where lesion size is measured, it was found that SpyCEP-positive strains produced smaller 
lesions than isogenic SpyCEP-negative strains (Sumby, et al. 2008). Furthermore, SpyCEP 
was found to be protective to the mouse when GAS was injected directly into the blood 
stream (Sjolinder, et al. 2008). These studies contradict the majority of SpyCEP research, 
where it was found to be important in virulence, neutrophil recruitment and dissemination of 
infection. Indeed, reduced immunopathology caused by reduced neutrophil recruitment 
explains both of these contradictory results. Other work using bacterial strains which express 
higher levels of SpyCEP have found that SpyCEP expression enhances infection, especially 
when experimental challenge was given by an intramuscular route to mimic NF type invasive 
infections (Edwards, et al. 2005, Hidalgo-Grass, et al. 2006, Kurupati, et al. 2010, Turner, et 
al. 2009a). Such effects on virulence are manifested as differences in bacterial loads both 
locally at the infection site, and systemically throughout the mouse. 
A difference in virulence and neutrophil recruitment between SpyCEP-positive and 
negative strains could be observed as early as three hours post infection in a thigh muscle 
SpyCEP interferes with the neutrophil response against Group A Streptococcus 
64 
 
infection model (Kurupati, et al. 2010). This demonstrates the importance of neutrophils in 
the early response to GAS infections. These differences in virulence were seen throughout 
early infection to 24 hours, with higher bacterial loads and increased mortality being 
observed when SpyCEP was produced (Kurupati, et al. 2010). Other researchers have not 
found such clear phenotypes for SpyCEP knock-out strains. However, these groups have used 
different measures of infection burden, and have used strains which are less prodigious 
expressers of SpyCEP, resulting in a less apparent phenotype (Sjolinder, et al. 2008, Sumby, 
et al. 2008). 
SpyCEP, like many virulence factors of GAS is regulated by CovR/S. It was found 
that ablation of either component of CovR/S led to a 100-fold increase in SpyCEP expression 
in particular strains (Turner, et al. 2009a). CovR/S mutations are associated with invasive 
disease (Cole, et al. 2010, Sumby, et al. 2006, Walker, et al. 2007), however this cannot be 
directly ascribed to increased SpyCEP expression, due to the multitude of virulence factors 
similarly regulated to SpyCEP by CovR/S.  
Research into SpyCEP is hindered by the array of GAS virulence factors which 
impact on neutrophil function, including SpeB, M protein, EndoS, IdeS, SIC, capsule, C5a 
peptidase, SLS, SLO and Sda1, many of which are regulated also by CovR/S, meaning that 
GAS has considerable redundancy in evading these cells. This redundancy masks results 
made using knock-out mutations of any one of these virulence factors. To avoid these 
problems, gain of function Lactococcus lactis strains have been constructed and used as 
model organisms, mimicking GAS, but lacking their own virulence factors. Indeed L. lactis 
expresses very few extracellular proteins of its own, preventing any confounding 
observations (Bolotin, et al. 2001, Poquet, et al. 1998, van Asseldonk, et al. 1990). Such 
experiments have demonstrated the important role of SpyCEP (Kurupati, et al. 2010, 
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Zinkernagel, et al. 2008), as well as M protein (Rezcallah, et al. 2005), SLS (Nizet, et al. 
2000) and SLO (Timmer, et al. 2009). The L. lactis strain expressing SpyCEP was found to 
be highly virulent, compared to the completely avirulent wild type L. lactis (Kurupati, et al. 
2010).  
Like C5a peptidase, a structurally similar, large extracellular protease, SpyCEP has 
been investigated as a potential vaccine candidate. It is well conserved between strains, and 
antibodies specific for SpyCEP have been found in the sera of convalescent GAS patients 
(Fritzer, et al. 2010). Using a recombinant fragment of the N terminus of SpyCEP, 
vaccination was found to be protective against systemic spread of GAS following 
intramuscular infection in mice. Furthermore, protection was also raised against 
Streptococcus equi which express a highly homologous protease to SpyCEP (Rodriguez-
Ortega, et al. 2006, Turner, et al. 2009b).  
 NETosis is the final means by which neutrophils kill bacteria, expelling their 
chromosomal DNA studded with antibacterial proteins (Brinkmann, et al. 2004). NETs are 
known to be induced upon incubation of neutrophils with CXCL8. It was found by 
visualising NETs and inhibiting the activity of Sda1, that SpyCEP-negative strains induced 
significantly more NETs than the SpyCEP-positive wild type strains. This was confirmed to 
be of potential significance for virulence, reducing killing of bacteria by purified neutrophils 
(Zinkernagel, et al. 2008). 
 These effects on virulence stem from the ability of SpyCEP to cleave neutrophil 
specific chemokines. Migration is impaired, as by cleaving chemokines the means by which 
neutrophils extravasate and migrate to infection sites are ablated (Amulic, et al. 2012, 
Edwards, et al. 2005). Indeed, it is known that cleaved chemokines have no functional 
activity (Edwards, et al. 2005, Sumby et al. 2008 Zinkernagel et al. 2008), and have been 
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shown to be unable to bind their receptors phamacokinetically (Goldblatt, personal 
communication). Effects on NETosis are due to reduced activation of neutrophils caused by 
lack of chemokine signalling. Interestingly, no other neutrophil behaviours which are known 
to involve chemokines, such as release from the bone marrow, or other functions, such as 
neutrophil phagocytosis, have been reported to be impacted by SpyCEP  
 
1.4.5 Related peptidases 
 
SpyCEP orthologues can be found in variety of pathogenic Streptococci, but have 
generally been studied in less detail than SpyCEP itself (Table 1-1). Their conservation 
between species indicates that they play important roles in bacterial growth and survival, and 
furthermore may represent attractive vaccine targets with cross-species coverage (Cleary, et 
al. 2004, Turner, et al. 2009b). These putative proteases are well conserved around the 
protease domain itself, but with more variation in the C terminal half of the protein, where 
substrate specificity is speculated to be determined. 
  
Streptococcus pyogenes 
The C5a peptidase of GAS is also a large surface bound protease, with 35% identity 
with SpyCEP. Its role in virulence, and its conservation in S. agalactiae have been discussed 
previously.  
 
Streptococcus pneumoniae 
 S. pneumoniae is a major cause of bacterial pneumonia (van der Poll and Opal 2009). 
This important pathogen expresses an orthologue of SpyCEP with 29% identity to SpyCEP, 
SpyCEP interferes with the neutrophil response against Group A Streptococcus 
67 
 
PrtA. PrtA mutants have been shown to be less virulent in the mouse model of infection, but 
further to this, little is known about the protein, and indeed its substrate specificity is 
unknown. (Bethe, et al. 2001).  
 
Streptococcus agalactiae 
 S. agalactiae is an opportunistic pathogen, of particular concern to neonates, being a 
cause of neonatal meningitis (Johri, et al. 2006). It produces a C5a peptidase, known as ScpB, 
which although sharing homology with SpyCEP, is a closer orthologue to the C5a peptidase 
of GAS. However, this protein has been reported to have degrading activity against some 
chemokines and fibrinogen (Bryan and Shelver 2009). A 1233aa protein of S. agalactiae has 
not been the subject of any study. This “SagCEP” has 34% identity to SpyCEP. A further 
protein, CspA, is described to be of importance to virulence through degradation of 
fibrinogen (Harris, et al. 2003) 
 
Streptococcus gordonii 
 S. gordonii is an oral streptococcus, which is typically an avirulent commensal, 
although has been associated with cardiac disease (Petersen, et al. 2010). It produces two 
proteases, SGO0316 and SGO0317, with identity to SpyCEP, but which have not been 
annotated or studied. Proteases expressed by S. gordonii have been reported to play a role in 
competition with other oral bacteria (Wang, et al. 2010).  
 
Streptococcus uberis 
 S. uberis expresses two proteins with homology to SpyCEP. Its C5a peptidase shares 
31% identity with SpyCEP, and a hypothetical protease with 28% homology with SpyCEP. 
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The majority of the homology is concentrated in the protease-like domains, however there is 
considerable difference in the C termini of the proteins, where functions have been less 
clearly defined. Both these putative peptidases express sortase motifs and are hence predicted 
to be cell envelope proteases as SpyCEP. They however have been studied to determine their 
role in virulence (Ward, et al. 2009). 
 
Streptococcus equi 
SeCEP, expressed by S. equi has been studied due to its extensive homology to 
SpyCEP, and indeed has been shown to cleave human CXCL8, along with its equine 
orthologue. Work also found that vaccination against SpyCEP conferred protection against S. 
equi infection in the mouse model due to cross-reactivity of antibody (Turner, et al. 2009b). 
However, its role in the virulence of S. equi is unknown.  
 
Protease Species Activity Identity to 
SpyCEP 
SeCEP S. equi Cleaves equine and human IL-8 (Turner, et al. 
2009b) 
63% 
SGO0316 S. gordonii Unknown 35% 
SGO0317 S. gordonii Unknown 36% 
PrtA S. 
pneumoniae 
Important for virulence, unknown (Bethe, et 
al. 2001) 
29% 
CspA S. agalactiae Cleaves fibrinogen, CXC chemokines (Bryan 
and Shelver 2009) 
39% 
1233aa S. agalactiae Unknown 34% 
Table 1-1 – Table showing SpyCEP orthologues 
SpyCEP orthologues have been found in related pathogenic species of Streptococcus using in 
silico analysis. Their known activity and identity to SpyCEP are shown 
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1.5 Hypothesis and Project Aims 
Chemokines are known to have an important role in neutrophil function. We hypothesise 
that SpyCEP, by cleaving all neutrophil specific chemokines, ablates neutrophil function in 
response to bacterial infection throughout their lifespan. Specifically, we will: 
 
 Confirm that SpyCEP cleaves all neutrophil specific chemokines 
 Examine if SpyCEP orthologues have similar substrate ranges 
 Determine the sections of the neutrophil life cycle that SpyCEP disrupts 
specifically: 
o Release from the bone marrow 
o Activation and phagocytosis 
 Confirm the mechanism responsible for any effects of SpyCEP 
 Determine structural requirements for SpyCEP to mediate these effects 
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Chapter 2 - Methods 
2.1 Bacterial strains 
Strain Species Characteristics Source 
H292 GAS 
Clinical strain, from patient with necrotizing fasciitis. 
Described in Turner et al. 2009 as a high SpyCEP 
producer  
Clinical 
isolate 
H575 GAS 
Isogenic mutant of H292. cepA is disrupted by single 
cross-over recombination using a plasmid homologous to 
an N-terminal region of the gene. 
Kurupati et 
al. 2010 
H887 GAS 
Isogenic mutant of H292. The sortase motif at the C 
terminus of SpyCEP has been disrupted by single cross-
over recombination using a plasmid homologous to the 
sortase motif. 
This study 
H486 L. lactis Wild type strain, containing an empty pDEST vector. 
Zinkernagel 
et al. 2008 
H487 L. lactis 
Isogenic strain of H486, containing the pDEST plasmid 
allowing the constitutive expression of SpyCEP, and 
conferring erythromycin resistance. 
Zinkernagel 
et al. 2008 
Table 2-1 – List of strains used in this study. 
 
2.2 Growth of bacterial strains 
GAS and L. lactis were grown at 37
o
C in an atmosphere of 5% CO2. GAS was grown on 
Todd-Hewitt (TH) media (Oxoid, UK), solidified with 1.5% agar (Oxoid, UK). Columbia 
blood agar plates (CBA) (Oxoid, UK) were also used where haemolysis was required as a 
means to identify GAS, especially when using the murine model. In all cases, the strains 
(Table 2-1) were grown o/n. GAS was also grown in liquid TH media as required o/n. L. 
lactis strains were grown on TH media identically to GAS. However, the media was 
supplemented with 5μg/ml of erythromycin lactobionate to maintain plasmids. The strains 
were also grown in liquid TH media with 5μg/ml erythromycin supplementation as required. 
Where E. coli strains were used for cloning purposes, the strains were grown on Luria-
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Bertani (LB) media, solidified where required with 1.5% agar. The media was supplemented 
with antibiotics as required, and described in more detail in the relevant chapters. 
 
2.3 Genomic DNA Preparation (Pospiech and Neumann 1995) 
50ml of the required strain was grown o/n in TH media and centrifuged for 10 minutes at 
2500xg. The supernatant was removed, and the pellet was resuspended in 1ml of phosphate 
buffered saline (PBS) (NaCl 137mM, KCl 2.7mM, Na2HPO4.2H2O 10mM, KH2PO4 
1.76mM). Cell walls were degraded with 20μl of 10000U/ml mutanolysin (Sigma Aldrich, 
UK) and 20μl of 100mg/ml lysozyme (Sigma Aldrich, UK) incubated at 37oC for 30 minutes. 
The subsequent protoplasts were then centrifuged at 200xg for 10 minutes. The resultant 
pellet was resuspended in 500μl SET buffer, 50μl 10% SDS and 5μl of proteinase K (at 
50mg/ml) (Sigma Aldrich, UK), and incubated at 55
o
C for 2 hours, to disrupt the membranes 
and degrade proteins. To this, 500μl of chloroform and 175μl of 5M NaCl were added and 
incubated at 25
o
C for 30 minutes. The resultant mixture was centrifuged at 13000xg for 15 
minutes, and the aqueous phase collected; the organic phase containing the degraded lipid 
membrane, and a precipitate resolving at the interface of the layers containing proteins made 
insoluble at the high salt concentration. To the aqueous phase (approximately 500µl), 500μl 
of isopropanol was added to precipitate the DNA, and centrifuged at 16000xg for 30 minutes 
to pellet the DNA. This pellet was washed with 70% ethanol (another apolar solvent) at 
16000xg for 10 minutes, and then allowed to air dry. The DNA was resuspended in 200μl of 
dH2O, and diluted 1 in 10 prior to polymerase chain reaction (PCR). Undiluted sample 
typically had a DNA concentration of 50-100ng/μl when assessed by Nanodrop spectroscopy 
(Thermo Scientific, USA). 
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2.4 Plasmid preparation 
Plasmid DNA was extracted from glycerol stocks (500µl stationary phase bacterial culture 
mixed with 500µl 50% glycerol) of Gram negative bacteria using a QIAPrep Spin Miniprep 
Kit (Qiagen, Germany) as per manufacturer’s instructions. Briefly, 10ml of bacterial culture 
grown o/n was centrifuged and the pellet retained. This was resuspended in resuspension 
buffer then mixed with a lysis buffer. The mix was neutralised with a neutralisation buffer, 
causing the precipitation of the chromosomal DNA, proteins and lipids. This was centrifuged 
to pellet this insoluble material, and the supernatant containing the plasmid was retained. This 
was then passed over a charged silica membrane to bind the plasmid DNA, and was 
subsequently washed to remove any contaminants. The plasmid DNA was eluted into dH2O, 
which due to its polarity, is able to disrupt the interactions between the DNA and the 
membrane. 
 
2.5 Polymerase chain reaction (PCR) and subsequent purification 
PCR for cloning reactions was done using Phusion DNA polymerase (New England Biolabs, 
USA). The components, including 1μM of specific primers were diluted and mixed according 
to manufacturer’s instructions, with 1μl of appropriate genomic DNA diluted 1 in 10 in 
ddH2O. Cycling conditions were: 98
o
C 60 seconds; 30 cycles of 98
o
C 15 seconds, (3
o
C + the 
lower melting temperature of the two primers) 30 seconds, 72
o
C 30 seconds per kilobase of 
target amplicon; 72
o
C 10 minutes. Products were assessed by agarose gel electrophoresis, 
using gels made with TAE buffer (40mM Tris, 1mM EDTA pH8), solidified with 1% agarose 
and containing 1x SYBR Safe DNA gel stain (Invitrogen, USA). Prior to loading, samples 
were mixed with 6x loading dye, made with 30% glycerol, and dyes bromophenol blue and 
xylene cyanol FF (Sigma Aldrich, USA). Where required, DNA bands were purified from 
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agarose gels using QIAquick PCR Purification Kit (Qiagen, Germany) according to 
manufacturer’s instructions. Briefly, bands were visualised under low power UV illumination, 
then excised using a clean scalpel blade. The resultant gel chips were dissolved in three 
volumes of a colour indicator buffer (Buffer QG) at 50
o
C. The buffer is optimised to allow 
binding of the linear DNA product to supplied silica membrane columns. After binding the 
DNA, these columns were washed repeatedly to remove any contaminating nucleotides, 
enzymes, salts and agarose. The DNA was eluted using water which disrupts the polar 
interactions between the membrane and the DNA. Products were also purified as required 
using a QIAquick PCR Purification Kit (Qiagen, Germany) according to the manufacturer’s 
instructions. This protocol is similar in principle to the previously described gel extraction 
protocol, using silica membrane columns and various wash steps to remove any contaminants 
before elution into dH2O. The identity of the PCR products were confirmed by sequencing. 
Sequencing was carried out by the MRC CSC Genomics Core Laboratory using a 3730xl 
DNA Analyser (Applied Biosystems, USA). 
 
2.6 Cloning of PCR products 
Purified plasmids or products with restriction enzyme sites added following the PCR reaction 
were digested according to the manufacturer’s protocol using appropriate, high fidelity, 
restriction enzymes (New England Biolabs, USA). Briefly, the reaction mixtures consisted of 
2µl enzyme appropriate buffer, 1µl enzyme and 7µl PCR product (in ddH2O) and 10µl 
ddH2O. These were incubated at 37
o
C for 2 hours. Following digestion, the samples were 
purified using a QIAquick PCR purification kit (described earlier), and DNA concentration 
measured using Nanodrop spectroscopy (Thermo Scientific, USA). If the subsequent ligation 
reaction was non-directional, the vector was dephoshorylated using Antarctic phosphatase 
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(New England Biolabs, USA) to reduce self-ligation. Ligation reactions were performed 
using Quick Ligase (New England Biolabs, USA). 1µl enzyme buffer, 1µl enzyme and 8µl 
DNA at a molar ratio of 3 inserts to 1 vector were mixed gently and incubated at room 
temperature for 1 hour. 1μl was taken and used to directly transform One Shot TOP10 
Chemically Competent Cells (Invitrogen, USA). The DNA was incubated with the cells for 
30 minutes at 0
o
C, before being transferred to a 42
o
C water bath for 30 seconds. The cells 
were then immediately cooled on ice and incubated with 200μl SOC media (Invitrogen, USA) 
for 1 hour at 37
oC. 100μl of the bacteria growing in SOC media was then spread onto LB 
agar plates supplemented with kanamycin 50µg/ml. 
 
2.7 Construction of pSortase 
pUCMut, a pUC19-based plasmid which lacks a Gram positive origin of replication and 
confers kanamycin resistance instead of ampicillin resistance was used as a vector to disrupt 
the LPXTG sortase motif of SpyCEP by single cross-over recombination. Sequence 
representing the C terminal 549bp of the SpyCEP gene with a premature stop codon upstream 
of the LPXTG motif was amplified using the primers RL0124 with a sequence GG GAATTC 
TGTTGT CAGGTAACAGTCTTATCTTGCC and RL0125 CC GAATTC ACAACA CTA 
GGCTTTTGCTGAGGTCGTTG. Underlined sequence indicates EcoRI sites introduced via 
PCR to allow insertion into pUCMut, and bold text indicates the introduced stop codon which 
is not found in the chromosomal template of cepA. The resultant amplicon was cloned into 
pUCMut, and the assembled plasmid was then transformed into GAS strain H292 and 
transformants were selected by kanamycin resistance. Mutants were further characterised by 
sequencing using primers which flank the mutagenised region to ensure replacement of the 
sortase coding region with a stop codon.  
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Figure 2-1 – Schematic of pSortase recombination 
Diagram showing construction of strain H887 by disrupting SpyCEP sortase motif of H292. 
Green line indicates plasmid backbone. 
2.8 Electroporation of GAS 
A liquid TH media culture of the required GAS strain was grown o/n to stationary phase, 
with an optical density measured at a wavelength of 600nm (OD600) of approximately 1.0, 
before being subcultured at a one in ten dilution into fresh TH media. This was grown to 
early logarithmic growth, with an OD600 of between 0.15 and 0.175. The bacteria were then 
harvested by centrifugation at 3500xg for 10 minutes at 4
o
C. The supernatant was carefully 
and completely removed, before the cells were washed twice in ice cold electroporation 
media (1mM MgCl2 pH 6.5; 272mM glucose) at 3500xg for 10 minutes at 4
o
C. The 
supernatant was then removed, and the cells were resuspended in 750μl of fresh ice cold 
electroporation media. Electrocompetent GAS were prepared freshly prior to any 
electroporation. 75μl of the electrocompetent GAS were incubated with 5μl of plasmid DNA 
(at a concentration of 200-300ng/ml in ddH2O) on ice; the concentration of plasmid DNA 
was sufficient such that at least 1μg of plasmid DNA was included in the electroporation 
GAS chromosome 
Plasmid 
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reaction. The cell DNA mix was transferred to a pre-chilled 1mm electrocuvette, before being 
electroporated at 1kV, 129Ω, 50μF. Time constants of between 3 and 4.5 milliseconds were 
expected. Immediately after electroporation, 1ml of freshly made TH media, enriched with 1% 
yeast extract (Oxoid, UK) (THY) was added, before later addition of  THY to a final volume 
of 10ml. The bacteria were incubated at 37
o
C for 3 hours to allow recovery. The cells were 
then centrifuged and resuspended in 500μl of fresh THY media. 100μl was spread onto THY 
plates containing erythromycin at a concentration of 2μg/ml. Included in all electroporation 
reactions was a control reaction using the plasmid pDL278. This plasmid confers resistance 
to spectinomycin, and is known to be efficiently uptaken by electrocompetent GAS. This was 
included to allow determination of electroporation efficiency. For such reactions, the same 
protocol was followed, however the strain was finally plated on media containing 50μg/ml 
spectinomycin. 
 
2.9 Bacterial growth curves 
Bacterial cultures were grown o/n in TH media with antibiotic where required to retain 
plasmids. The bacterial cultures were diluted in triplicate 1 in 20 into fresh TH media to give 
a final culture volume of 50ml, without antibiotic, and grown at 37
o
C. Every 60 minutes, a 
1ml sample was removed, and the OD600 was measured. 
 
2.10 Lancefield antigen test 
Bacterial cultures of either GAS or L. lactis were grown o/n in TH media supplemented with 
appropriate antibiotic as required. A control culture was grown where required without 
antibiotic to ensure that remaining antibiotic had no negative impact on the ability or not of 
blood to kill bacteria. The cultures were sub-cultured at a 1 in 10 dilution into fresh TH media 
SpyCEP interferes with the neutrophil response against Group A Streptococcus 
77 
 
lacking antibiotic and allowed to reach early logarithmic phase growth (OD600 0.15-0.175). 
These were diluted in tissue culture grade sterile PBS (Invitrogen, USA) such that GAS 
strains were at approximately 10
3
CFU/ml, and L. lactis at 10
4
CFU/ml. The precise starting 
inoculum of each strain was determined by plating the inoculum on CBA plates. 100µl of the 
inocula were mixed separately with freshly extracted heparinised whole blood, using 
approximately 30 CFU per 270μl of blood per reaction. Samples were incubated at 37oC with 
rotation for up to 3 hours, with a sample of 50µl taken every 1 hour and plated onto CBA 
plates. Colonies from all plates were counted, allowing calculation of multiplication indices: 
 
(Colonies obtained at time point x 20) / No Inocula colonies 
 
Data points were obtained from experimental triplicates, and are representative of results 
obtained using 3 donors.  
 
2.11 Enzyme Linked Immunosorbant Assays (ELISAs) 
All chemokine ELISA reactions performed were carried using kits bought from 
manufacturers, and manufacturer’s instructions were followed. Reactions performed were 
primarily used to measure rates of chemokine cleavage, but also to measure cytokine 
concentrations in murine infection models. Sample preparation and specific kits are discussed 
in further details in specific methods sections of results chapters. Briefly, high binding 96-
well plates pre-incubated with specific antibody to the desired substrates were blocked with a 
bovine serum albumin (BSA) blocking buffer. Following washing each well three times using 
PBS containing 0.05% Tween 20, 100µl of samples together with controls and a standard of 
known concentrations provided by the manufacturer and diluted accordingly was added and 
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incubated for up to two hours to allow binding to the primary antibody. The samples were 
initially diluted 1 in 10 using the same dilution buffer as the standard for a pilot experiment. 
Adjustments were made to the dilution of the samples such that their concentrations fell 
within the standard curve following completion of the pilot experiment. After incubating with 
the primary antibody, samples were removed and after a further three washes using PBS + 
0.05% Tween 20, a secondary antibody was added. An enzymatic peroxidase component was 
introduced, either covalently bound to the secondary antibody, or by adding a further reagent 
with specific binding against the secondary antibody. 50µl of colourimetric substrate of the 
enzyme was added and allowed to react before the reaction was stopped using 50µl 3M 
H2SO4. Protein concentration relative to a series of standards was measured by determining 
light absorbance at 450nm. 
ELISA was also carried out to measure SpyCEP levels in bacterial supernatants. Here, 
bacteria cultures were grown overnight and their supernatants were collected by 
centrifugation at 2500xg for 10 minutes. The supernatant was filter-sterilised using a 0.2µm 
filter. The reagents used for this ELISA were developed and are described in Turner et al. 
2009. Briefly, an ELISA plate was coated with 100µl of 0.4µg/ml of unlabelled anti-SpyCEP 
antiserum, diluted in PBS, for two hours, before washing the plate three times using PBS + 
0.05% Tween 20. To the washed plate, 100µl of the prepared supernatants, diluted one in ten 
with PBS, were added, and allowed to bind to the antibody for 2 hours. These were again 
washed, before adding 100µl of biotin labelled anti-SpyCEP antibody at 20µg/ml in PBS to 
detect SpyCEP. 50µl of streptavidin conjugated to peroxidase was used as the enzymatic 
component. 50µl of colourimetric substrate of the enzyme was added and allowed to react 
before the reaction was stopped using 50µl 3M H2SO4. Protein concentration relative to a 
series of standards was measured by determining light absorbance at 450nm. The standards 
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used for this ELISA was recombinant N-terminal fragment of SpyCEP in PBS, with a 
maximum concentration of 2000pg/ml and a minimum concentration of 31.25pg/ml.  
 
2.12 Chemokine cleavage rate calculation ELISA 
An ELISA based method was used to measure chemokine cleavage rate. The kits used are 
shown in Table 2-2. 
Kit Chemokine Manufacturer 
Human GRO/MGSA Mini ELISA Development Kit CXCL1 Peprotech (UK) 
Human Groβ Mini ELISA Development Kit CXCL2 Peprotech 
DuoSet ELISA Development System CXCL5/ENA-78 CXCL5 R&D Systems (UK) 
DuoSet ELISA Development System CXCL6/GCP2 CXCL6 R&D Systems 
DuoSet ELISA Development System CXCL7/NAP-2 CXCL7 R&D Systems 
Human IL-8 Mini ELISA Development Kit CXCL8 Peprotech 
Human CXCL16 Mini ELISA Development Kit CXCL16 Peprotech 
Table 2-2 – ELISA Kits used 
 
No ELISA kit was available for CXCL3, hence this was not measured. CXCL16 was 
included as a control known not to be cleaved by SpyCEP. 
 
The 1ml reaction mix for ELISA consisted of: 20μl of neat filtered bacterial culture 
supernatant (Chapter 2) or 20μl washed bacterial cells in PBS at OD600 0.5 for GAS 
(measured at a final concentration of 3.66-5.32x10
6
 CFU/ml), 1μl of specified recombinant 
chemokine (starting concentration 1ng/μl) (Peprotech, UK), 100μl BSA (22mg/ml), 10μl of 
specific cysteine protease inhibitor E64 (100μg/μl) (Invitrogen, USA) and 869μl of TH media. 
At 1, 2 and 24 hour time points, 75μl of sample was collected, 3μl of a specific serine 
protease inhibitor, Pefabloc (1μg/μl) (Invitrogen, USA) was added and the sample was placed 
on ice to stop the enzymatic reaction. When the samples were prepared for ELISA, 225μl of 
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fresh TH media was added, and the samples were plated on ELISA plates (Chapter 2) in three 
100μl replicates. 
In all rate reactions, controls were included which used H575, the ΔcepA isogenic 
GAS strain to allow determination of the specific contribution of SpyCEP to chemokine 
cleavage. The concentration of remaining chemokine was calculated at the time points 
measured by comparison with the included standard. The difference in chemokine 
concentration between the SpyCEP-positive and negative samples was calculated and this 
value used as the SpyCEP specific contribution to chemokine degradation. The rate was 
calculated from this number by, where applicable, standardising CFU to 10
6
 CFU/ml, and 
standardising the measured concentrations of chemokine to a starting value 1ng/ml using 
control wells containing a known 1ng/ml of chemokine alone.  Controls were also included 
which included the individual components of the reaction mix alone and mixed with 
chemokine. 
 
2.13 Cleavage assay of substrates by SpyCEP 
Cleavage assays were carried out using supernatants from 16 hour cultures or whole live cells. 
Supernatants were prepared by centrifugation of 5ml TH bacterial cultures at 2500xg for 10 
minutes at 4
o
C. These supernatants were then passed through a 0.2μm filter (VWR, UK) and 
the filtrate collected. The supernatant was split into aliquots, and immediately stored at -20
o
C. 
The cell pellets obtained were washed twice in PBS at 16000xg for 30 seconds and 
resuspended in 1ml of PBS.  
Recombinant chemokines used for this assay were purchased from Peprotech, UK, 
and reconstituted at 100ng/μl in dH2O. 5μl of chemokine was mixed with 20μl of supernatant, 
or 2μl of cells (comprising approximately 105 CFU per sample) with 18μl of fresh TH media, 
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or 20μl of fresh TH media as negative control. The TH was added to the cell reactions to 
block the surface of the reaction tubes to which the chemokines were found to stick very 
readily. The assembled reactions were incubated at 37
o
C o/n. Before being examined by 
LDS-PAGE analysis (see below), the samples were centrifuged at 16000xg for 30 seconds to 
collect any condensed sample in the tube lid, and to pellet the cells, and 20μl of supernatant 
was collected. 
Other cleavage reactions involved using 5μl of protein extracted from activated 
neutrophils, 500ng murine G-CSF (Peprotech, UK), 500ng of recombinant human fibrinogen 
(Peprotech, UK) or 500ng recombinant human fibronectin 
 
2.14 LDS-PAGE of cleavage reaction samples 
20μl of the cleavage reaction sample was mixed with 3.5μl of LDS sample loading buffer 
(Invitrogen, USA) and 1.5μl of 1M DTT (Sigma Aldrich, USA). The samples were heated to 
80
o
C to help disrupt secondary structures within the protein sample before being loaded 
alongside 5μl of SeeBlue Plus 2 Prestained Standard (Invitrogen, UK) onto NuPAGE Novex 
12% Bis-Tris gels (Invitrogen, USA). The gels was run in 1x 2- (N-morpholino) 
ethanesulfonic acid running buffer (Invitrogen, USA) supplemented with 0.5% v/v 
antioxidant (Invitrogen, USA) for 35 minutes at 200V constant voltage. The gels were 
removed and stained using NOVEX Colloidal Blue Staining Kit (Invitrogen) overnight, 
before being destained with water. Fibronectin was too large to be used in method. The 
protocol used was similar, but instead used 3-8% Tris Acetate Gels (Invitrogen, USA), and 
band weight was judged compared to HiMark Pre-Stained Protein Standard (Invitrogen, USA) 
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2.15 Immunoblotting  
Protein gels were run according to the above protocol. However, rather than staining, the 
proteins were transferred using a wet transfer method to Hybond LFP membrane (GE 
Healthcare Life Sciences, UK) for 60 minutes using 100V at 4
o
C. The membranes were 
blocked with PBS supplemented with 5% w/v Marvel skim milk powder and 0.05% v/v 
Tween 20 (Sigma Aldrich, UK) if horseradish peroxidise (HRP) conjugated secondary 
antibodies were to be used, or with PBS supplemented with 1% BSA (Sigma Aldrich, UK) 
and 0.05% Tween 20 for 1 hour if streptavidin HRP was to be used in lieu of secondary 
antibody when probing with biotinylated primary antibody. Following blocking, primary 
antibodies were added at concentrations optimised from an initial dilution of 1 in 5000 and 
incubated overnight at 4
o
C with rocking. The membrane was washed three times with 
washing buffer (0.05% Tween 20 in PBS). HRP-conjugated secondary antibody (Invitrogen, 
USA) in Marvel skim milk powder blocking buffer was added at a dilution of 1 in 80000 or 
HRP conjugated streptavidin (R&D Systems, UK) was added at a dilution of 1 in 200 in BSA 
blocking solution. In both methods, secondary antibody or streptavidin was incubated for 1 
hour at room temperature with rocking. After repeated washing, the membrane was 
developed using Amersham ECL Western Blotting Detection Kit (GE Healthcare Life 
Sciences, UK), and bands visualised using Hyperfilm ECL (VWR, USA). Where cell wall 
extracts were required for immunoblotting, the method described in Cole et al. 2008 was 
followed, where bacterial culture was washed 3 times at 16000xg in PBS, before being 
treated with mutanolysin and N-acetylmuraminadase as described. 
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2.16 Ethics Statement 
All animals were handled in strict accordance with good animal practice as defined by the 
UK Home Office, and all animal work was approved by the local ethics committee. 
 
Blood samples from healthy consenting volunteers were obtained through a sub collection  of 
the Imperial College Healthcare NHS Trust Tissue Bank. The Tissue Bank is funded by the 
National Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial 
College Healthcare NHS Trust and Imperial College London and is compliant with the 
Human Tissues Act. 
 
2.17 Extraction of human serum 
Blood was taken into additive free polyethylene terephthalate tubes (BD Vacutainer), and 
blood was allowed to clot at room temperature for 30 minutes. The blood was then 
centrifuged at 1000xg for 10 minutes. The serum layer was collected ensuring the cell pellet 
was not disturbed. The serum was immediately transferred to ice, and was used on the day of 
extraction. Immediately prior to use, the serum was passed through a 0.2μm filter to remove 
any clumped proteins. 
 
2.18 Neutrophil extraction from whole blood  
Blood was collected into polyethylene terephthalate tubes containing sodium heparin (BD 
Vacutainer). The extracted blood was mixed with an equal volume of 3% w/v dextran 
Mw>100000Da (Fluka, Canada) in 0.9% NaCl (VWR, USA) solution to encourage 
erythrocyte rouleaux formation and thus their sedimentation. The blood and dextran solution 
was allowed to sediment for at least 30 minutes, until a clear interface between layers 
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developed. The yellow top layer consisting of serum and leukocytes was centrifuged at 250xg 
for 5 minutes, and the subsequent cell pellet was resuspended in an equal volume of 0.9% 
NaCl, before being layered onto an equal volume of Ficoll Hypaque. This was centrifuged at 
700xg for 30 minutes at 20
o
C with no brake. The pellet formed contained granulocytes and 
erythrocytes was resuspended in an equal volume of ice cold hypotonic 0.2% NaCl, to lyse 
the erythrocytes, for 30 seconds. The solution made isotonic with addition of ice cold 
hypertonic 1.6% NaCl, and the resultant was centrifuged to collect intact granulocytes. The 
process was repeated, and the cells were quantified using an Improved Neubauer 
Haemocytometer, and kept on ice until required for a maximum of 1 hour. The cells were 
judged to be at least 90% neutrophils by examination of morphology following Giemsa stain.    
 
2.19 Monocyte extraction from whole blood 
Blood was collected into polyethylene terephthalate tubes containing sodium heparin. The 
extracted blood was mixed with an equal volume of Hanks buffered saline solution (HBSS) 
(Sigma Aldrich, UK), before 30ml was layered onto 20ml Ficoll Hypaque Plus (VWR, USA). 
This was centrifuged at 700xg for 30 minutes at 20
o
C with no brake, and the buffy coat layer 
containing predominantly B and T lymphocytes and monocytes was collected with a sterile 
Pasteur pipette. The cells were diluted at least two fold with HBSS, and pelleted by 
centrifugation at 250xg for five minutes. The cells were resuspended in 1ml of pre-heated 
Roswell Park Memorial Institute (RPMI) media, supplemented with 200μM L-glutamine 
(Invitrogen, USA). The cells were then adjusted to a concentration of 2x10
6
 cells/ml with 
further pre-heated glutamine supplemented RPMI, and transferred to sufficient vented tissue 
culture flasks (i.e. 25ml per 75cm
2
 flask) to allow the monocytes to adhere for 1 hour at 37
o
C, 
5% CO2, ~95% humidity. Following incubation, the non-adherent cells were discarded, and 
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the cells were rinsed three times with further fresh HBSS to dislodge any loosely adhered 
cells. 5ml of fresh HBSS was added to each flask, and the adherent cells were detached from 
the flask surface using a cell scraper. The subsequent cell suspension was centrifuged at 
250xg for 5 minutes, and resuspended in fresh HBSS. The cells were quantified using an 
Improved Neubauer Haemocytometer. The cells were judged to be at least 50% monocytes 
by analysis of forward and side scatter using a FACSCalibur (BD, USA).   
 
2.20 HL60 propagation and differentiation (Collins, et al. 1979) 
HL60 cells are a granulocyte cell line which have been used in the investigation of 
neutrophils (Collins et al. 1979). The HL60 cell line used in this study was a kind gift from 
Dr P. Elkington. Cells were grown in RPMI media supplemented with 10% foetal calf serum 
(FCS), glutamine and 1% tissue culture penicillin/streptomycin (all Invitrogen, USA) at 37
o
C, 
5% CO2, ~95% humidity. Cell stocks were maintained by regular dilution of existing cultures 
into pre-warmed fresh media. When cells were required for experimentation, cells were 
diluted 1 in 25 into fresh media, supplemented with 1.3% dimethyl sulphoxide (DMSO) 
Hybri-Max (Sigma Aldrich, UK) and were grown for 72 hours to allow their differentiation 
into neutrophil-like cells. Following this differentiation, the cells were collected by 
centrifugation at 250xg for 5 minutes. The cells were then washed repeatedly at 250xg for 5 
minutes in fresh tissue culture PBS to ensure all antibiotic was removed from the cells. The 
cells were quantified using an Improved Neubauer Haemocytometer and were stored on ice 
until required for a maximum of 1 hour.  
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2.21 Staining bacteria with fluorescein isothiocyanate (FITC) 
A 5ml culture of a strain listed in Table 2-1 was grown o/n and the bacteria collected by 
centrifugation at 2500xg for 10 minutes at 4
oC. The pellet was resuspended in 500μl of pH9.0 
carbonate/bicarbonate buffer containing 20μg/ml FITC (Sigma Aldrich, USA), and was 
incubated with shaking protected from light for 30 minutes to allow the FITC to make non-
specific interactions to primary amines. Following incubation, the cells were washed twice at 
16000xg for 30 seconds in tissue culture PBS (Sigma Aldrich) to remove any unbound FITC. 
The cells were then diluted to an OD600 of 0.35 with further PBS, and stored on ice, protected 
from light until required, for a maximum of one hour. 
 
2.22 Flow cytometric phagocytosis assay (Bjerknes and Bassoe 1983) 
To assess the phagocytosis of bacteria by purified cells, 500μl FITC-stained cells at OD600 of 
0.35 were mixed with 1000μl of PBS and 1000μl of opsonin source (fresh human serum, 
specifically depleted human serum or IVIg at manufacturer’s suggested dilution) and 
incubated at 37
o
C with shaking protected from light for 15 minutes. Following incubation, 
2500μl of freshly extracted cells at a concentration of 2x106 cells/ml were added. 
Immediately after addition of cells, a sample was removed and run through a FACS Calibur 
flow cytometer, pre-calibrated using Calibrite 3 Beads (both BD, USA). The specific cell 
type being investigated was gated based on their morphology assessed by forward and side 
scatter. The gated cells were assessed for green fluorescence by excitation at 488nm and 
absorbance at 515-545nm. 20000 gated events were counted. Immediately following 
completion of the run, an equal volume of 0.4% v/v trypan blue (Invitrogen, USA) was added 
to quench extracellular fluorescence to exclude cells with adherent rather than internalised 
bacteria (Bjerknes and Bassoe 1984). Analysis was later performed using FloJo analysis 
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software. Gating to define cells positive for green fluorescence was done independently 
during each experiment, due to varying autofluorescence of different donor cells. Fortunately, 
positive and negative cells were clearly distinguishable due to the brightness of the bacteria. 
Later were experiments were performed where exogenous reagents were added. These were 
added by reducing volume of PBS included in the reaction mixture, including 10% v/v 
supernatant from bacterial growth, or exogenous chemokine diluted in PBS. 
The addition of cells to the opsonised bacterial strains was staggered to ensure that 
multiple bacterial strains could be compared at the same time points using the same 
preparation of donor cells. Following addition of the cells to the bacteria, samples were taken 
every 15 minutes for 60 minutes. At all time points, immediately following completion of the 
sample, trypan blue was added to quench extracellular fluorescence. A neutrophil or 
monocyte only control was included at all time points to correct for autofluorescence. All 
experiments were repeated in three independent donors. 
 
2.23 Mouse model of neutrophil release from bone marrow 
5 or 6 female CD1 8 to 10 week mice were used per infection group. Bacterial strains were 
grown o/n in TH media containing appropriate antibiotic to maintain plasmids. Strains were 
washed three times in PBS at 16000xg for 30 seconds to remove any residual antibiotic and 
were then resuspended in sterile PBS (Invitrogen, USA) at an OD600 of 20 for GAS strains 
and 2 for L. lactis strains. 50μl, containing 108 CFU, was injected intramuscularly into the 
thigh without anaesthesia. Alternative experiments were carried out where 50μl of 
recombinant murine chemokine KC (10ng/μl) was administered intramuscularly into the 
thigh without anaesthesia. In all cases, a control group of six mice were used which were 
sham infected with 50μl of sterile PBS. At three and six hours post-infection, the mice of 
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each group were separately and briefly warmed before blood was taken using a tail bleed 
technique using a clean scalpel blade. The blood was collected and immediately mixed with 
sodium heparin. At 24 hours, the mice were euthanized using a rising concentration of CO2 
and blood was collected via immediate cardiac puncture. This was again transferred to 
sodium heparin. When using bacterial strains, the infected thigh was dissected, weighed and 
the tissue homogenised using sterile scissors in 5μl/mg of sterile PBS, to allow quantification 
of bacterial load by plating onto CBA plates.  
 
2.24 Isolation and quantification of murine neutrophils 
20μl of the freshly collected murine blood was mixed with 50μl of 3% w/v dextran 
Mw>100000Da (Fluka, Canada) in 0.9% NaCl (VWR, UK) solution to encourage 
erythrocyte rouleaux formation and thus their sedimentation. The mix was allowed to 
sediment for at least 30 minutes, until a clear interface between layers developed. 2μl of the 
upper layer was collected and used to quantify total cells using an Improved Neubauer 
Haemocytometer. Very small cells and cells which had taken up trypan blue (Invitrogen, 
USA) were excluded. A further 18μl was mixed with 30μl of PBS and 1μl of Purified Rat 
Anti-Mouse CD16/CD32 (Mouse Fc Block) Clone 2.42G2 (BD Pharmingen, USA) to 
prevent non-specific antibody binding by Fc receptors for 10 minutes on ice. Following this, 
1μl of PE conjugated Rat Anti-Mouse Ly6G (BD Pharmingen, USA)(Wengner, et al. 2008) 
to stain neutrophils was added or an appropriate isotype control (BD Pharmingen, USA) and 
then incubated on ice for 30 minutes protected from light. Following incubation, the cells 
were washed three times in tissue culture grade PBS at 1000xg for 3 minutes, before being 
resuspended in a further 500μl of PBS. 
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Following staining, the cells were run through a FACSCalibur, pre-calibrated using 
Calibrite 3 Beads (BD, USA). Cells were initially sorted by forward and side scatter to 
exclude remaining erythrocytes and debris. The remaining cells were analysed using the FL2 
channel (excitation 488nm, emission 564-606nm) to measure the surface levels of CD11b 
(Ly6G). Neutrophils are CD11b bright, monocytes CD11b dim and lymphocytes CD11b 
negative, hence the proportion of bright cells was calculated using FloJo software. This was 
combined with data from total cell counts to allow calculation of total neutrophil circulation. 
 
2.25 Luminex assay to cytokine concentration 
6 female CD1 mice aged 8 to 10 weeks were used per infection group. Strains were grown 
o/n in TH media containing appropriate antibiotic to preserve plasmids. Strains were washed 
three times in PBS to remove any residual antibiotic and were then prepared in tissue culture 
sterile PBS (Invitrogen, USA) at an OD600 of 20 for GAS strains and 2 for L. lactis strains. In 
all cases 50μl, containing approximately 108 CFU was injected intramuscularly into the thigh 
without anaesthesia. A control group of six mice were used which were sham infected with 
50μl of sterile tissue culture PBS. At 6 hours, the mice were euthanized using a rising 
concentration of CO2 and blood was collected via immediate cardiac puncture and allowed to 
clot for 30 minutes. The infected thigh was dissected and the tissue homogenised in 5μl/mg 
of tissue culture grade PBS, to allow quantification of bacterial load by plating onto CBA 
plates. Furthermore, the draining superficial inguinal lymph node and spleen were also 
dissected; the lymph node was homogenised in 200μl of PBS, and the spleen in 10μl/mg of 
PBS before being plated. 
The clotted blood was centrifuged at 16000xg for 30 minutes. The serum layer was 
collected, transferred into aliquots and stored at -20
oC. 50μl of each of these samples was 
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analysed using a Mouse Cytokine 20plex Panel (Invitrogen, USA) following the 
manufacturer’s protocol. Briefly, a mix of beads conjugated to antibodies against the 20 
cytokines of the panel was added to a membrane base 96 well plate. To these, the samples - 
or a serially diluted standard mix of each of the 20 cytokines - were added and incubated with 
the beads for 2 hours to allow binding. The residual sample was removed under a vacuum, 
leaving the substrates attached to the beads. A mix of secondary antibodies against the 20 
cytokines, each with unique fluorescent conjugates, was then added, and allowed to bind the 
substrates. The binding levels of each secondary antibody were measured using a Luminex 
platform Bio-Plex 200 system (Bio-Rad, UK). Bio-Plex manager software (version 5.0) was 
used to construct standard curves and calculate unknowns by comparison with the standard 
curves. 
 
2.26 Confocal microscopy of phagocytosis of GAS by neutrophils 
GAS strains were grown o/n in 5ml of TH media, and were then washed twice at 16000xg for 
30 seconds in tissue culture PBS (Invitrogen, USA). The bacteria were resuspended in 500μl 
of PBS supplemented with 1% w/v BSA (Sigma Aldrich, USA) and 0.2% w/v FITC 
conjugated rabbit polyclonal antibody against Streptococcus group A antigen (Abcam, UK) 
or an isotype control. Following incubation for 30 minutes at 4
o
C protected from light, the 
bacteria were washed three times in PBS followed by centrifugation at 16000xg for 30 
seconds, before being finally resuspended at an OD600 of 7.0 in PBS supplemented with 1% 
w/v BSA. The bacteria were opsonised in an equal volume of fresh whole human serum as 
previously described. Following opsonisation, 50μl of the fluorescent bacteria was mixed 
with 50μl of freshly extracted human neutrophils at a final concentration of 2x107 
neutrophils/ml.  
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Immediately after mixing, 10μl of bacteria and cells were spotted onto a glass 
microscope slide and were visualised using a confocal microscope under bright field and a 
488nm laser to visualise green fluorescence.  
 
2.27 Depletion of serum of opsonin 
Complement was depleted from serum by heating to 56
o
C for 30 minutes, before being 
immediately cooled on ice (Morgan 2000). To the serum, two volumes of tissue culture grade 
PBS were added to mimic the dilution during depletion of antibody. To deplete antibody 
from serum, 1ml of serum was diluted with 1ml of tissue culture grade PBS. The serum was 
passed over a Nab Protein A/G Spin Column (Thermo Scientific, USA) three times to bind 
the IgG. A further 1ml of PBS was added to the column to wash any unbound serum off the 
column. Where serum was to be depleted of both complement and serum, serum was first 
depleted of antibody, before being heat inactivated. In all cases the serum was diluted in two 
volumes of tissue culture grade PBS either through the protocol, or prior to use. For 
experiments using complement or antibody depleted serum, the opsonisation protocol was 
modified slightly from the general protocol described earlier. Rather than using 500μl of 
bacteria mixed with 1000μl of PBS and 1000μl of serum, 500μl of bacteria were mixed with 
2000μl of depleted serum.  
 
2.28 Measuring opsonisation of bacteria 
Bacteria grown o/n in TH media were washed in PBS and collected by centrifugation at 
16000xg for 30 seconds and resuspended in PBS at an OD600 of 0.35. 50μl of bacteria were 
mixed with 100μl of PBS and 100μl of freshly extracted whole serum, and incubated with 
shaking for 15 minutes at 37
o
C (to mimic the opsonisation protocol used for the flow 
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cytometric phagocytosis assay). Following incubation, the bacterial cells were washed three 
times in PBS and collected by centrifugation at 16000xg for 30 seconds, before being 
resuspended in 100μl of PBS supplemented with 1% BSA and placed on ice. To these, 1μl of 
Purified Rat Anti-Mouse CD16/CD32 (Mouse Fc Block) (BD, USA) was added as a source 
of non-specific non-staining antibody to reduce effects of antibody degradation by GAS. 
0.5μl of each conjugated antibody or appropriate isotype controls were also added to measure 
deposition of opsonins: Goat anti human IgG FITC (Invitrogen, USA) conjugate was used to 
measure antibody deposition, and PE conjugated Anti-human complement C3b mouse 
monoclonal antibody (Thermo Scientific, Canada) to measure C3b deposition. This was 
incubated on ice, protected from light for 30 minutes. The bacteria were then washed three 
times in PBS and collected by centrifugation at 16000xg for 30 seconds, before being 
resuspended in 500μl of PBS. The samples were stored on ice before being analysed using a 
FACSCalibur flow cytometer (BD, USA), pre-calibrated using Calibrite 3 Beads (BD, USA). 
Compensation was performed using singly stained samples. 20000 bacterial events were 
measured, and the median fluorescence intensity of both green and red fluorescence was 
measured using FL1 and FL2 channels, using FloJo software for subsequent analysis. 
Experiments were repeated in triplicate using three independent serum donors. 
 
2.29 Antibody staining of neutrophils 
Neutrophils and bacteria were prepared as previously although with unlabelled bacteria. 
Following thirty minutes of incubation of bacteria with cells at 37
oC, 100μl was removed and 
immediately placed on ice. To this 1μl of relevant conjugated antibody was added, or isotype 
control, and incubated on ice protected from light for 30 minutes with occasional mixing. The 
antibodies used in the study were anti-Human CD11b (Mac-1) FITC conjugate (Invitrogen, 
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USA) and anti-Human IL-8/FITC (eBiosciences, UK). After incubation, the cells were 
washed three times at 1000xg for 3 minutes to remove unbound antibody. Cells were 
resuspended in 500μl of tissue culture grade PBS and stored on ice until analysed using a 
FACSCalibur flow cytometer (BD, USA), pre-calibrated using Calibrite 3 Beads (BD, USA). 
Cells were initially positively gated on the basis of their morphology, as judged by forward 
and side scatter. 20000 of these cells were counted and the median fluorescence intensity of 
green fluorescence was measured in comparison to isotype controls. Data were later analysed 
using FloJo software. Experiments were repeated in triplicate using independent neutrophil 
donors. Further experiments were performed using recombinant human chemokines CXCL5, 
8 and 10 (Peprotech, UK) before measuring the surface levels of CD11b. For this, 50μl of 
freshly extracted neutrophils at a concentration of 2x10
6
 were mixed with chemokine serially 
diluted in 50μl of tissue culture grade PBS (Invitrogen, USA) and incubated at 37oC for 15 
minutes, before being placed on ice. Staining and subsequent flow cytometric analysis was 
identical to that described above.  
 
2.30 Isolation of neutrophil proteins 
Freshly extracted neutrophils at a concentration of 3x10
7
 cells/ml were lysed in 1ml of lysis 
buffer (150mM NaCl (VWR, USA), 1% Triton X-100 (Sigma Aldrich, USA), and 50mM 
Tris (VWR, USA) pH8). It was found that without the addition of a broad range of small 
molecule protease inhibitors, no CD11b could be isolated, thus Calbiochem protease inhibitor 
cocktail III (Novagen, USA) was included at 10% v/v of final volume (Edwards et al. 2005). 
However, protease inhibitor cocktail III includes serine protease inhibitors, at a sufficient 
concentration to inhibit SpyCEP activity, hence the lysate was passed through a Amicon 
Ultra 10kDa protein column (Millipore, USA) to remove the protease inhibitors.   
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2.31 Preparation of a chemokine receptor antagonist 
Chemokine receptor CXCR2 antagonist PD0220245 99% (Axon Medchem, Netherlands) was 
reconstituted at 107μg/ml in dH2O, twenty times the IC50 of CXCL8 binding to CXCR1 (Li, 
et al. 2003) as a ten times concentrated stock. The antagonist was used for experiments 
measuring phagocytosis of FITC labelled bacteria and in bacterial growth curves. For 
phagocytosis assays the antagonist was added at 1 times working concentration (10.7μg/ml) 
to the neutrophils for 15 minutes at 37
o
C prior to the addition of the opsonised bacteria. For 
growth curve work, the antagonist was added at 0.5, 1 and 2 times working concentration 90 
minutes subsequent to the initial sub-culturing step. Growth curve experiments with the 
antagonist were repeated in triplicate.   
 
2.32 Expression of recombinant CEP5 protein 
Turner et al. 2009 expressed an N terminal fragment of the cepA gene, CEP5, which proved 
able to effectively vaccinate mice against GAS infection. The pET100 plasmid used in this 
work, which expresses CEP5 with a 6xHis tag under the control of an IPTG inducible 
promoter, was extracted and transformed into BL21 expression E. coli cells (Invitrogen, USA) 
using standard transformation protocol. These cells were transferred into fresh liquid LB 
media immediately after recovery in SOC media (Invitrogen, USA) and grown overnight 
with ampicillin supplementation to maintain the plasmid. After 16 hours of growth at 37
o
C 
with shaking, the bacteria were subcultured at a 1 in 20 dilution into fresh LB media 
containing antibiotic. After the bacteria had reached an OD600 of 0.5-0.8, further antibiotic 
was added with 1mM of IPTG to induce expression. After three hours, the bacteria were 
harvested by centrifugation at 2500xg for 10 minutes. The bacterial pellet was lysed using 
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3ml of BugBuster Protein Extraction Reagent (Novagen, USA) per 50ml of original bacterial 
culture, with vigorous shaking for 20 minutes. The resultant lysate was centrifuged at 
16000xg for 20 minutes to pellet any insoluble debris and the supernatant was applied to a 
pre-charged nickel resin column. The column was prepared using a Novagen Histag Kit 
(Novagen, USA) following manufacturer’s instructions. Briefly, per gravity flow column, 
2ml of a slurry of nickel ion resin was washed with 3ml of dH2O, 5ml of a charge buffer, then 
3ml of binding buffer to optimise the binding of the His tag to the Ni resin. 3ml of bacterial 
lysate was applied to each column twice, before a further 10ml of binding buffer was added 
to enhance the histidine-nickel interactions. The column was then washed with 12ml of wash 
buffer before the CEP5 was eluted in elution buffer. The elutate was immediately mixed with 
an excess of PBS to prevent degradation of the protein in the elution buffer. The protein was 
dialysed and concentrated by repeated centrifugation and PBS buffer replacement using 
Amicon Ultra 10kDa protein columns (Millipore, USA). The protein was concentrated to 
2mg/ml in tissue culture grade PBS. 
 
2.33 Vaccination model 
4-6 week old Balb/C mice were used (Turner, et al. 2009b). One group of 15 received the full 
vaccination protocol, and 15 mice received a sham vaccination protocol, with the aim of 
challenging mice in each group with either H292 or H887. The full vaccination protocol used 
25μl of 2mg/ml (50μg) CEP5 protein in sterile PBS that was thoroughly mixed with 25μl of 
Freund's Complete (first prime vaccination) or Incomplete (second and third boost 
vaccination) adjuvant (Turner, et al. 2009b). The first prime vaccination was given at day 0 
of the experiment. At day 14 and 21, boost vaccinations were given. The sham vaccinees 
underwent the same procedures, but were injected with PBS + adjuvant rather than 
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recombinant protein. In all cases, vaccination was intramuscular into the thigh tissue, 
alternating between thighs throughout the protocol. At day 24, tail bleeds were obtained from 
3 mice in each group (Chapter 4), allowed to clot for 30 minutes, and then centrifuged at 
16000xg for 20 minutes. Collected serum was used to confirm immunity using a dot blot 
method. On day 28, mice were challenged with GAS strains (washed three times in tissue 
culture grade PBS) at an OD600 of 20. 50μl, containing approximately 10
8
 CFU was injected 
intramuscularly into the thigh without anaesthesia. Six mice received H292, six received 
H887 and three a sham PBS infection. At twenty four hours post-infection, the mice were 
euthanized using a rising concentration of CO2 and blood was collected via immediate cardiac 
puncture. This was transferred to sodium heparin. The infected thigh was dissected and the 
tissue homogenised in 5μl/mg of tissue culture grade PBS, to allow quantification of bacterial 
load by plating on CBA plates. Furthermore, the draining inguinal lymph node, spleen and 
liver were also dissected; the lymph node was homogenised in 200μl of PBS, and the spleen 
and liver in 10μl/mg of PBS before being plated. The blood was also plated. 
 
2.34 Statistical analysis 
Any statistical analysis was performed using GraphPad Prism 5. All data sets were non-
parametric; where two groups were compared, Mann-Whitney tests were performed. For 
comparison between more than 2 groups, a Kruskal Wallis test (non-parametric one way 
ANOVA) was performed. P values of less than 0.05 were considered statistically significant, 
and is labelled throughout this work with *, P values of less than 0.01 are indicated by **, 
and less than 0.001 indicated *** 
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Chapter 3 - Results: Substrate specificity and kinetics of SpyCEP 
and its orthologues 
 
3.1 Introduction 
Previous work on SpyCEP has investigated its substrate range and role in GAS 
virulence. The first substrates discovered were human CXCL8, and its murine orthologues 
MIP-2 and KC (Edwards, et al. 2005). These were implicated due to clinical observations 
that neutrophils were scarce at infection foci during necrotizing fasciitis. Chemokines play a 
vital role in the early immune response, activating and attracting anti-microbial neutrophils to 
the site of infection. Other neutrophil chemoattractants were subsequently found to also be 
substrates of SpyCEP. CXCL1, CXCL6 (Sumby, et al. 2008) and CXCL2 (Kurupati, et al. 
2010) were next discovered. Whilst these chemokines include many of the neutrophil specific 
chemokines, they do not include many other chemokine ligands that bind either chemokine 
receptor expressed by the neutrophil (Table 3-1). A major aim of this chapter was to explore 
the substrate range of SpyCEP with particular regard for the chemokines cleaved and rate of 
cleavage.  
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Systematic 
name 
Functional 
name 
ELR 
motif 
Responsive cell type 
Known receptor 
specificity 
CXCL1 GROα + Neutrophil CXCR1>CXCR2 
CXCL2 GROβ + Neutrophil CXCR2 
CXCL3 GROγ + Neutrophil CXCR2 
CXCL4 PF-4 - Fibroblast unknown 
CXCL5 ENA-78 + Neutrophil CXCR2 
CXCL6 GCP-2 + Neutrophil CXCR1, CXCR2 
CXCL7 NAP-2 + Neutrophil CXCR1, CXCR2 
CXCL8 IL-8 + Neutrophil CXCR1, CXCR2 
CXCL9 MIG - natural killer cell CXCR3 
CXCL10 IP-10 - 
natural killer cell; 
macrophage 
CXCR3 
Table 3-1- List showing CXC1-10 chemokines  
Adapted from (Pease 2011) 
Subsequent to the commencement of this study, recombinant SpyCEP was expressed, 
and used to determine that, CXCL3, 5, 7 and also to a limited extent CXCL10 could be 
cleaved by SpyCEP (Zingaretti, et al. 2010) in addition to the previously determined 
substrates. With the exception of CXCL10, this forms a more rational list of substrates, 
including all chemokines able to bind CXCR1 and/or 2, offering an explanation of specificity. 
CXCL10 has been shown to be directly antibacterial towards GAS, hence this apparent cross-
reactivity may be beneficial for GAS (Egesten, et al. 2007). Importantly, SpyCEP-cleaved 
substrates were identified in those studies using the recombinant protein only, and human 
substrates cleaved by native SpyCEP were unknown except for CXCL8, CXCL1, CXCL2 
and CXCL6 at the start of this project (Edwards, et al. 2005, Hidalgo-Grass, et al. 2006, 
Sumby, et al. 2008). 
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3.2 Results 
3.2.1 Substrate range of SpyCEP 
 
To investigate the substrate range of SpyCEP, two strains of GAS were used, H292, a 
high SpyCEP producing clinical isolate, and H575, an isogenic cepA mutant of H292. The 
expression of SpyCEP by H292, and its ablation in H575 were confirmed using 
immunoblotting with an antibody raised against the N-terminus of SpyCEP (Results not 
shown but have been repeated previously (Kurupati, et al. 2010)). To ensure that the role of 
SpyCEP was not to allow the maturation of an alternative protease exported via the ExPortal, 
SpeB levels of an equal volume of H292 and H575 supernatants were measured using 
immunoblotting. SpeB has previously been used as a marker for external protein maturation 
(Cole, et al. 2007). Supernatant was taken from both strains of GAS grown in liquid media at 
various growth phases: mid-logarithmic, late-logarithmic and stationary (overnight growth). 
In each case, the amount of SpeB was identical between H292 and H575, showing that 
SpyCEP ablation did not affect the function of the ExPortal (Figure 3-1). 
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Figure 3-1– Immunoblotting of isogenic bacterial supernatants against SpeB 
Supernatant of bacterial cultures were collected at specified stages of growth, subject to LDS-
PAGE and transferred to hydrophobic membrane, before being probed using anti-SpeB mAb.  
SpeB is known to be expressed in stationary phase. o/n overnight culture 
The known substrate range of SpyCEP has expanded from the originally described 
activity against CXCL8 to include some of the other CXC chemokines (Edwards, et al. 2005, 
Kurupati, et al. 2010). This list does not include all the ELR+ chemokines, nor does it include 
all those chemokines which bind CXCR1 and 2. A list of such chemokines is shown in Table 
3-1. Linear polypeptides representing sequences flanking the CXCL8 cleavage site are not 
cleaved by SpyCEP (Kurupati, unpublished data). As no common primary or secondary 
structural features have been found in common between the known substrates of SpyCEP, the 
structural basis for substrate specificity remains unknown. To determine the wider substrate 
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range of SpyCEP, all known CXCL chemokines were incubated with the both supernatant 
and washed whole cells from H292 and H575, and the samples analysed by gel 
electrophoresis. 
 When incubated with supernatant from wild type GAS H292 o/n, CXCL1, 2, 3 and 8 
were cleaved, as evidenced by a clearly defined reduction in the apparent molecular weight 
compared to untreated chemokine (Figure 3-2). Similar work examining SpeB cleavage of 
chemokines showed chemokines incubated with SpeB completely disappeared from protein 
gels, indicative of the non-specific mode of action of SpeB (Egesten, et al. 2009). Such 
activity was not observed using these strains. The band of reduced size appears to 
demonstrate that one discrete cleavage reaction had taken place. CXCL5 and CXCL6 
underwent partial cleavage by SpyCEP, evidenced by two bands, one at the same molecular 
weight as the native chemokine, one of a reduced molecular weight. These reductions in 
weight were not seen when incubated with the SpyCEP-negative GAS H575, showing that 
SpyCEP alone is responsible for this apparent cleavage (Figure 3-2). CXCL 4, 7, 9 and 10 
were not cleaved by either strain (Figure 3-2), nor were CXCL 11-16 (results not shown). 
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Figure 3-2 – Chemokine cleavage by GAS supernatant 
500ng of the chemokines CXCL1-10 (Table 3-1) were incubated with supernatant of either 
wild type GAS (H292) or an isogenic cepA mutant (H575). These were examined by protein 
electrophoresis and stained with colloidal blue.  
The same range of chemokines, when incubated with washed live cells of H292 or 
H575 o/n, revealed an extended substrate range compared with using supernatant alone. Once 
again, H575 was not able to cleave any chemokines, demonstrating all the cleavage effects 
seen were due to SpyCEP. In addition to those cleaved by supernatant, CXCL5, 6 and 7, and 
to a lesser extent CXCL10 were cleaved by H292 cells (Figure 3-3). Interestingly, CXCL5 
was cleaved yielding two bands, perhaps indicating two SpyCEP cleavage sites within this 
chemokine. The range found comprises the entire repertoire of CXC chemokines which bind 
to CXCR1 and/or 2 and contain the ELR motif, essential for neutrophil chemotaxis (Table 
3-1), along with CXCL10 at a low level. CXCL4 and 9 were not cleaved by SpyCEP. These 
chemokines neither bind CXCR1 or 2, nor have an ELR motif. These findings indicate that 
the probable substrate recognition sequence of SpyCEP is very similar to that of CXCR1/2. 
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Figure 3-3 - Chemokine cleavage by GAS cells 
500ng of the chemokines CXCL1-10 (Table 3-1) were incubated with 2μl of either washed 
wild type GAS cells (H292) or an isogenic cepA mutant (H575). These were examined by 
protein electrophoresis and stained with colloidal blue.  
In addition to these substrates, other proteins were tested to examine any further 
cleaving activity of SpyCEP. These included IL-1β, IL-6, complement protein C3, collagen, 
fibrinogen, fibronectin and RANTES (Results not shown). No evidence of any cleavage was 
found using this method.  This, along with previous work showing that the substrate range of 
SpyCEP is limited to the CXC chemokines indicates that the substrate range of SpyCEP 
includes all, but is restricted to, the ELR+ CXC neutrophil tropic chemokines (Edwards, et al. 
2005, Hidalgo-Grass, et al. 2006, Kurupati, et al. 2010, Sumby, et al. 2008). Subsequent to 
this work, full length SpyCEP was expressed recombinantly in E. coli and its substrate range 
was investigated (Zingaretti, et al. 2010). The substrate range in that study was identical to 
that found in this work, including the slight cleavage of CXCL10. The authors used the 
recombinant protein to investigate structural features of SpyCEP. As the recombinant protein 
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showed substrate range identical to SpyCEP expressed by GAS, we can be confident that the 
recombinant protein is highly similar to SpyCEP expressed by GAS. Thus we can have 
confidence that the structural conclusions drawn in this work are applicable to SpyCEP 
expressed by GAS.  
 L. lactis strains H486 and H487  have previously been used as a model organism for 
in vivo work to examine the effects of SpyCEP on virulence (Kurupati, et al. 2010). These 
strains contain a plasmid carrying the cepA gene (H487) with its native promoter and LPXTG 
sortase motif (pDESTcepA) (Zinkernagel, et al. 2008), or the empty plasmid (H486). 
Previous work using this strain has shown that SpyCEP is essential and sufficient for 
virulence in soft tissue infection (Kurupati, et al. 2010). 
 The expression of SpyCEP by the SpyCEP-positive L. lactis strain H487, and its 
absence from the SpyCEP-negative L. lactis strain H486 was confirmed using 
immunoblotting (Results not shown) (Zinkernagel, et al. 2008). These strains were 
investigated for their chemokine cleavage to further confirm that the effects observed were 
solely due to direct SpyCEP activity, rather than a combination of streptococcal proteases that 
are processed or activated by SpyCEP. They were further investigated to confirm that they 
were an appropriate model organism to use in subsequent studies. Supernatant of H486 and 
H487 was incubated with the entire repertoire of CXC chemokines o/n, and it was observed 
that the supernatant of H487 could cleave CXCL 1, 2, 3 and 8, whereas the H486 showed no 
such activity (Figure 3-4).  
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Figure 3-4 – Chemokine cleavage by L. lactis supernatant 
500ng of the chemokines CXCL1-10 (Table 3-1) were incubated with supernatant of either 
SpyCEP-negative L. lactis (H486) or SpyCEP-positive L. lactis (H487). These were 
examined by protein electrophoresis and stained with colloidal blue.  
The experiment was repeated using washed live cells. Here all the neutrophil tropic 
chemokines underwent some cleavage (Figure 3-5). CXCL10 was not cleaved by L. lactis, a 
difference compared to GAS, and once again, CXCL4 and 9 are not cleaved.  
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Figure 3-5 – Chemokine cleavage by L. lactis cells  
500ng of the chemokines CXCL1-10 (Table 3-1) were incubated with 2μl of either washed 
wild type L. lactis cells (H486) or containing pDESTcepA (H487). These were examined by 
SDS-PAGE and stained with colloidal blue.  
These data, when coupled to the results seen previously with GAS, confirmed that 
SpyCEP is responsible for the chemokine cleavage observed, and further demonstrate that the 
specificity of SpyCEP mirrors that of CXCR1/2. However, chemokine cleavage by L. lactis 
seemed less efficient than that by GAS. For instance, L. lactis cells were only able to partially 
cleave CXCL6, and intact chemokine seems to be the dominant form with CXCL5 and 
CXCL7, whereas these were all fully cleaved by GAS H292 cells. The expression level of 
SpyCEP by these strains was examined to ensure that these differences were simply due to 
differences in expression. Supernatants of H292, H575, H486 and H487 were examined by 
ELISA using antibody specific against the N terminus of SpyCEP (Figure 3-6). 
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Figure 3-6 – ELISA measuring SpyCEP in bacterial supernatants 
Supernatants collected after 16 hours of growth of each of the four strains were tested by 
ELISA to measure concentration of SpyCEP. Bars indicate the average of three separate 
wells. Data represents the mean of three separate experiments (+standard deviation). 
 As expected, GAS strain H292 expresses much more SpyCEP than H487, offering an 
explanation of the differences observed in substrate cleavage. SpyCEP is also detectable in 
the supernatant of H575. This is because H575 is able to make an N terminal fragment of 
SpyCEP which is detected by the antibody used in this ELISA. 
 
3.2.2 Rate of chemokine cleavage by SpyCEP 
 
The work of this chapter, coupled with work by other groups (Zingaretti, et al. 2010), 
demonstrated conclusively that SpyCEP cleaved all neutrophil specific CXCL chemokines, 
CXCL1, 2, 3, 5, 6, 7 and 8. However, the results of the protein gel electrophoresis suggested 
that SpyCEP was not able to cleave all chemokines equally efficiently. Several chemokines 
were only partially cleaved by bacterial supernatant, whereas others seemed to be fully 
SpyCEP interferes with the neutrophil response against Group A Streptococcus 
108 
 
cleaved. Work was hence undertaken to determine the cleavage rates by SpyCEP of these 
chemokines. The cleavage rate of CXCL8 has been calculated in previous work using 
bacterial supernatant incubated with chemokine for 24 hours. The rate of reaction of most 
chemical reactions is dependent on the concentration of substrate, unless the substrate is at 
very high, saturating, concentrations, thus as a reaction continues, its rate will vary. 
Measuring rate of reaction over a long duration will produce an average of a constantly 
changing reaction rate (Figure 3-7). However, the studies typically used to measure 
Michaelis-Menten constants using exceptionally short reaction times are not applicable for 
this work, as we cannot measure the emergence of the cleaved chemokine products.  
 
Figure 3-7 – Idealised rate of reaction curve 
As the concentration of substrate declines over time, the gradient (rate of reaction) decreases. 
Blue dotted line indicates average rate of reaction which is measured 
Edwards et al. used an ELISA based method to determine the cleavage rate of 
CXCL8. This method is limited in that we can only measure the loss of substrate rather than 
the emergence of product. Unfortunately, as we have no straightforward method to measure 
the emergence of the product, the ELISA based method was also used in this study using kits 
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which were readily available, for CXCL1, 2, 5, 6 and 8. ELISA kits for CXCL3 and 7 were 
not readily available.  
This method was dependent upon the specific antibodies in the ELISA kits being able 
to specifically bind only uncleaved recombinant chemokine, but not SpyCEP cleaved 
recombinant chemokine. Immunoblotting was hence carried out to confirm this using 
recombinant chemokine alone and chemokine treated with either H292 or H575 cells o/n. 
Chemokine alone and chemokine treated with SpyCEP-negative cells were detected by the 
specific antibodies as expected at the predicted full length molecular weight. Chemokine 
incubated with SpyCEP-positive cells either disappeared completely from the immunoblot, or 
appeared as a fainter band of identical molecular weight to uncleaved product, indicative that 
the cleavage reaction had not gone to completion. In all cases, no chemokine was detected at 
a lower molecular weight (Results not shown). These results show that the all the antibodies 
to be used in the ELISA kits are specific for uncleaved chemokine, and can thus be used to 
measure rate of reaction. 
The method used briefly comprised incubating 1ng/ml of recombinant chemokine 
with bacterial supernatant or washed cells for 1, 2 and 24 hours. The reaction was stopped 
using specific protease inhibitors and ice, based on previous studies (Edwards et al. 2005). 
The remaining chemokine concentration was measured using ELISA. The difference in the 
remaining chemokine between the SpyCEP-positive and negative strains was measured to 
allow a measure of SpyCEP specific activity. As the rate of enzymatic reaction is dependent 
on chemokine concentration, the shortest time point where chemokine concentration 
differences could be accurately measured for all substrates were used. Conversely, the 
ELISA-based method measures the loss of a substrate rather than the emergence of a product, 
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and as such, we had to wait for a sufficiently long time point so as to achieve a significant 
loss of the substrate to be detectable. 
 
3.2.2.1 Chemokine cleavage rates by GAS supernatants 
At 1 and 2 hour timepoints, no SpyCEP specific cleavage was detectable against any 
chemokines except CXCL8. However, by 24 hours, SpyCEP specific activity could be 
detected. Edwards, et al. also used a 24 hour timepoint to measure chemokine cleavage. The 
fastest rate of reaction was observed for SpyCEP cleaving CXCL8, with a rate of 1.5pg/hr/μl 
(Figure 3-8). This compared with 10pg/hr/μl over the first 8 hours of incubation reported in 
the previous work (Edwards, et al. 2005), indicating the method used in this study produced 
comparable results to those previously reported. CXCL6 was cleaved at a rate of 1.0pg/hr/μl, 
CXCL2 at 0.4pg/hr/μl and CXCL1 at 0.3ph/hr/μl. This result was somewhat unexpected, 
Figure 3-2 shows CXCL1 and CXCL2 being cleaved completely, whereas CXCL6 appeared 
only to be partially cleaved. More accordingly with Figure 3-2, CXCL5 had the slowest 
cleavage rate at 0.1pg/hr/μl. The rate of rate reaction measured closely mirrors the order of 
discovery of substrates. CXCL8, 1 and 2 were among the first discovered, whereas CXCL5 
was only found to be a substrate in this work and using recombinant SpyCEP (Zingaretti, et 
al. 2010). 
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Figure 3-8 – Chemokine cleavage rates by GAS supernatant 
GAS supernatants were incubated with 1ng/ml of chemokine for 24 hours, and the average 
rate of reaction was calculated. Error bars indicate standard deviation of three independent 
experiments. 
 
3.2.2.2 Chemokine cleavage rates by whole GAS cells 
Whole washed cells were next incubated with the recombinant chemokine. As the 
cells used in this method were alive, they were actively producing SpyCEP, so along with 
SpyCEP bound to the cell surface, soluble SpyCEP was also present at a rising concentration. 
Thus, this is a more accurate representation of bacteria in an infection site than measuring 
rate using supernatant. All chemokines were observed to have undergone measurable 
cleavage after just one hour, thus this was used to calculate rate. Whilst this means that the 
values obtained were a more accurate measure of rate of reaction when substrate 
concentration is 1ng/ml, the values cannot be directly compared to those for the bacterial 
supernatants. Trends however remain comparable. 
pg/hr/µl 
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The fastest cleavage rate using bacterial cells was again measured for CXCL8, at 
709pg/hr/10
6
CFU. CXCL2 was cleaved at a rate of 115pg/hr/10
6
CFU and CXCL1 at 
110pg/hr/10
6
CFU. CXCL6 was cleaved more slowly at rate of 50pg/hr/10
6
CFU, and CXCL5 
at 27pg/hr/10
6
CFU (Figure 3-9). This data matches better the chemokine cleavage data 
obtained using protein gel electrophoresis, whereby CXCL1, 2 and 8 were cleaved by 
SpyCEP containing supernatants and washed cell preparations, and CXCL5 and 6 were only 
cleaved partially. The CXCL16 negative control, known not to be a substrate of SpyCEP, 
showed no cleavage.  
 
Figure 3-9 – Chemokine cleavage rate by live GAS cells 
Live GAS cells were incubated with 1ng/ml of chemokine for 1 hour, and the average rate of 
reaction was calculated. Error bars indicate standard deviation of three independent 
experiments. 
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3.2.3 SpyCEP orthologues in species related to GAS 
 
 Previous work has identified various SpyCEP orthologues in related pathogenic 
streptococci which share secondary sequence homology (Turner, unpublished data; Table 
1-1). All the proteases examined have a very similar structure to SpyCEP, consisting of an N-
terminal signal sequence, a protease domain bisected by a PA (protease associated) domain, 
with a C-terminal sortase motif. Their homology is concentrated around the protease domain, 
with the greatest variation being in the C-terminal region of the protein.  
Supernatants of the related streptococcus S. pneumoniae were incubated with a variety 
of substrates including IL-1β, IL-6, C3, collagen and RANTES, as well as the CXCL 
chemokines, to determine if any cleavage was observed. However, the resultant gel 
electrophoresis analysis did not demonstrate cleavage of any CXCL chemokines, or the other 
substrates tested. Supernatant of S. pneumoniae was however able to cleave the α and β 
chains of fibrinogen, an observation that has not previously been observed, which we 
speculate may be attributable to the SpyCEP orthologue PrtA (Figure 3-10) (Hermans and 
McDonagh 1982). S. pneumoniae undergoes autolysis, leading to the release of cytosolic 
proteins into the supernatant, hence many putative enzymes may mediate the observed 
cleavage (Martner, et al. 2009). Although biochemical purification might allow identification 
of the responsible protease, the development of an L .lactis strain expressing PrtA would 
allow definitive identification of its substrates.  
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Figure 3-10 – Fibrinogen degradation by S. pneumoniae supernatant  
500ng of the fibrinogen was incubated with 7μl of either supernatant from overnight growth 
of either GAS (H292) or S. pneumoniae (H400). These were examined by SDS-PAGE and 
stained with colloidal blue.  
 
For many of the target Gram positive pathogens, genetic manipulation is very difficult 
and potential virulence implications of these proteases may be missed due to redundancy 
between virulence factors. The data above, coupled with previous work (Kurupati, et al. 2010, 
Zinkernagel, et al. 2008) demonstrate the advantages of L. lactis as a heterologous expression 
system for Gram positive proteases.  
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3.3 Discussion 
 
3.3.1 Substrate range of SpyCEP 
 
This section of the study examined the substrate range of SpyCEP and the rate at which 
SpyCEP was able to cleave these substrates. Previous work using GAS products reported an 
incomplete list of SpyCEP substrates and failed to provide a coherent description of the 
specificity of SpyCEP. Interestingly, work examining CspA of S. agalactiae identified a 
similar substrate range of the CXCL chemokines (Bryan and Shelver 2009). Here however, 
the protease was not limited to the neutrophil specific chemokines, cut the chemokines at 
many sites indicating poor site specificity, and failed to cleave CXCL8 at all. The authors 
could not offer explanations for these findings (Bryan and Shelver 2009).  
Work by Zingaretti et al. 2010 provided a more complete and logical substrate list, using 
a recombinant SpyCEP preparation, however these findings had not been repeated using a 
GAS strain. This work found an identical substrate range to that found by Zingaretti et al., 
including the low level cleavage of CXCL10 by GAS cells. This work hence validates the 
findings made using the recombinant enzyme. Furthermore, it provides the logical substrate 
list for SpyCEP; it cleaves all proteins that bind to chemokine receptors CXCR1 and CXCR2, 
and presumably its active site shares some structural homology with the binding domains of 
these receptors. Chemokines bind to their cognate receptors in a two-step process, firstly, 
binding GAGs with their C termini, before the N terminus binds to the receptor itself.  This 
two-step binding process provides an explanation as to why cleaving a small fragment from 
chemokine can prevent their ability to bind and trigger receptor signalling (Edwards et al. 
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2005, Zingaretti et al. 2008) – SpyCEP may interfere with the initial GAG interaction. By 
cleaving all chemokines which act on neutrophils (Table 3-1), we hypothesise that SpyCEP 
will have wide ranging activity on the function of neutrophils in an infection setting. 
It seemed likely that the variable substrate patterns found using the GAS and L. lactis 
supernatants and cells was due to varying concentrations of SpyCEP. This especially 
impacted on the results observed using poorly cleaved substrates, such as CXCL5. It was 
indeed found that GAS supernatants contained much more SpyCEP than those of the 
SpyCEP+ve L. lactis strain (Figure 3-6). Indeed, H292, the SpyCEP-positive GAS strain used 
in this work was originally highlighted due to its exceptionally high SpyCEP expression 
(Edwards, et al. 2005). If other groups examining substrate specificity have utilised a strain 
which expresses less SpyCEP, it would be expected that the apparently poorly cleaved 
substrates such as CXCL5 would be overlooked. Cell preparations did not have SpyCEP 
expression levels measured using ELISA, as ELISAs cannot be performed against cell bound 
proteins.   
It is unclear why SpyCEP-positive L. lactis strain H487 produces so much less soluble 
SpyCEP than wild type GAS H292. The mechanism by which SpyCEP is released from the 
surface of GAS is unclear. It is hypothesised to occur due to the sortase mechanism being too 
slow to catalyse reactions using all the SpyCEP produced. However, it may be that GAS 
actively releases SpyCEP from its surface using an enzyme not expressed by L. lactis. It is 
known that SpyCEP does not catalyse its own release from the GAS cell wall (Zingaretti, et 
al. 2010). 
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3.3.2 Rate of chemokine cleavage by SpyCEP 
 
The rate calculations made in this section further support the idea that the newly 
confirmed substrates of SpyCEP are those which are least efficiently cleaved by SpyCEP. 
The reason for this reduced rate of substrate cleavage may be caused by the ability of 
SpyCEP to bind the substrate, or its ability to release cleaved products. The rates of reaction 
found show that CXCL8 is the optimal substrate of SpyCEP with the fastest cleavage rate. A 
second group of substrates including CXCL1, 2 and 6 appear as a group with similar cleavage 
rates, cleaved more slowly than CXCL8, yet better substrates than CXCL5. This pattern 
matches the order of discovery of proteins as substrates of SpyCEP, CXCL8 was the first 
discovered, followed by CXCL1, 2 and 6, with CXCL5 only being found to be a substrate 
using recombinant SpyCEP or in this study using the live cells of a high SpyCEP producing 
strain.  
It is unfortunate that rate calculations could not be carried out using CXCL3 and 7. 
These have also not been previously observed as SpyCEP substrates using GAS products, 
hence it would be expected that their rate of reaction would be slow. CXCL7 remains only 
partially cleaved when incubated with GAS cells, so it would be expected that its cleavage 
rate would be even slower than that of CXCL5 (Figure 3-3). Such results would have further 
validated this method. 
The ELISA based method used to determine rates of reaction has been previously used 
by other groups (Edwards, et al. 2005), however does have limitations. The classical way to 
determine enzyme kinetics and rate constants has been to perform short time point 
experiments measuring the rate of emergence of product at various substrate concentrations. 
By using such short time points, the assumption that the concentration of substrate does not 
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change throughout the period measured can be safely made. Unfortunately, we did not have a 
method to measure the emergence of all the chemokine products, and thus had to measure the 
loss of substrate. Antibodies have been made against the C terminus of cleaved CXCL8, 
which only detect cleaved CXCL8. While this would be useful in future work, without 
similar such antibodies against the other cleaved products, fair comparisons cannot be made. 
This method, by definition, cannot assume constant concentration of substrate, and rate 
constants cannot be determined.  
The values obtained using this method are not constants, rather they are the rates of 
reaction observed when using a particular set of experimental conditions and a particular 
concentration of substrate. Although this limits their utility in predicting the cleavage rate 
when using different substrate concentrations, they do allow us to compare the individual 
substrates, as the experimental conditions did not change. The concentrations of each 
substrate were set at a concentration of 1ng/ml, rather than a fixed number of moles, in order 
to better fit the outputs made by the ELISA kits. However, due to the structural similarity 
between these substrates, including in their molecular weight, the effect on the rates 
calculated would be very small. 
The rates calculated demonstrated a very large discrepancy between the rates per μl of 
supernatant and per 10
6
CFU. This was caused by two separate effects. The values calculated 
for the supernatant were taken over 24 hours, and are hence an average of relative fast rates 
early in the time course and much slower rates later in the time course (Figure 3-7), whereas 
the values calculated using cells were over a one hour time course. The other factor 
influencing rate calculations is the difference in amount of SpyCEP in the reaction mixtures. 
An immunoblot was carried out loading the same amount of washed cells and supernatant as 
used in the rate reactions. The SpyCEP specific bands seen using the cell preparation were 
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much brighter than those seen using the supernatants, indicating there is indeed much more 
SpyCEP in the cell preparation (Results not shown). Thus, the two separate experiments 
cannot be compared. As the washed live cells were producing SpyCEP throughout the 
experiment, they more accurately mimic an infection setting of SpyCEP activity. 
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Chapter 4 - Results: Impact of SpyCEP in the very early phase of 
the neutrophil response to GAS infection  
 
4.1 Introduction 
Neutrophils are cells capable of delivering highly toxic compounds to infection sites 
with accuracy against the invading organism. Their potency against pathogens is such that 
they must be tightly regulated to prevent damage against tissue. Neutrophils are produced at 
high levels in the bone marrow, where they are stored until required to clear infection. It is 
estimated that in a healthy human, 98% of neutrophils are stored in the bone marrow (Amulic 
et al. 2012). They are retained in the bone marrow through a balance between CXCR4 and 
CXCR2 signalling (Figure 1-5). Furthermore, they have an extremely short half-life of six 
hours (Furze and Rankin 2008b), which some have suggested is to ensure that they maintain 
proper membrane integrity, preventing unwanted leakage of these antimicrobial toxic 
compounds from neutrophil granules (Amulic, et al. 2012). 
Work has shown that CXCL chemokines have a role in potentiating the release of 
neutrophils from the bone marrow as summarised in Figure 1-5. The CXCR2 signalling by 
CXCL chemokines acts to both inhibit CXCR4 signalling (which constitutively acts to hold 
neutrophils in the bone marrow), and to provide a gradient to leave the bone marrow. This 
balance between CXCR4 and CXCR2 signalling means that a small increase in CXCR2 
agonists gives rise to a large increase in circulating neutrophils (Furze and Rankin 2008b).  
Neutrophils are known to play a vital role in clearing GAS infections, Furthermore, 
patients with severe GAS infections are frequently neutrophil poor (Edwards, et al. 2005, 
Stevens, et al. 1989, Taylor, et al. 1999), further suggesting the importance of neutrophils in 
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preventing the establishment of severe infection. By cleaving these chemokines, SpyCEP 
provides a potential mechanism that explains the clinical observations frequently made by 
clinicians treating severe GAS infections. In this chapter, I sought to determine whether GAS 
infection could result in mobilisation of neutrophils from the bone marrow, and to investigate 
whether SpyCEP, a CXCR2 chemokine inactivator, might impede this process. 
 
  
  
SpyCEP interferes with the neutrophil response against Group A Streptococcus 
122 
 
4.2 Results 
4.2.1 SpyCEP expression impacts on circulating neutrophil levels 
 
To test this hypothesis, mice were injected intramuscularly with SpyCEP-positive and 
negative strains of GAS and L. lactis. At three, six and twenty four hours post infection, 
peripheral blood was taken from the mice, depleted of erythrocytes, and a total white cell 
count made. The cells were then stained using a fluorescently conjugated antibody against 
Ly6G, a highly expressed surface protein of murine neutrophils (Wengner, et al. 2008). The 
results following infection with L. lactis are shown in Figure 4-1. 
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Figure 4-1 – Peripheral neutrophil levels following L. lactis infection 
Five female CD1 mice were injected with 10
8
 CFU of H486 (wild type L. lactis – SpyCEP-
negative – pale blue), H487 (SpyCEP +ve L. lactis – dark blue) or sham infected with PBS 
(green). Mouse blood was collected by tail bleed at 3 and 6 hours and cardiac puncture at 24 
hours, and peripheral circulating neutrophils counted by flow cytometry. * = P<0.05 by Mann 
Whitney analysis. Time course plot shows medians alone.  
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At 24 hours post infection, the mice were euthanized and the infected thigh tissue was 
homogenised to allow determination of bacterial load. The results are shown in Figure 4-2.  
 
Figure 4-2 – L. lactis CFU recovered 24 hours post infection of thigh 
24 hours post infection, the mice were euthanized and thigh tissue was collected and 
homogenised. Colony forming units observed are shown. ** = P<0.01 by Mann Whitney. 
Lines indicate median ND: not detected (<200CFU/mg). 
 At three hours, peripheral circulating neutrophil levels in both challenged groups and 
the PBS group were similar. However at 6 hours, neutrophils counts increased in mice 
challenged with H486 SpyCEP-ve L. lactis, whereas H487 SpyCEP+ve L. lactis challenged 
mice had significantly fewer neutrophils. The results are consistent with SpyCEP having an 
impact on neutrophil levels in the peripheral blood. The PBS sham infected mice also had 
increased circulating neutrophils at 6 hours. This was probably due to the method of blood 
extraction, using a tail bleed method. This process performed at 3 hours would lead to an 
acute phase response itself, which was probably being detected at 6 hours. Later work was 
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performed measuring cytokine levels in mice at six hours which had not been subjected to tail 
bleeding. In the latter case, the sham infected mice had low levels of cytokines such as IL-6, a 
typical acute phase response indicator, compared to mice infected with bacteria (4.2.3. 
Cytokine levels in peripheral blood following infection).  
 At 24 hours, mice infected with SpyCEP-ve H486 had completely cleared their 
infection, whereas those infected with SpyCEP+ve H487 retained a substantial bacterial load 
at the infection site. This would suggest that the difference in neutrophil count seen at 6 hours 
is not due to a lower level of H487 infection compared to H486, and instead further indicates 
the importance of the neutrophil response in the clearance of bacterial infections.  
At 24 hours post infection, all groups showed low peripheral neutrophil counts. This 
may indicate the typical resting state of neutrophil counts in mice. However, the blood for 
this experiment was obtained using a cardiac puncture technique rather than tail bleed. As a 
result, care should be taken when comparing the results at 24 hours to those obtained at 3 and 
6 hours. L. lactis strains express no virulence factors of their own. We hypothesised that there 
would hence be a more striking phenotype difference between the strains, that any differences 
in peripheral neutrophil counts caused by SpyCEP expression would be more clearly 
displayed using L. lactis than the corresponding SpyCEP+/- GAS strains. However, the 
experiment was repeated using GAS, with results shown in Figure 4-3. 
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Figure 4-3 - Peripheral neutrophil levels following GAS infection 
Six female CD1 mice were injected with 10
8
 CFU of H292 (wild type GAS – SpyCEP-
positive – dark red) or H575 (SpyCEP -ve GAS – pink). Mouse blood was collected at 3,6 
and 24 hours, and peripheral circulating neutrophil counted. Time course plot shows medians 
alone. 
The results obtained at 3 and 6 hours post infection closely resembled those obtained 
using the L. lactis strains. At three hours post infection, both groups of mice demonstrated 
low levels of neutrophils, with little difference between the strains. At 6 hours post infection, 
mice infected with the SpyCEP-ve GAS strain appeared to mount a more substantial 
neutrophil response in the circulation compared with mice infected with wild type GAS, 
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however this difference was not statistically significant. This result was not unexpected; GAS 
produce an array of virulence factors, including factors such as streptolysin O which acts to 
lyse neutrophils (Timmer, et al. 2009), potentially masking any differences between the 
strains. The trend here however does seem to be maintained compared to L. lactis. 
At 24 hours, all infected mice infected with both strains showed an increased number 
of circulating neutrophils. As previously mentioned, the mode of blood extraction was 
changed between 6 and 24 hours, so comparisons between these time points must be made 
cautiously. It may be that the GAS, being much more virulent than L. lactis, elicits a more 
sustained innate immune response, which continues throughout the duration of the infection. 
Indeed, when thighs were homogenised at 24 hours, both strains exhibited an active infection, 
in contrast to L. lactis infected mice which cleared the infection. 
 
Figure 4-4 - GAS CFU recovered 24 hours post infection of thigh 
24 hours post infection, the mice in Figure 4-3 were euthanized and thigh tissue was collected 
and homogenised. Colony forming units observed are shown. Lines indicate median. 
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 This work measured peripheral blood neutrophil levels following infection, rather 
than directly measuring release from the bone marrow. It was assumed that these neutrophils 
have entered the circulation from the bone marrow, the sole known source of neutrophil 
reserve; however alternative sources of neutrophils were not excluded. 
 
4.2.2 Intramuscularly injected CXC chemokines increase circulating neutrophils  
 
Previous work where CXC chemokines have been definitively shown to be important 
in driving the emergence of neutrophils from the bone marrow used an infusion based method, 
whereby chemokines were administered into bone marrow and the output from the bone 
marrow could be measured (Martin, et al. 2003). A further method used intraperitoneal 
injection of chemokine into the mouse model, allowing subsequent collection of infiltrated 
cells, although this study therefore measured the additive effects of both neutrophil 
mobilisation and recruitment into the peritoneum (Wengner, et al. 2008). Whilst these 
methods are informative to our study of the role of SpyCEP in neutrophil release from the 
bone marrow, I wanted to determine whether chemokine released at a site of infection distant 
from the bone marrow was also able to induce increased neutrophil mobilisation into the 
circulation. This was important to confirm, as bacterial products have not been reported to 
affect neutrophil release in this way previously. I hypothesised that SpyCEP produced by 
GAS at the site of infection would cleave and inactivate chemokines at the site of infection 
and systemically. This would prevent chemokine translocation across the endothelial barriers 
both at the site of infection and in the bone marrow. To emulate this, chemokine was directly 
administered into the muscle without bacterial infection. 
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500ng of the murine CXCL8 functional orthologue KC was injected into the thigh 
muscle while a sham injection of PBS was administered to a control group. This chemokine 
and amount was chosen based on previous work examining neutrophil release by chemokines 
(Wengner, et al. 2008). In this experiment, significantly more neutrophils were detected in 
the peripheral blood of the mouse 3 hours post inoculation with KC compared to PBS. At 6 
and 24 hours, neutrophil counts between these groups were identical. The mice were weighed 
at the end of the experiment to ensure that the chemokine injection had not impacted on the 
general health of the mice and so confound these findings. Both groups were observed to 
have gained a small amount of weight over the course of the experiment (Figure 4-6).  
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Figure 4-5 - Peripheral neutrophil levels following chemokine KC injection 
Five female CD1 mice were injected with 500ng of chemokine KC (bright green) or sham 
injected with PBS (dark green). Mouse blood was collected at 3,6 and 24 hours, and 
peripheral circulating neutrophil counted. * = P<0.05 by Mann Whitney analysis. Time 
course plot shows medians alone. 
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Figure 4-6 – Mouse weight 24 hours post injection with PBS or chemokine KC 
24 hours following the injection of Figure 4-5, the mice were weighed and this was compared 
to their starting weight. Horizontal lines indicate median.  
 The effect on circulating neutrophil levels using chemokine was observed more 
quickly post injection than using bacterial infection. This was not unexpected; time would be 
required for a chemokine response to develop in response to the infection in the mouse tissue, 
whereas pre-formed chemokine was injected in this instance. Again, at 6 hours, the PBS 
infected mice show an increase in neutrophil levels, most likely due to a response against the 
tail bleed performed at three hours. At 6 hours, both groups of mice demonstrated similar 
peripheral neutrophil counts. As there was no active infection and chemokines were not being 
actively expressed, it is likely that the chemokine injected was either broken down or bound 
to receptors and internalised, although KC levels were not measured following the injection. 
The results supported the hypothesis that chemokines produced at a site distant to the marrow 
can elicit systemic mobilisation of neutrophils into the circulation, and provide a mechanism 
for the action of SpyCEP on neutrophil mobilisation. 
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4.2.3 Cytokine levels in peripheral blood following infection 
 
Neutrophils are often considered to be cells, which whilst carrying highly toxic anti-
microbial chemicals, have limited productive capability. However, they are known to release 
important cytokines required for the establishment of later elements of the immune response 
(Scapini, et al. 2000). It was hence hypothesised that those strains which reduce peripheral 
neutrophil levels through SpyCEP expression would also reduce other early cytokines of the 
immune response.  
Furthermore, the explanations offered in section 4.2.1 assume that there is a difference in 
the circulating levels of murine neutrophil specific chemokines, such as KC, in the mouse 
blood following infection with SpyCEP-positive and negative bacterial strains. The 
concentrations of many important cytokines and chemokines, including KC, were thus 
measured 6 hours following infection with SpyCEP-positive and negative bacterial strains. 
Six female CD1 mice per group were infected with 10
8
CFU (Figure 4-7) of the SpyCEP-
positive and negative GAS or L. lactis strains. 6 hours post infection, mice were euthanized, 
blood extracted by cardiac puncture, and the infected thigh and organs were removed and 
homogenised to allow determination of bacterial load (Figure 4-7). The mice were not tail 
bled at 3 hours as had been done in the previous experiments. 
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Figure 4-7 – Bacterial load 6 hours post infection with SpyCEP +/- L. lactis or GAS 
Six CD1 female mice were infected intramuscularly with either H487 (SpyCEP+ve L. lactis – 
dark blue), H486 (wild type L. lactis SpyCEP-ve – pale blue), H292 (wild type GAS, 
SpyCEP+ve – dark red) or H575 (SpyCEP-ve GAS – pale red). The inoculum of each strain 
is shown in the top left graph. 6 hours post infection, the mice were euthanized and thigh 
tissue, spleen and inguinal lymph nodes harvested and homogenised. Bacterial loads were 
quantified. Horizontal lines indicate median. P values determined by Mann Whitney analysis, 
* = P<0.05, **=P<0.01. PBS groups not shown, no bacteria detectable ND: not detectable. 
 Mice were infected with H487, H292 and H575 (SpyCEP+ve L. lactis, SpyCEP+ve 
GAS and SpyCEP-ve GAS respectively). All were injected with a similar CFU of bacteria, 
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between 2 and 4x10
7
 CFU. Mice infected with wild type SpyCEP-ve L. lactis H486 however 
received over 1 log fold more bacteria than mice infected with the SpyCEP producing strain 
H487. Despite this, at 6 hours, H486 was almost entirely cleared by the mice, with no 
bacteria detectable anywhere, except a very low level in the infection sites of two mice. The 
SpyCEP+ve L. lactis strain caused a productive infection in the thigh tissue that had spread to 
the locally draining lymph node, further highlighting the importance of SpyCEP in virulence. 
 GAS isogenic strains H292 and H575 also caused infection in the thigh and the local 
draining lymph node similar to SpyCEP+ve L. lactis, but also caused more sustained 
systemic infection, with spread to the mouse spleen. Differences between SpyCEP+ve and –
ve GAS strains were less obvious than those observed between isogenic L. lactis strains, 
although there were significantly more bacteria in the thighs of mice infected with the 
SpyCEP-positive strain in this experiment. This is indicative that SpyCEP is important in 
GAS virulence, although clearly additional GAS virulence mechanisms allow H575 to cause 
infection. Sera from infected mice were then analysed to measure circulating levels of KC 
and G-CSF, another cytokine known to have a central role in releasing neutrophils from the 
bone marrow (Figure 4-8). 
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Figure 4-8 – Serum concentrations of KC and G-CSF 6 hours post infection 
Six CD1 female mice were injected intramuscularly with either H487 (SpyCEP+ve L. lactis – 
dark blue), H486 (wild type L. lactis SpyCEP-ve – pale blue), H292 (wild type GAS, 
SpyCEP+ve – dark red), H575 (SpyCEP-ve GAS – pale red) or PBS (dark green). 6 hours 
post infection, the mice were euthanized and blood collected and processed to serum. KC and 
G-CSF were quantified using Luminex and ELISA respectively. ND represents below 
500pg/ml. Horizontal lines indicate median. P values determined by Mann Whitney analysis 
between paired strains, * = P<0.05, **=P<0.01.  
ng/ml 
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 As previously reported, mice infected with SpyCEP-positive GAS had less circulating 
serum KC than mice infected with SpyCEP-negative GAS (Kurupati, et al. 2010). Again, as 
previously reported, the reverse observation was seen using the L. lactis strains, with 
significantly less KC circulating in the SpyCEP-negative strains (Kurupati, et al. 2010). 
However, as mice infected with SpyCEP-negative L. lactis had cleared the infection 
(Kurupati, et al. 2010), lower KC levels were expected. The G-CSF measurement using L. 
lactis was unsuccessful, as serum was used at too high a concentration, and hence G-CSF 
readings were above the standard curve. This experiment used all the serum collected, hence 
the assay could not be repeated. The optical densities of the ELISA observed are shown in 
Figure 4-8, as a surrogate for quantification. The results were similar to those seen with KC, 
with more G-CSF detectable in the SpyCEP-positive infected mice. Again, as the SpyCEP-
negative L. lactis infection had been cleared, the lower observed levels of G-CSF were 
expected. G-CSF could be quantified in the mice infected with GAS, and no difference was 
observed between SpyCEP-positive and negative strains. All infected mice showed increased 
levels of both cytokines compared to sham PBS infected mice.  
SpyCEP interferes with the neutrophil response against Group A Streptococcus 
137 
 
 
Figure 4-9 – Serum concentrations of cytokines 6 hours post infection 
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Six CD1 female mice were infected intramuscularly with either H487 (SpyCEP+ve L. lactis – 
dark blue), H486 (wild type L. lactis SpyCEP-ve – pale blue), H292 (wild type GAS, 
SpyCEP+ve – dark red), H575 (SpyCEP-ve GAS – pale red) or PBS (dark green). 6 hours 
post infection, the mice were euthanized and blood collected and processed to serum. 
Cytokines were quantified using Luminex. Horizontal lines indicate median. P values 
determined by Mann Whitney analysis between paired strains, * = P<0.05, **=P<0.01. 
 A Luminex assay was carried out to measure other murine chemokines. No significant 
differences between mice infected with SpyCEP-positive and negative strains were observed. 
This was expected for cytokines such as VEGF, a growth factor released in hypoxia to 
encourage growth of the vasculature. We expected to see more inflammatory chemokines, 
such as IL-1β, IL-12 and TNFα, in strains infected with SpyCEP-negative mice, due to their 
increased peripheral neutrophils (Scapini, et al. 2000). However the relative contribution of 
circulating neutrophils balanced against infection severity was of uncertain importance. There 
was a trend for higher cytokine levels in mice infected with SpyCEP-positive strains, perhaps 
due to these mice having a more severe infection, however this was most marked, but not 
significant, with regard to TNFα and GAS infection.  
 A similar trend was observed using the L. lactis strains, with a trend towards higher 
cytokine concentrations where SpyCEP was present. Mice infected with SpyCEP-negative L. 
lactis had cleared the infection by six hours (Figure 4-7), hence explaining the lower 
concentrations of inflammatory cytokines. Indeed, mice infected with SpyCEP-positive L. 
lactis H487 had significantly higher serum concentrations of IL-5 and MCP1, GMCSF, IL-1α. 
IL-13 and IL-17 were also measured, but the concentrations were too low to be detected in all 
mice. 
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4.3 Discussion 
 
4.3.1 Circulating neutrophil levels 
 
The results in Figure 4-1 show that L. lactis strains expressing SpyCEP are able to 
significantly reduce the number of neutrophils circulating in peripheral mouse blood 
compared to the response seen to wild type L. lactis. This is despite the fact that there are 
significantly more SpyCEP expressing L. lactis in the mouse thigh (Figure 4-2). Similar 
results were seen using the GAS strains, although the difference in circulating neutrophils 
was not sufficient to reach statistical significance (Figure 4-3). The L. lactis strains examined 
express no virulence factors of their own, thus any difference observed between the two 
strains must be being directly mediated by SpyCEP. Such a system allows us to clearly and 
cleanly study the effects of SpyCEP. GAS express a range of virulence factors which are 
unaffected between the SpyCEP-negative and positive strains, including factors which are 
known to act on neutrophils, such as Streptolysin O (SLO) (Timmer, et al. 2009). Such other 
virulence factors make observations about virulence factors more challenging, explaining 
why the differences observed using GAS were not considered statistically significant. 
The observations made are interesting when considered together with earlier research 
examining the effects of SpyCEP on infiltration of infection foci by neutrophils (Kurupati, et 
al. 2010). In vivo work has demonstrated that the migration of neutrophils through 
endothelium into the infection site is disrupted by SpyCEP, a finding that has been confirmed 
in vitro using transwell assays with known numbers of cells (Edwards, et al. 2005, 
Zinkernagel, et al. 2008). This study adds to previous findings; not only are neutrophils 
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deficient at leaving the circulation to reach the infection focus, but there are also fewer 
neutrophils entering the blood at the time of infection, before any migration takes place. It 
would be interesting to look at the later stages of neutrophil function such as bacterial killing 
to see if these are also disrupted by SpyCEP. The very final stage in the bactericidal lifespan 
of the neutrophil, release of neutrophil extracellular traps (Brinkmann, et al. 2004), has 
indeed been shown to be impaired in SpyCEP-positive strains (Zinkernagel, et al. 2008). 
 Chemokines have been previously reported to have a role in neutrophil release from 
the bone marrow (Martin, et al. 2003). The mechanism described has separate chemokine 
axes either retaining or encouraging neutrophil release from the bone marrow, mediated by 
CXCR4 and CXCR2 signalling respectively. These signals are mutually antagonistic, such 
that a small change in one has a large overall effect on neutrophil release (Furze and Rankin 
2008a). Prior to this study, this chemokine interplay has not been studied in the context of a 
bacterial infection. The results obtained in this study fit with these previous reports. GAS 
expressing SpyCEP does indeed reduce the circulating level of CXCR2 binding chemokine 
KC in the mouse serum (Figure 4-8).  
Considering that wild type L. lactis not expressing SpyCEP was cleared by 6 hours, it is 
interesting that neutrophils were not detected at higher numbers in the peripheral blood at 
three hours (Figure 4-1). Furthermore, by 6 hours post infection, systemic KC was much 
lower in mice infected with wild type L. lactis than SpyCEP expressing L. lactis (Figure 4-8). 
This is most likely explained by the choice of time points in this study. It may have been too 
early to see a neutrophil response at three hours, but too late to see a KC response at six hours. 
The chemokine response may well be peaking at 2-3 hours following infection with wild type 
L. lactis strain. The neutrophil peak will lag behind this at 4-5 hours with concomitant 
bacterial killing (and subsequent loss of KC production), and may well have returned to 
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normal levels by 6 hours. This seems likely, as the timing of the neutrophil response seen 
using GAS matches that of L. lactis (Figure 4-3). Furthermore the administration of 
recombinant KC would lead to an immediate spike in circulating levels, circumventing the 
time required to express endogenous KC, allowing the difference in neutrophil release being 
detected at just three hours (Figure 4-5). 
We considered the possibility that the main neutrophil response seen in this experiment 
was in reaction to the tail bleed technique itself at three hours, caused by an acute phase 
response to the injury. Soluble SpyCEP produced by bacterial strains would have been 
equally able to neutralise chemokine release triggered by tail bleeding as chemokine release 
from thigh muscle infection. Importantly however, there were global differences in neutrophil 
numbers between three and six hours, suggesting that the bleed technique could not alone 
account for such differences (Figure 4-1). Nonetheless, there was a rise in neutrophil numbers 
at six hours even in response to PBS. 
It is also interesting that in mice infected with GAS, G-CSF is greatly upregulated 
compared to mice injected with PBS (Figure 4-8) at 6 hours post infection. G-CSF alone is 
known to induce neutrophil release. It would thus be expected that the mice infected with 
either strain of GAS would have many more neutrophils (Figure 4-3) circulating than those in 
the PBS control (Figure 4-1). G-CSF measurements were taken without performing a tail 
bleed at three hours, and thus the circulating G-CSF in the PBS control group may well be 
much higher in the neutrophil count experiment than the cytokine measurement experiment. 
The results obtained using SpyCEP-positive and negative strains were supported by the 
results obtained using intramuscular injection of murine chemokine KC (Figure 4-5). As 
expected, chemokine injected into the muscle was able to elicit an increase in circulating 
neutrophils at three hours. This effect had completely disappeared at six hours post injection, 
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with very similar numbers of circulating neutrophils between the two groups. This was 
presumably due to clearance of the chemokine by six hours, and loss of subsequent effect. 
The idea that KC remains active in the mouse for a short period only is strengthened by the 
data observed measuring levels of KC during L. lactis infection (Figure 4-8).  
 
4.3.2 Cytokine levels in peripheral blood following infection 
 
As expected, the serum levels of KC, a substrate of SpyCEP, were lower in mice infected 
with a GAS strain expressing SpyCEP than those infected with a SpyCEP mutant strain 
(Kurupati, et al. 2010). The same result was not seen using L. lactis, as the wild type strain 
had been cleared from the infected mice before the six hour time point (Figure 4-7), and thus 
KC levels were returning to resting state. This was also observed in a previously published 
study (Kurupati, et al. 2010). It is hypothesised that had levels of KC been measured at three 
hours, the same pattern as was observed with GAS would have been measured, with higher 
chemokine levels in the absence of SpyCEP. 
It was expected that as neutrophil mobilisation and recruitment was affected by SpyCEP, 
the levels of cytokines and other chemokines associated with neutrophils might also be 
affected (Scapini, et al. 2000). This was however not observed. Global differences were not 
observed between mice infected with different strains of GAS, although there was a trend 
towards higher levels of pro-inflammatory cytokines in the mice infected with SpyCEP-
positive GAS, indicated by higher TNFα in the SpyCEP-positive group (Figure 4-9). The 
same trend was observed using the L. lactis strains, and indeed two pro-inflammatory 
cytokines IL-5 and MCP1 were significantly higher in the serum of mice infected with 
SpyCEP-positive L. lactis (Figure 4-9). We hypothesise that the burden of infection, which 
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was greater in mice infected with SpyCEP producing strains, is the major contributory factor 
of proinflammatory cytokine levels, rather than circulating neutrophil counts. 
Differences in immunology between mice and humans limit the conclusions which can 
be drawn from such studies, especially when studying neutrophils. Neutrophils play a much 
less important role in the mouse immune response than in human. Indeed neutrophils make 
up just 10% of the resting mouse leukocyte count, compared to up to 70% in humans. 
Furthermore, mice produce fewer chemokines for neutrophils, and only express the CXCR2 
receptor (Amulic, et al. 2012). Nevertheless, the results obtained in this study, especially 
those measuring peripheral neutrophil counts, are consistent with clinical data from human 
infection, strengthening their validity (Edwards, et al. 2005).  
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Chapter 5 - Results: Phagocytosis of GAS by neutrophils 
 
5.1 Introduction 
 
Work in Chapter 4 of this study has demonstrated that SpyCEP is able to disrupt 
neutrophil release from the bone marrow, an early stage in the nascent neutrophil response 
against a GAS infection. Previous work using the intramuscular model of invasive infection 
using SpyCEP-positive and negative strains of L. lactis and GAS suggested that SpyCEP may 
prevent killing of bacteria (Kurupati, et al. 2010). This was in part confirmed by work 
demonstrating reduced killing of SpyCEP-positive GAS by NETs (Zinkernagel, et al. 2008). 
Phagocytosis by neutrophils is a poorly studied field, due to the fact they are not 
amenable to genetic manipulation, and have only a short lifespan. Proposed mechanisms of 
neutrophil phagocytosis are hence closely based on those derived from studying macrophages, 
despite the differences in these cells (Lee, et al. 2003). Neutrophils predominantly 
phagocytose opsonised particles, using receptors able to bind deposited antibody or 
complement. The receptors then cluster beneath the particle, forming a signalling platform 
beneath which cell changes can occur. The internalisation mechanism of an antibody 
opsonised particle is different from that of a complement opsonised particle. Apart from 
different receptors being used, the actin mediated cell changes required are also different, 
with complement opsonised particle apparently sinking inside the cell, whereas antibody 
opsonised particles are uptaken by extending pseudopods (Greenberg and Grinstein 2002).    
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GAS is known to bear many defences against both antibody and complement mediated 
phagocytosis. Antibodies against GAS have been explored in a variety of ways including a 
shaving proteolysis technique to find surface exposed GAS proteins that are recognised by 
antibody (Rodriguez-Ortega, et al. 2006), and using pooled convalescent sera to probe a 
panel of target GAS antigens (Fritzer, et al. 2010). Serotype defining antibody against the M 
protein is thought to be especially important, and despite its variability, is the subject of many 
vaccine efforts (Lynskey, et al. 2011). It is the major surface protein of GAS, and is itself 
anti-phagocytic. L. lactis unlike GAS, does not express factors to actively prevent 
opsonisation, but it is coated in a polysaccharide pellicle, which is known to be anti-
phagocytic by an unknown mechanism (Chapot-Chartier, et al. 2010). L. lactis does not 
infect humans or mice, and hence antibodies are not expected to have been raised against this 
bacterium. Complement deposition does not require prior exposure to the pathogen however. 
As L. lactis was efficiently cleared from a mouse model of infection (Figure 4-2), we assume 
that it must be successfully opsonised by complement, although an alternative mechanism of 
killing, such as by anti-microbial peptides may also explain these observations. 
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5.2 Results 
 
5.2.1 Lancefield Assay using SpyCEP-positive and negative strains 
 
To examine the reasons underlying failed killing of bacteria in mice exposed to 
SpyCEP-expressing bacteria, we re-examined thin sections from thighs of GAS or L. lactis 
infected mice in collaboration with Professor Ken Smith (Royal Veterinary College).  
From the microscopy images (Figure 5-1), it was apparent that neutrophils that had 
entered the areas infected with SpyCEP-negative strains were able to engulf many Gram 
positive cocci – often up to 10 per cell, while other neutrophils had not engulfed any visible 
bacteria. This was interesting and suggests that neutrophils undergoing phagocytosis enhance 
their phagocytic capacity. Neutrophils undergoing phagocytosis have been reported to release 
high levels of chemokine, much of which binds to the source neutrophil, potentially 
explaining these observations (Bazzoni, et al. 1991, Marie, et al. 1997), and implying that 
endogenous chemokine is important for phagocytosis. In contrast, where bacteria were 
expressing SpyCEP, there were, as predicted, fewer apparent neutrophils. For instance, there 
are no visible neutrophils in the sections infected with SpyCEP positive strain H292, unlike 
sections infected with SpyCEP negative H575. Even where neutrophils had reached the 
infected field, there was no evidence of interaction or phagocytosis of bacteria (Figure 5-1). 
This strongly suggested a potential role for SpyCEP in the prevention of phagocytosis.   
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Figure 5-1 – Histology taken from infected mouse thighs 
Mice were infected for 3 hours with H486 (SpyCEP-ve L. lactis), H487 (SpyCEP+ve L. 
lactis), H292, (SpyCEP+ve GAS) or H575 (SpyCEP-ve GAS). Mice were then euthanized 
and thigh tissue collected for histology. Sections were Gram stained. B indicates bacteria, M 
muscle and N neutrophils. Lower case n indicates necrosis. Representative sections shown. 
Magnification 400x. 
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 Phagocytosis of GAS is classically measured using a Lancefield assay, where a small 
number of GAS CFU are inoculated into a volume of blood and incubated at 37
o
C with 
rolling for 3 hours. The blood provides complement and antibody to opsonise the bacteria, 
and the phagocytes in the blood then phagocytose and kill the GAS. If the bacteria are able to 
grow in the blood, the donor is considered non-immune to that particular serotype. A 
limitation of this assay is that the number of colonies obtained at the end of the experiment is 
determined both by the rate of killing of the bacteria and the simultaneous rate of growth of 
the bacteria (ie the net growth). 
 Approximately 30 CFU of H292, a wild type, high SpyCEP producing M81 strain, 
and its isogenic SpyCEP mutant H575 were inoculated separately into freshly extracted blood 
from three donors, in experimental triplicates. In all donors, no bacteria were detectable at 
any time point in the experiment (Figure 5-2), consistent with all donors being immune to this 
serotype. 
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Figure 5-2 – Lancefield assay using GAS strains 
Approximately 30 CFU (1 CFU/µl) of H292 (SpyCEP+ve GAS) and H575 (SpyCEP-ve GAS) 
were inoculated into 270μl of freshly extracted blood from three different donors in 
experimental triplicate. At 60, 120, and 180 minutes, a 100µl sample was taken and plated to 
allow quantification of bacteria. 
 As L. lactis is not a pathogen of humans, it was hoped that these strains could be used 
in a whole blood assay as antibody against L. lactis was not expected to be present (Bolotin, 
et al. 2001, Poquet, et al. 1998, van Asseldonk, et al. 1990). A comparison was made 
between SpyCEP expressing L. lactis and the isogenic wild type strain; results were 
expressed as a multiplication factor (ratio of bacteria after : input culture bacteria). 
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Figure 5-3 – Lancefield assay using L. lactis strains 
Approximately 300 CFU of H487 (SpyCEP+ve L. lactis) and H486 (SpyCEP-ve L. lactis) 
were inoculated into 270μl of freshly extracted blood from three different donors in 
experimental triplicate. At 60, 120, and 180 minutes, a sample was taken and plated to allow 
quantification of bacteria. P<0.05 between the two strains at specific time points as assessed 
by Mann Whitney. Data shows the mean of three experimental replicates and the mean of 
three different donors. 
 Unlike GAS, the L. lactis strains survived and grew in whole blood. The L lactis 
strain expressing SpyCEP grew significantly better than the wild type organism in blood. As 
the strains are not known to have any differences in their growth (Zinkernagel, et al. 2008), 
we hypothesise that the difference was due to an enhanced ability of the SpyCEP expressing 
strain to evade killing. 300 rather than 30 CFU were used in this experiment which may 
explain why these strains grew compared to GAS. A drawback of this assay was that growth 
of GAS was a requirement. Whilst it appears that SpyCEP was protective against killing in 
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blood, presumably by phagocytes, a different assay was needed which specifically measured 
phagocytosis, and could be used to examine the GAS strains. 
  
5.2.2 SpyCEP impacts on phagocytosis as assessed by flow cytometry 
 
A technique has been previously described where bacterial phagocytosis was 
measured using flow cytometry (Bjerknes and Bassoe 1983). Briefly, bacteria are 
fluorescently labelled, opsonised and then mixed with purified leukocytes of interest. Thus 
cells that have phagocytosed bacteria become fluorescent themselves and can be 
distinguished by flow cytometry. Subsequent addition of trypan blue acts to quench 
fluorescent signalling due to extracellular bacteria, allowing the differentiation of cells which 
have actually undergone phagocytosis from those that have bacteria attached to their surface. 
To determine whether this protocol would be useful using GAS, a pilot experiment was 
performed using confocal microscopy, to confirm that cells did indeed become fluorescent in 
the protocol (Figure 5-4). 
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Figure 5-4 – Confocal microscopy of fluorescent GAS and neutrophils 
GAS cells were stained with FITC, opsonised using whole serum and incubated with freshly 
extracted neutrophils. 
 
It was observed that neutrophils were themselves not fluorescent, that bacteria could 
be made fluorescent using FITC, and upon phagocytosis of these bacteria, neutrophils 
became fluorescent (Figure 5-4). Thus flow cytometry analysis was performed to specifically 
measure phagocytosis of bacteria using purified human neutrophils opsonised with human 
serum. The L. lactis strains H487 and H486 (SpyCEP+ve and –ve respectively) were initially 
used, as these strains had previously demonstrated differences using the Lancefield assay. 
The bacteria were first labelled non-specifically using FITC, prior to opsonisation in serum 
and neutrophil co-incubation. To ensure that any signals observed were not due to labelled 
bacteria binding to the neutrophil outer membrane, trypan blue was included in the sample to 
quench extracellular fluorescence (Bjerknes and Bassoe 1984). The results are shown in 
Figure 5-5. 
 
 
40µm 
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Figure 5-5 – Phagocytosis of L. lactis by purified neutrophils 
(A): Percentage of neutrophils positive for fluorescence following incubation with FITC-
stained H486 (wild type) and H487 (SpyCEP+ve) L. lactis for 15, 30, 45 and 60 minutes. 
Each time point represents 20000 gated events (gating made around neutrophils based on 
morphology). Data representative of three separate experiments using different donors. (B): 
Phagocytosis levels of the three donors 30 minutes post addition of bacteria to neutrophils. 
Values shown are phagocytosis levels for SpyCEP-positive strain observed, relative the 
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values obtained for SpyCEP-negative strain in each experiment. Error bars indicate SD, * = 
P<0.05 (Mann Whitney). 
 The wild type L. lactis SpyCEP-negative H486 was rapidly phagocytosed, with 
approximately 75% of neutrophils emitting a fluorescent signal 15 minutes post infection, 
reaching a plateau of 95% by 45 minutes. Conversely, the SpyCEP-positive L. lactis strain 
H487 was much more slowly phagocytosed, with only 20% of neutrophils having 
phagocytosed labelled bacteria at 15 minutes and only 45% by 60 minutes (Figure 5-5). This 
difference was preserved between the different donors. 
 
Figure 5-6 – Histograms of green fluorescent signal after phagocytosis of L. lactis 
Histogram of events and FL1 channel FITC detection at 0, 30 and 60 minutes. Left panel 
indicates results using H486 (SpyCEP-ve), right panel H487 (SpyCEP+ve). Line colours 
indicate time points: red 0 minutes, blue 30 minutes, green 60 minutes incubation of bacteria 
with neutrophils.  
There was a slightly increased median fluorescence intensity (MFI) among 
neutrophils that had internalised H487, and this may be the result of uneven staining between 
H486 and H487 (Figure 5-6). Despite this, it was clear that far fewer neutrophils had 
internalised bacteria when exposed to H487. The results shown in Figure 5-5 were 
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representative of three independent donors, but a further experiment was performed using six 
different donors where neutrophils of the six donors were mixed with the six different sera 
collected, to ensure this result was robust and repeatable. 
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Figure 5-7 - Phagocytosis of L. lactis by purified neutrophils using a panel of donors 
(A): Percentage of neutrophils positive for fluorescence following incubation with FITC-
stained H486 (wild type) and H487 (SpyCEP +ve) L. lactis for 30 minutes. Each bar 20000 
gated events (gating made around neutrophils based on morphology). (B): Phagocytosis 
levels of the six donors with six sera (36 samples in total) 30 minutes post addition of 
bacteria to neutrophils. Values shown are phagocytosis levels for SpyCEP-positive strain 
observed, relative the values obtained for SpyCEP-negative strain in each experiment. Error 
bars indicate SD, * = P<0.0001 (Mann Whitney). 
 Among 5 out of 6 donors, SpyCEP-negative L. lactis was phagocytosed more than the 
isogenic SpyCEP-positive L. lactis. Interestingly, not all samples demonstrated this 
difference, and indeed when opsonised using the serum of donor 6, the differences between 
the two strains were smaller or non-existent (Figure 5-7). The interperson variability in the 
results appeared to be primarily due to serum. Although antibodies to L. lactis were not 
expected among human donors, it is feasible that strong anti SpyCEP activity could explain 
this anomaly. This data however shows that the findings are robust and observed in the 
majority of donors.  
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Using both flow cytometry and the Lancefield assay, SpyCEP has been proven to 
interfere with the phagocytosis of L. lactis. It was next decided to test whether these 
observations could also be made using SpyCEP+ve and –ve GAS strains (Figure 5-8), given 
that the Lancefield assay could not be used for the M81 serotype.   
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Figure 5-8 – Phagocytosis of GAS by purified neutrophils 
(A): Percentage of neutrophils positive for fluorescence at following incubation with FITC-
stained H292 (wild type) and H575 (SpyCEP-ve) GAS for 15, 30, 45 and 60 minutes. Each 
time point represents 20000 gated events (gating made around neutrophils based on 
morphology). Data representative of three separate experiments using different donors. (B): 
Phagocytosis levels of the three donors 30 minutes post addition of bacteria to neutrophils. 
Values shown are phagocytosis levels for SpyCEP-positive strain observed, relative the 
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values obtained for SpyCEP-negative strain in each experiment. Error bars indicate SD, * = 
P<0.05 (Mann Whitney). 
SpyCEP-negative H575 was more quickly phagocytosed than the wild type SpyCEP 
expressing counterpart H292 (Figure 5-8). Approximately 75% of neutrophils incubated with 
H575 were positive for a fluorescent signal 15 minutes post infection, reaching a plateau of 
95% by 45 minutes. Neutrophils co-incubated with SpyCEP-positive GAS strain H292 
demonstrated green fluorescence among 25% of the population 15 minutes post infection, 
rising to 75% positive by 60 minutes. As expected and seen throughout this study, the 
difference between the SpyCEP-positive and negative GAS strains was less obvious than 
seen using the L. lactis strains, but was still clearly measurable and significant. 
 
Figure 5-9 - Histograms of green fluorescent signal after phagocytosis of GAS  
Histogram of events and FL1 channel FITC detection at 0, 30 and 60 minutes. Left panel 
indicates results using H292 (SpyCEP+ve), right panel H575 (SpyCEP-ve). Line colours 
indicate time points: red 0 minutes, blue 30 minutes, green 60 minutes incubation of bacteria 
with neutrophils.  
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The MFI of neutrophils that had phagocytosed bacteria was similar between the two 
GAS strains, again indicating that the reduced percentage of cells positive for green 
fluorescence was not due to a technical difficulty of staining (Figure 5-9).  
 
5.2.3 Impact of serum depletion of antibody and complement on phagocytosis of 
SpyCEP +/- strains 
 
Bacteria in the experiments of the previous section were opsonised using whole human 
serum. Although neutrophils are able to phagocytose some unopsonised particles (Lee, et al. 
2003), this opsonisation source was found to be vitally important for phagocytosis of the 
strains tested here. An experiment was performed using foetal calf serum (FCS) rather than 
human serum with L. lactis strains. This serum contains only very low levels of bovine 
antibody, and has been heat inactivated, which disrupts the complement system (Morgan 
2000). No phagocytosis was observed (Figure 5-10).  
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Figure 5-10 – Phagocytosis of L. lactis without opsonisation source 
Percentage of neutrophils positive for fluorescence following incubation with FCS incubated 
FITC-stained H487 (SpyCEP+ve) and H486 (SpyCEP-ve) L. lactis for 15, 30, 45 and 60 
minutes. Each time point represents 20000 gated events (gating made around neutrophils 
based on morphology), and was performed once. 
 As previous work (Figure 5-7) showed that differences in phagocytosis between 
donors were primarily due to sera, it was decided to determine what particular opsonin in the 
sera was important for phagocytosis of the strains. Initially, each of the four bacterial strains 
were incubated in freshly extracted whole human serum, as per the phagocytosis experiments, 
before being probed using fluorescently conjugated antibodies against human antibody or 
C3b, an important opsonin of the complement cascade (Figure 5-11). 
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Figure 5-11 – Opsonisation of GAS and L. lactis 
GAS strains H292 and H575 (SpyCEP+ve and SpyCEP-ve respectively) and L. lactis strains 
H487 and H486 (SpyCEP+ve and SpyCEP-ve respectively) were incubated with whole 
human serum for 15 minutes. This was removed and cells were probed using fluorescently 
conjugated antibody against bound C3b (left panel) and IgG (right panel). Bars indicate mean 
and error bars SD of three independent experiments. 
 SpyCEP did not affect the binding of either complement or antibody to either the 
GAS or L. lactis strains, with no significant differences observed within the pairs of strains 
(Figure 5-11). GAS was observed to bind more complement than L. lactis. L. lactis is an 
avirulent bacterium that produces no virulence factors of its own (Bolotin, et al. 2001, Poquet, 
et al. 1998, van Asseldonk, et al. 1990). Furthermore it is coated in a polysaccharide pellicle, 
which is known to be anti-phagocytic (Chapot-Chartier, et al. 2010). This is interesting when 
considering the results of Figure 4-7, where wild type L. lactis was cleared within six hours. 
This bacterium is avirulent, and hence seems to require very little response from the immune 
system to clear the infection. This might explain why L. lactis able to express SpyCEP causes 
severe disease in the mouse model, being almost refractory to the immune system, but now 
expressing a virulence factor. L. lactis also was not bound by antibodies using the sera tested 
C3b 
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in this experiment, although human antibodies were not expected as this organism does not 
cause disease in humans. GAS was opsonised by antibody, being a common pathogen of 
humans. However, as both these values had only low median fluorescence intensities, it is 
possible that this method of measuring antibody deposition is not very sensitive and limited 
binding of antibodies against L. lactis may be missed. Furthermore, Figure 5-7 shows that 
phagocytosis of L. lactis is varied among donors, and thus a minority of donors may express 
anti-L. lactis antibodies. 
 Fresh human serum was then depleted of complement by heat inactivation or 
antibodies by passage over columns bound with antibody binding proteins (Chapter 2). 
Double depleted sera were also produced by combining these methods. GAS phagocytosis by 
neutrophils was found to be optimal when both complement and antibody were present in 
whole serum (Figure 5-12). A slight reduction in phagocytosis was observed when antibody 
was depleted from the serum. Complement depletion had a more profound impact on 
phagocytosis, and only 15% of neutrophils demonstrated fluorescence at 60 minutes post-
coinoculation. There was little difference between the SpyCEP-positive and negative strains 
using this serum. However, as phagocytosis rates were so low, it may be that this method was 
not sensitive enough to determine any differences here. Double depleted sera demonstrated 
no phagocytosis (Figure 5-12). When this experiment was repeated, high levels of 
phagocytosis were observed despite depleting the serum using the same method. Double 
depleted serum still phagocytosed 60% as well as whole serum. The trends observed were the 
same, but the fold changes were different due to this high residual phagocytosis (Figure 5-12).  
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Figure 5-12 – Phagocytosis of GAS opsonised with depleted sera 
(A): Percentage of neutrophils positive for fluorescence at following incubation with FITC-
stained H292 (wild type) and H575 (ΔcepA) GAS opsonised in variously depleted sera for 20, 
40 and 60 minutes. Each time point represents 20000 gated events (gating made around 
neutrophils based on morphology). Data from one of two separate experiments using 
different donors. (B): Phagocytosis levels of the two donors 40 minutes post addition of 
bacteria to neutrophils. Values shown are phagocytosis levels, relative to the values obtained 
for SpyCEP-negative strain in each experiment opsonised with whole serum. Error bars 
indicate SD, * = P<0.05 (Mann Whitney). 
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 Similarly prepared sera were also used with the L. lactis strains. Here the results using 
antibody depleted sera were less repeatable, with some antibody only sera able to opsonise 
successfully whereas others could not. This was probably due to these donors containing an 
antibody which could opsonise L. lactis whereas others did not have these antibodies. Two 
results are shown in Figure 5-13, showing both types of donor. 
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Figure 5-13 – Phagocytosis of L. lactis opsonised with depleted sera 
Percentage of neutrophils positive for fluorescence at following incubation with FITC-stained 
H486 (wild type) and H487 (SpyCEP+ve) L. lactis opsonised in variously depleted sera for 
20, 40 and 60 minutes. Each time point represents 20000 gated events (gating made around 
neutrophils based on morphology). Data shows two of three donors. 
  Figure 5-13 shows the phagocytosis of L. lactis by two different donors. In both 
donors, bacteria were effectively opsonised where whole sera were used, and this was 
inhibited by SpyCEP. Neither strain was effectively phagocytosed when opsonised with 
Donor 2 
Donor 1 
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double depleted sera. When antibody alone was depleted, in both sera, the remaining 
complement was able to opsonise the bacteria, and subsequent phagocytosis was inhibited by 
the presence of SpyCEP. 
 
Figure 5-14 – Relative phagocytosis of L. lactis opsonised with depleted serum 
Phagocytosis levels of the three donors (Figure 5-13) 40 minutes post addition of bacteria to 
neutrophils. Values shown are phagocytosis levels, relative to the values obtained for 
SpyCEP-negative strain in each experiment opsonised with whole serum. Error bars indicate 
SD, * = P<0.05 (Mann Whitney). 
 The data showed that complement is very important in the opsonisation of GAS and L. 
lactis strains. Antibody appears to have a limited opsonic role against GAS compared to 
complement with antibody depleted serum allowing considerable residual phagocytosis, 
unlike complement depleted or double depleted serum (Figure 5-14).  
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5.3 Discussion 
 
5.3.1 SpyCEP impacts on neutrophil phagocytosis 
 
The Lancefield assay was originally used to determine whether or not a particular 
blood sample demonstrated immunity to a particular serotype of GAS. In this study, we 
attempted to use it as measure of phagocytosis. This assay however is not a measure of 
phagocytosis, rather it is a measure of two competing factors, bacterial growth and bacterial 
killing. Using GAS strains, the method proved to be uninformative, with all donors used able 
to kill both SpyCEP+ve and SpyCEP-ve GAS strains within one hour. The SpyCEP+ve and  
–ve L. lactis strains yielded an interesting result however, in that significantly more bacteria 
survived if SpyCEP was present than where absent. The difference between GAS and L. 
lactis was presumably due to the specific donors used having immunity against GAS 
infection due to exposure, but not against L. lactis which does not cause disease. 
Although this assay proved to be unhelpful when trying to measure differences in 
phagocytosis using GAS strains, the results with L. lactis did appear more instructive. 
However, this assay was not designed to allow quantification of phagocytosis, rather a yes/no 
answer to immunity. Figure 5-15 shows the problems with using this method. This Figure has 
been drawn to simulate results from a Lancefield assay, where bacteria are killed at a constant 
rate, and are growing logarithmically with a doubling time of 30 minutes after a 30 minute 
lag phase. Such a model suggests that the starting CFU is very important in the results 
obtained, and differences in killing capacity between two strains are only revealed clearly 
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when an optimal CFU is used. The results of Figure 5-2 and Figure 5-15 indicated that a more 
quantitative and specific measure of phagocytosis was required.  
 
 
Figure 5-15 – Hypothetical Lancefield assay results 
CFU recovered using a model Lancefield assay, whereby bacteria are killed at constant rate 
(60 CFU/hr), while bacteria were modelled to grow logarithmically following a 30 minute lag 
phase. Each line represents a different starting titre 
To this end, the flow cytometric method of determining phagocytosis (Bjerknes and 
Bassoe 1983) was used. Such a method is not dependent on bacterial growth or killing for its 
results, only upon the internalisation of bacteria. Indeed this method provides no information 
about the killing of bacteria, and any effect that SpyCEP may have on this process. A large 
difference in neutrophil phagocytosis between SpyCEP+ve and –ve L. lactis strains could be 
observed, with the SpyCEP-positive strain being phagocytosed considerably less well than 
the SpyCEP-positive wild type strain (Figure 5-5). As the only known substrates of SpyCEP 
are chemokines, this result suggests that by cleaving chemokines, SpyCEP inhibits neutrophil 
phagocytosis of L. lactis. Confocal microscopy confirmed that fluorescence of neutrophils 
was caused by internalised bacteria 
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The FITC labelling procedure is non-specific, and is mediated by covalent binding to 
primary amines. These are only found at the amino terminus of proteins. As FITC is a small 
molecule, with a molecular weight of 389Da, and is binding only to the very terminal-most 
amino acid of proteins, it is unlikely that it disrupts the protein function of the strains. L. 
lactis expresses very few extracellular proteins of its own, and has a polysaccharide pellicle 
repeating unit outer coat (Chapot-Chartier, et al. 2010). The SpyCEP-negative strain is hence 
predictably dimmer than the SpyCEP-positive strain due to number of FITC binding targets 
(Figure 5-6), and both strains are dimmer than the GAS strains (Figure 5-9). However, this 
has not prevented the method from being useful, as the dimmest bacteria were still 
sufficiently bright to allow positive and negative groups of neutrophils to be clearly 
distinguished by flow cytometry (Figure 5-6). 
The results obtained using this method were broadly repeatable using different donors, 
with wild type L. lactis being significantly better phagocytosed by neutrophils than SpyCEP 
expressing L. lactis (Figure 5-7). However, some interperson variation was observed, 
mediated by differences in sera rather than cells. This implied that opsonisation of bacteria 
represented the source of any interperson differences. It is possible that donor 5 had 
antibodies against SpyCEP, as these have been reported following GAS infection (Fritzer, et 
al. 2010). By neutralising this virulence factor with antibody, any difference attributable to 
that antibody would disappear. These interperson differences meant that throughout this 
chapter, only representative rather than pooled data could be shown, and statistics were 
performed on relative differences between the SpyCEP positive and negative strains within 
experiments.  
The differences in neutrophil phagocytosis between SpyCEP+ve and –ve strains of 
GAS were smaller than those seen using L. lactis, presumably due to other virulence factors 
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expressed by GAS which also target neutrophils. Nevertheless, a clear difference in the 
phagocytosis of these two strains was clearly observed by flow cytometry (Figure 5-8).  
Previous work has reported that SpyCEP expression protects GAS from killing by 
purified neutrophils. This was assessed by measuring viable CFU following incubation with 
purified neutrophils. Such observations were attributed to SpyCEP preventing NETosis by 
neutrophils, reducing bacterial killing (Zinkernagel, et al. 2008). In addition to preventing 
NETosis, this study revealed that SpyCEP is also able to prevent killing by neutrophils by 
preventing phagocytosis. NET based killing of bacteria is extracellular, thus signal from 
FITC labelled bacteria within NETs is quenched by the trypan blue. Hence this difference in 
NETosis is not responsible for the observed differences in bacterial phagocytosis. 
 
5.3.2 Impact of serum depletion of complement and antibody on phagocytosis by 
neutrophils 
 
Work in this section has demonstrated that SpyCEP-positive and negative strains of 
the same species of bacteria were opsonised with antibody and complement to a similar level. 
GAS is known to make virulence factors which impair opsonisation and thus phagocytosis 
(1.3.2 - Defence against opsonisation), but the differences observed in this study of 
phagocytosis by neutrophils are not due to differences in opsonisation. GAS demonstrated 
greater opsonisation by C3b, an opsonin of the complement system, than L. lactis. 
Complement is deposited on the surface by both a reversible random process, and using a 
microbe specific process. By expressing its repetitive polysaccharide pellicle rather than a 
multi protein surface of several virulence factors, L. lactis seemed to be protected from at 
least one of these modes of complement deposition as evidenced by the low complement 
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deposition seen on the L .lactis strains (Figure 5-11). The pellicle has been reported to be 
anti-phagocytic previously (Chapot-Chartier, et al. 2010), and these results suggest a 
mechanism by which this may occur, acting to prevent complement deposition. 
The three serum donors used displayed antibody binding against only GAS (Figure 
5-11). The result here was expected, as GAS causes regular human infection, whereas L. 
lactis does not. Although some specific donors may have antibody against L. lactis due to 
occupational exposure, the three donors used in this particular study did not (Figure 5-11). 
In contrast to the donors used in Figure 5-11, it was apparent that one donor in further 
experiments could successfully opsonise L. lactis with antibody alone resulting in 
phagocytosis by neutrophils (Figure 5-13). All donors used for these studies were laboratory 
workers, thus it is conceivable that occupational exposure has resulted in antibodies being 
raised against L. lactis. It is hence likely that the results where antibody was not able to 
opsonise L. lactis are more representative of the general population. Complement was cases 
able to successfully opsonise L. lactis in all cases. Phagocytosis by neutrophils, whether 
opsonised by whole serum, complement, or, where applicable, antibody, was inhibited by 
SpyCEP, indicating a general inhibition rather than pathway specific mechanism. 
GAS was optimally opsonised for neutrophil phagocytosis when both complement 
and antibody were present. When antibody was depleted, complement was still able to 
opsonise GAS well, and phagocytosis by neutrophils in both these experiments was inhibited 
by SpyCEP expression (Figure 5-12). Antibody was able to opsonise GAS slightly and 
subsequent phagocytosis by neutrophils was not inhibited by SpyCEP expression. Such 
results raise interesting questions about the role and target of antibody in opsonisation of 
GAS. The serotype specific antibody raised against GAS is against the M protein. The M 
protein is itself anti-opsonic by interfering with complement deposition and its subsequent 
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interaction with the complement receptors on neutrophils (Peterson, et al. 1979, Weis, et al. 
1985). Thus, antibody against this protein could enhance phagocytosis by both direct 
opsonisation, or by neutralising this protein, enhancing complement deposition. Confusingly, 
a further role of opsonising antibody is to provide a focal point for complement deposition, 
enhancing the process. Thus, determining the precise function of the antibody is very difficult. 
Interestingly, other researchers have found that blockade of antibody receptors on the surface 
of neutrophils had no impact on phagocytosis, whereas blockade of complement receptors 
caused a complete ablation of phagocytosis (Nilsson, et al. 2005).   
As antibody depleted serum containing only complement had reduced neutrophil 
phagocytosis compared to whole serum, the antibody clearly aided opsonisation when 
complement was present. However, phagocytosis of bacteria opsonised with antibody alone 
was very poor. These results suggest that the antibody raised against GAS acts primarily to 
enhance complement deposition or its interaction with complement receptors. When using 
antibody and complement depleted serum, both strains were scarcely phagocytosed by 
neutrophils, indicating that the depletion methods used in this study were effective. 
The only known substrates of SpyCEP are neutrophil specific chemokines. Hence, the 
mechanism by which SpyCEP inhibits neutrophil phagocytosis presumably involves a 
chemokine dependent process. Variation in antibody specificity and opsonisation between 
donors makes its study is challenging. However, the complement system seems very 
important in the phagocytosis of both L. lactis and GAS, and results between donors are 
much more repeatable. Furthermore, complement mediated neutrophil phagocytosis was 
always disrupted by SpyCEP expression.  
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Chapter 6 - Results: SpyCEP impedes phagocytosis by 
neutrophils by interfering with complement receptor 3 
 
6.1 Introduction 
 
In the previous chapter, I made the novel finding that SpyCEP was able to impede 
phagocytosis of bacteria. In this chapter, I aim to elucidate the mechanism responsible for this. 
Recent work has shown that chemokines which have been cleaved by SpyCEP may 
demonstrate reduced binding to CXCR1 and CXCR2 (Goldblatt personal communication). 
Signalling after the binding of these receptors by their ligands is known to be important in 
neutrophil activation (Amulic, et al. 2012). This includes the upregulation of complement 
receptor 3 (CR3), known to be vitally important in phagocytosis of GAS (DeMaster, et al. 
2002, Detmers, et al. 1990, Nilsson, et al. 2005, Weineisen, et al. 2004). 
As such, I hypothesise that cleavage of chemokines by SpyCEP reduces the activation 
of neutrophils by preventing chemokine signalling, reducing surface expression of CR3. As 
CR3 is known to be important in GAS phagocytosis, such a hypothesis would explain the 
results observed in the previous chapter. However, importantly, no effects on phagocytosis 
have been reported when using chemokine receptor antagonist, such as the drug reparixin and 
neutralising antibodies (Stillie, et al. 2009). This suggests that the link between ligand 
binding of CXCR1/2 and phagocytosis is unclear. 
Effects on neutrophil activation by SpyCEP have been previously reported, though only 
in situations where activation was induced by exogenous CXCL8. For example, SpyCEP-
expressing strains were able to prevent neutrophil NETosis (Zinkernagel 2008), and SpyCEP 
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inhibited shedding of CD62L, a feature characteristic of neutrophil activation mediating 
binding to activated endothelium (Edwards, et al. 2005).  
To fully elucidate the mechanism behind SpyCEP-impaired phagocytosis, my 
hypothesis was tested using flow cytometric assays using phagocytes which are relatively 
unresponsive to CXCR1 and 2 chemokine ligands, by measuring chemokine levels in 
reaction mixtures, and by measuring complement receptor levels on the surface of neutrophils.  
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6.2 Results 
 
6.2.1 Internalisation of bacteria by other cell types 
 
To determine whether the observed impact of SpyCEP on neutrophil phagocytosis could 
be explained by a generalised impact on phagocytosis or internalisation, the effect of SpyCEP 
on other cell types was determined. HL60 cells are an immortalised leukocyte cell line, which 
can be induced to differentiate into neutrophil-like phagocytic cells, and which express 
receptors for C3b and the Fc region of antibodies, allowing phagocytosis of opsonised 
particles (Collins, et al. 1979). HL60 cells however express approximately one tenth of the 
number of CXCR receptors that are expressed by primary human neutrophils (Grob, et al. 
1990, Zahn, et al. 1997). HL60 cells are hence less responsive to CXCL chemokines, the 
substrates of SpyCEP, than human neutrophils. 
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 Figure 6-1  - Impact of SpyCEP on HL60 cell phagocytosis of bacteria 
 (A): Percentage of HL60 cells positive for fluorescence following incubation with FITC-
stained L. lactis strains H486 (wild type) and H487 (SpyCEP+ve) or GAS strains H292 
(SpyCEP+ve) and H575 (SpyCEP-ve) for 15, 30, 45 and 60 minutes. Each time point 
represents 20000 gated events (gating made around HL60 cells based on morphology). Data 
representative of two separate experiments using different cell preparations. (B): Relative 
phagocytosis of SpyCEP+ bacteria compared to their isogenic SpyCEP negative strain by 
HL60 30 minutes after the addition of bacteria. Data combined from two experiments. Values 
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shown are phagocytosis levels for SpyCEP positive strain observed, relative to the values 
obtained for SpyCEP-negative strain in each experiment. Error bars indicate SD. 
Unlike the situation using fresh human neutrophils in Chapter 5, SpyCEP-positive and 
negative L. lactis and GAS strains were equally phagocytosed by HL60 cells (Figure 6-1). 
The L. lactis strains were both phagocytosed by 20% of the HL60 cells in 15 minutes, rising 
to approximately 30% by 60 minutes. Phagocytosis occurred more slowly than had been 
observed using freshly extracted neutrophils. The GAS strains were phagocytosed at a similar 
rate to the L. lactis strains, again reaching 30% cells positive for phagocytosis by 60 minutes, 
regardless of SpyCEP expression. These results indicate that the mechanism by which 
SpyCEP impairs phagocytosis in neutrophils cannot be replicated in HL60 cells. Despite the 
similarity in range of phagocytosis receptors expressed by HL60 and neutrophils, the much 
lower expression of CXCR1 and 2 receptors by HL60 provides a possible explanation for 
these results, through an effect of SpyCEP on CXCR1/2 signalling. HL60 are also however 
not genuine phagocytes, but a cell line, and may have alterations at several points in the 
phagocytosis signalling in addition to near absent CXCR1/2 signalling. To determine if 
SpyCEP-mediated effects on phagocytosis could be observed in all bona fide phagocytes, 
regardless of CXCR1/2 signalling, freshly extracted primary monocytes were also evaluated 
in phagocytosis assays (Figure 6-2). 
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Figure 6-2 – Monocyte phagocytosis  
(A): Percentage of monocytes positive for fluorescence following incubation with FITC-
stained L. lactis strains H486 (wild type) and H487 (SpyCEP+ve) or GAS strains H292 
(SpyCEP+ve) and H575 (SpyCEP-ve) for 15, 30, 45 and 60 minutes. Each time point 
represents 20000 gated events (gating made around monocytes based on morphology). Data 
representative of three separate experiments using different donors. (B): Monocyte 
phagocytosis levels 30 minutes post addition of bacteria to monocytes (n=3 donors). Values 
shown are phagocytosis levels for SpyCEP-positive strain observed, relative the values 
obtained for isogenic SpyCEP-negative strain in each experiment. Error bars indicate SD. 
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 SpyCEP-positive and negative L. lactis and GAS strains were equally phagocytosed 
by monocytes (Figure 6-2). The L. lactis strains were phagocytosed by 20% of the monocytes 
in 15 minutes, rising to approximately 35% by 60 minutes. Approximately 25% of monocytes 
incubated with the GAS strains demonstrated fluorescence at 20 minutes post inoculation. 50% 
of the monocytes were positive for phagocytosis by 60 minutes. These results indicate that 
the mechanism by which SpyCEP impairs phagocytosis is also not seen using monocytes. 
Like HL60, monocytes are also low expressers of CXCR1 and 2 compared to neutrophils 
(Shi and Palmer 2011). Hence the similarity of trends between the monocytes and the HL60 
cells, and their differences from neutrophils, were expected. Together these results suggest 
that SpyCEP mediates an effect on neutrophil phagocytosis through the CXCR1 and 2 
receptor pathways, as only phagocytes which express high levels of these receptors are 
affected by SpyCEP. As the ligands for these receptors form the substrate range of SpyCEP, 
such an observation is not unexpected. Furthermore, it is known that CXCR1 and 2 signalling 
leads to the upregulation of receptors involved in GAS phagocytosis (DeMaster, et al. 2002, 
Detmers, et al. 1990, Nilsson, et al. 2005, Weineisen, et al. 2004).  
 The phagocytosis of GAS by monocytes was further investigated using depleted sera. 
This was to determine which opsonisation pathways are important in the phagocytosis of 
GAS by monocytes. Macrophages are known to be important phagocytes of GAS in infection 
(Goldmann, et al. 2004). 
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Figure 6-3 – Monocyte phagocytosis of GAS opsonised with depleted sera 
Percentage of primary human monocytes positive for fluorescence following incubation with 
FITC-stained GAS strains. H292 (wild type) and H575 (ΔcepA) GAS were opsonised in 
variously depleted sera. Samples for flow cytometry were obtained 20, 40 and 60 minutes 
after co-incubation. Each time point represents 20000 gated events (gating made around 
monocytes based on morphology) and the experiment was performed once. 
 The results obtained using depleted sera to opsonise GAS for phagocytosis by 
monocytes were similar to those obtained for neutrophil phagocytosis using similarly 
depleted sera (Figure 6-3). Antibody depletion from the serum in this experiment had little 
impact on phagocytosis compared to complement depletion. Both SpyCEP-positive and 
SpyCEP-negative GAS strains were phagocytosed by approximately 40% of monocytes by 
60 minutes using whole and antibody depleted serum. Complement depletion however had a 
profound impact on phagocytosis, with only 15% of monocytes demonstrating fluorescence 
at 60 minutes post inoculation. Double depleted sera demonstrated no phagocytosis (Figure 
6-3). In all cases, the expression of SpyCEP had no impact on phagocytosis by fresh primary 
monocytes. Taken together, there was no evidence that SpyCEP expression could influence 
uptake of bacteria by HL60 cells or monocytes.  
SpyCEP interferes with the neutrophil response against Group A Streptococcus 
183 
 
Work has been performed by other investigators which suggested that SpyCEP 
prevents internalisation of GAS into epithelial cells, which do not express CXCR1 or CXCR2, 
highlighting a potential role for SpyCEP entirely distinct from any effect on chemokines 
(Andreoni and Zinkernagel, Abstract at XVIII Lancefield Symposium). These investigators 
found their observation to be dependent on SpyCEP retaining its active protease site, but not 
on chemokine cleavage, indicating, an alternative substrate and mechanism of SpyCEP 
activity. This raised the possibility that the phenomenon observed in neutrophils was not a 
function of phagocytosis, but might be replicated in other cell types which express low levels 
of CXCR1 and 2. Although we did not specifically evaluate uptake of bacteria by epithelial 
cells, as had been undertaken by Andreoni and colleagues, we did not find that SpyCEP had a 
generalised effect on internalisation based on data from HL60 and monocytes. 
 
6.2.2 Investigating the impact of CXCR receptors on neutrophil phagocytosis 
 
 
The experiments using other cell types indicated that SpyCEP may impair 
phagocytosis via disruption of CXCR1 and 2 dependent processes. An approach was 
followed whereby an antagonist against the chemokine receptors CXCR1 and 2 was included 
prior to the addition of bacteria to neutrophils to further investigate this hypothesis. By 
blocking signalling through these receptors, it was hypothesised that the effects of SpyCEP 
could be mimicked, and the wild type L. lactis strain protected from phagocytosis to the same 
extent as SpyCEP-positive L. lactis.  
The CXCR antagonist was however a coloured chemical, which absorbed the laser 
light of the flow cytometer, and emitted light over a wide spectrum. Although this prevented 
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the antagonist having utility in flow cytometric assays, it was hoped that the reagent could be 
used for Lancefield assays which are not colourimetric using L. lactis. However, the 
antagonist was found to have antibacterial activity against L. lactis at working concentrations 
(Figure 6-4). 
 
 
Figure 6-4 – Growth curve of L. lactis with CXCR antagonist 
Growth curve of SpyCEP-negative L lactis (H486) over 420 minutes. After 60 minutes, 
antagonist (PD0220245 99% (Axon Medchem, Netherlands)) was added (dashed line) at 0.5x, 
1x or 2x the working concentration (1x working concentration was 10.7μg/ml), and bacterial 
growth measured over 420 minutes. Results show mean of 3 repeats, error bars indicate 
standard deviation 
 As experiments where antagonising the binding of chemokine to their receptors failed 
to produce meaningful results, an alternative strategy was used. Here, soluble, exogenous 
chemokine was added to the cells, to overwhelm the cleavage effects of SpyCEP and thus 
overcome the SpyCEP-positive phenotype. CXCL8, as the most abundant inflammatory 
CXCL chemokine, with the highest specific activity on neutrophils (Mortier, et al. 2011), was 
used for initial experiments. Furthermore, the recombinant CXCL8 used for this experiment 
has been reported to be cleaved relatively slowly by SpyCEP, but still has biological activity 
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as indicated by chemotaxis assays (Goldblatt, personal communication).  It is also known that 
cleaved chemokines are have low affinity for their chemokine receptors (Goldblatt personal 
communication). This experiment was performed to prove that differences in the amount of 
chemokine in the neutrophil phagocytosis reactions were the cause of the observed phenotype. 
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Figure 6-5 – Neutrophil phagocytosis of L. lactis with exogenous CXCL8 titration 
(A): Percentage of human neutrophils positive for fluorescence following incubation with 
FITC-stained H486 (wild type) and H487 (SpyCEP+ve) L. lactis incubated with serial 
dilutions of CXCL8 for 30 minutes. Each time point represents 20000 gated events (gating 
made around neutrophils based on morphology). Data representative of three separate 
experiments using different donors. (B): Phagocytosis by neutrophils from the three donors 
30 minutes post addition of bacteria to neutrophils with different concentrations of CXCL8. 
Values shown are phagocytosis of SpyCEP-positive strains, relative to the values obtained for 
SpyCEP-negative strain in each experiment. Error bars indicate SD, * = P<0.05 (Mann 
Whitney). All values were significant. 
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 Despite the clear impact of SpyCEP expression by L. lactis on phagocytosis, the 
addition of exogenous of soluble CXCL8 had no effect on phagocytosis of L. lactis (Figure 
6-5). SpyCEP also cleaves the other CXCL chemokines which are specific for neutrophils. 
Hence, the experiment of Figure 6-5 was repeated using a chemokine cocktail of all the 
known substrates of SpyCEP, to ensure that other chemokines were not responsible for the 
phenotype previously observed. 
 
Figure 6-6 - Neutrophil phagocytosis of L. lactis with exogenous chemokine cocktail titration 
Percentage of neutrophils positive for fluorescence following incubation with FITC-stained 
H486 (wild type) and H487 (SpyCEP+ve) L. lactis incubated with serial dilutions of a 
chemokine cocktail including an equal concentration of all known SpyCEP substrates 
(CXCL1, 2, 3, 5, 6, 7 and 8) for 30 minutes. Each time point represents 20000 gated events 
(gating made around neutrophils based on morphology) and performed once. 
 Again, addition of exogenous chemokine did not impact on the phenotype actually 
conferred by SpyCEP (Figure 6-6). The chemokines used for these experiments were 
recombinant, and hence may not have the same biological activity as neutrophil released 
chemokines, due to potential differences in folding or post-translation modification. It is 
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known for instance that the 77aa form of CXCL8 (Peprotech) used in this experiment is a less 
potent neutrophil chemoattractant than the 72aa form (Mortier, et al. 2011).  
The results observed in Chapter 5 were achieved independently of any exogenous 
chemokine, hence any chemokine dependent effects were due to differences in endogenous 
chemokine levels. CXCL8 ELISAs were performed separately on the opsonising serum and 
the supernatant of the neutrophil preparation alone, as these represented the only two 
potential sources of exogenous or pre-formed soluble chemokine. Furthermore, a typical 
phagocytosis reaction was prepared, using the L. lactis strains H487 (SpyCEP-positive) and 
H486 (SpyCEP-negative). An aliquot of reaction supernatant was removed every 15 minutes 
and a specific serine protease inhibitor (Pefabloc) was then added to the aliquot to prevent 
any further SpyCEP cleavage activity. The samples were all analysed by ELISA to measure 
concentrations of soluble CXCL8. In all cases, no CXCL8 could be detected (Results not 
shown). The sensitivity of this ELISA was 16pg/ml.  
As neutrophils are known to release large quantities of preformed CXCL8 by 
degranulation rapidly upon encountering bacterial products (Cassatella, et al. 1992), the 
failure to find soluble CXCL8 in any of these situations, including neutrophils incubated with 
opsonised SpyCEP-negative L. lactis, was surprising. A flow cytometric approach was next 
used to measure CXCL8 expressed on the surface or binding to the surface of the neutrophils, 
as such CXCL8 would not be detected using the previous ELISA method. A fluorescently 
conjugated antibody against CXCL8 was used, and median fluorescence intensity thus 
provided a measure of chemokine at the cell surface (Figure 6-7). 
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Figure 6-7 – CXCL8 at the neutrophil surface 
(A): Human neutrophils were incubated with L. lactis H487 (SpyCEP+ve), H486 (SpyCEP-
ve) or GAS strains H292 (SpyCEP+ve) or H575 (SpyCEP-ve) for 30 minutes and CXCL8 
levels on the neutrophil surface were measured using FITC conjugated anti CXCL8. Each 
point shows median fluorescence intensity relative to isotype control and represents 20000 
gated events (gating made around neutrophils based on morphology). Results representative 
of three independent experiments. (B): CXCL8 binding levels of all tested serum/neutrophils 
30 minutes post addition of bacteria to neutrophils. Values shown are CXCL8 levels, relative 
to the values obtained for SpyCEP-negative strain in each experiment. Error bars indicate SD, 
* = P<0.05 (Mann Whitney). 
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 Neutrophils that had been incubated with SpyCEP-negative L. lactis were observed to 
have higher levels of CXCL8 at the cell surface, compared to SpyCEP-positive L. lactis. This 
experiment did not determine whether different amounts of CXCL8 were bound to the 
chemokine receptors expressed on the surface of neutrophils. The same results were seen 
using GAS strains, with more CXCL8 attached to the cell surface of neutrophils incubated 
with SpyCEP-negative GAS compared to SpyCEP-positive GAS. As no soluble CXCL8 
could be detected using the ELISA method, it seems likely that the CXCL8 detected is 
endogenously produced by neutrophils upon interacting with bacterial components, which 
then binds rapidly with high avidity to the surface of the neutrophil, leading to neutrophil 
activation 
A further experiment was performed to strengthen the hypothesis that by cleaving 
chemokines, SpyCEP was able to prevent neutrophil activation and thus phagocytosis. 
Supernatants from SpyCEP-expressing bacteria are also able to cleave chemokines (Figure 
3-2). Thus, SpyCEP-negative strains should be protected from phagocytosis by the addition 
of soluble SpyCEP expressed by an alternative strain. This experiment was performed to 
confirm that the protease activity of SpyCEP is sufficient to prevent phagocytosis. Initially, 
SpyCEP-positive and negative L. lactis strains were incubated with supernatants from GAS 
strains. These were used as they were known to contain higher levels of SpyCEP than the 
supernatants of the L. lactis strains (Figure 3-6). Both L. lactis strains were however 
protected by both of the GAS supernatants, regardless of the presence or absence of SpyCEP. 
This was likely due to the large number of other soluble virulence factors expressed by GAS, 
which are able to prevent the relatively weakly opsonised L. lactis (Figure 5-11) from being 
phagocytosed (Results not shown).   
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 The experiment was hence repeated using the supernatants from L. lactis. This 
provided a source of SpyCEP free from other soluble virulence factors which might interfere 
with phagocytosis (Figure 6-8), but with a very much lower concentration of SpyCEP.  
 
Figure 6-8 – Neutrophil phagocytosis of L. lactis incubated with soluble SpyCEP 
Percentage of neutrophils positive for fluorescence following incubation with FITC-stained 
H486 (wild type) and H487 (SpyCEP+ve) L. lactis incubated with supernatant from 
SpyCEP+ or SpyCEP- L. lactis strains for 20, 40 and 60 minutes. Each time point represents 
20000 gated events (gating made around neutrophils based on morphology) and the study 
was performed once. 
 The data suggested that soluble SpyCEP could not protect L. lactis against neutrophil 
phagocytosis. We had hypothesised that chemokine cleavage was mediating the observed 
difference in phagocytosis, hence this result was unexpected. As soluble SpyCEP had no 
effect on phagocytosis, it seemed likely that bacterial cell surface expressed SpyCEP was 
critical for this effect, potentially interacting and inactivating chemokines exposed on the 
surface of neutrophils in order to evade phagocytosis. Work was carried out in the next 
chapter using a GAS strain which expresses only soluble SpyCEP. 
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6.2.3 Assessing the levels of CD11b on the neutrophil surface 
 
The results obtained in Chapter 5 demonstrate that SpyCEP is able to disrupt 
neutrophil phagocytosis, and work in this chapter shows SpyCEP is able to reduce the 
binding of CXCL8 to the neutrophil surface. Thus, the hypothesis that the mechanism by 
which SpyCEP impacted on phagocytosis was by cleaving chemokines has been supported. 
Chemokines play a role in neutrophil activation by binding the chemokine receptors CXCR1 
and CXCR2 expressed at high levels on the surface of neutrophils (Grob, et al. 1990). 
Following CXCL binding of these receptors, neutrophils are known to release granules that 
contain further chemokines including CXCL8 (Scapini, et al. 2000), components of the 
complement receptor heterodimers, including CR3, (Detmers, et al. 1990, Paccaud, et al. 
1990), and Fc receptors (Elghetany 2002). By cleaving chemokines, it was hypothesised that 
SpyCEP may prevent the upregulation of surface expression of receptors involved in 
phagocytosis, and thus prevent phagocytosis. As complement has been shown to be vitally 
important for GAS phagocytosis, both in this work and by other investigators (DeMaster et al. 
2002) neutrophil cell surface expression of complement receptors was measured.   
Initial experiments were carried out to confirm that the chemokine substrates of 
SpyCEP, but not other CXCL chemokines were able to activate neutrophils, and result in 
expression of complement receptors. Neutrophil activation is classically measured by the 
surface expression of CD11b (Nicholson, et al. 2007), which acts as a surrogate for all 
activation-induced surface markers (Elghetany 2002). Further, CD11b is itself part of  CR3 
(Hynes 1992), the blockade of which has been reported to prevent GAS phagocytosis 
(DeMaster, et al. 2002). Blockade of other complement receptors including CR1 has been 
reported to have little effect on GAS phagocytosis (Nilsson, et al. 2005, Weineisen, et al. 
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2004). Hence, by measuring CD11b surface levels, a receptor known to be critically involved 
in GAS phagocytosis is being measured, furthering the utility of this approach. CXCL8 and 
CXCL5, both agonists of CXCR1 and 2, and substrates of SpyCEP were incubated with 
neutrophils along with CXCL10, known to not bind neutrophils and not be a substrate of 
SpyCEP. Surface CD11b was labelled using a specific fluorescently conjugated antibody, and 
fluorescence intensity was measured by flow cytometry (Figure 6-9). 
 
Figure 6-9 – Neutrophil CD11b levels following incubation with CXCL chemokines 
Human neutrophils were incubated with varying concentrations of CXCL chemokines for 30 
minutes, and CD11b levels measured using FITC-conjugated anti-CD11b. Each point shows 
median fluorescence intensity relative to the isotype control and represents 20000 gated 
events (gating made around neutrophils based on morphology), and was performed once. 
 Neutrophil specific CXCL chemokines (CXCL5 and CXCL8) increased surface levels 
of CD11b compared with a non-neutrophil specific chemokine CXCL10 (Figure 6-9). Further 
work was performed to examine whether SpyCEP-cleaved chemokines were also capable of 
increasing CD11b levels on the cell surface. It was found that chemokine incubated with the 
supernatant of SpyCEP-negative GAS strain H575 raised CD11b significantly more than 
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chemokine incubated with supernatant from SpyCEP-positive GAS strain H292. In both 
cases however, CD11b was raised more than chemokine alone, presumably due to neutrophils 
being activated by bacterial products in the supernatants and generic inflammatory mediators 
within the TH media itself (Figure 6-10). 
 
Figure 6-10 – CD11b on neutrophil surface in response to cleaved and uncleaved CXCL8 
10nM of CXCL8 incubated o/n with TH supernatant from GAS strains H292 (SpyCEP +ve) 
or H575 (SpyCEP –ve) was incubated with human neutrophils for 30 minutes. CD11b levels 
measured using FITC-conjugated anti-CD11b. Each point shows median fluorescence 
intensity relative to a control using H292 and H575 supernatants combined alone, and 
represents 20000 gated events (gating made around neutrophils based on morphology). 
Values shown are CD11b levels, relative the values obtained for SpyCEP-negative strain in 
each experiment. Error bars indicate SD, * = P<0.05 (Mann Whitney).  
Next, measurements were taken to determine the levels of CD11b on the neutrophil 
surface following co-incubation with SpyCEP-positive and negative strains of bacteria 
(Figure 6-11). 
 
Comment [RL3]: SS thinks I should 
have used RPMI 
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Figure 6-11 – Neutrophil CD11b surface expression following incubation with bacteria  
(A): Neutrophils were incubated with L. lactis strains H487 (SpyCEP+ve) and H486 
(SpyCEP-ve), or GAS strains H292 (SpyCEP+ve) and H575 (SpyCEP-ve) for 30 minutes. 
CD11b levels were measured using FITC conjugated anti CD11b, compared to a FITC 
labelled isotype control. Each point shows median fluorescence intensity relative to a PBS 
control and represents 20000 gated events (gating made around neutrophils based on 
morphology). Results representative of 5 independent experiments using L. lactis strains and 
3 using GAS strains. (B): CD11b levels of all tested donors 30 minutes post addition of 
bacteria to neutrophils. Values shown are CD11b levels, relative to values obtained for 
SpyCEP-negative strain in each experiment. Error bars indicate SD, * = P<0.05, **=P<0.01 
(Mann Whitney). 
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 SpyCEP expressing bacteria caused neutrophils to express less CD11b on their 
surface than SpyCEP-negative strains (Figure 6-11). This difference was more clearly seen 
using L. lactis strains than the GAS strains, but both were still significant. Taking CD11b as a 
surrogate of activation, the data suggest that SpyCEP expressing strains were able to prevent 
neutrophil activation. As CD11b is a phagocytosis receptor itself important for phagocytosis 
of GAS (DeMaster, et al. 2002, Nilsson, et al. 2005, Weineisen, et al. 2004), reduced levels 
provide a direct mechanism by which SpyCEP expressing bacteria impede phagocytosis 
compared to their SpyCEP-negative counterparts.  
Whilst chemokine cleavage is the most likely mechanism that underlies reduced 
CD11b and neutrophil activation, further investigations were undertaken to determine 
whether this was indeed the case. Firstly, the alternative explanation that SpyCEP directly 
degrades CD11b was explored. CD11b was extracted from activated neutrophils and 
incubated with high SpyCEP containing GAS supernatants (Figure 3-6) or a negative control 
to determine whether SpyCEP could directly cleave this protein. Immunoblotting was 
performed in triplicate using a CD11b antibody, and the band density at approximately 
100kDa (full length CD11b) was measured (Figure 6-12). 
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Figure 6-12 – Densitometry of CD11b incubated with SpyCEP 
CD11b extracted from neutrophils was incubated overnight with GAS supernatants of various 
concentrations or alone. Above shows neat results obtained with neat supernatant. This was 
then immunoblotted using an antibody against CD11b in independent triplicate. The three 
immunoblots were analysed using ImageJ, and mean band density plotted relative to a CD11b 
alone control included in each experiment. Bars indicate standard deviation.  
 CD11b was present at the same concentration whether incubated with SpyCEP-
positive or negative supernatants (Figure 6-12), confirming that SpyCEP does not cleave 
CD11b. Taken together, the data showed that SpyCEP expression caused reduced neutrophil 
surface CR3, but that there was no evidence that this was related to SpyCEP cleavage of 
CD11b. Rather the reduced CD11b, could be attributed to cleavage of neutrophil surface-
expressed CXCL chemokines. 
  
Comment [RAL4]: POSTSS – She 
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6.3 Discussion 
6.3.1 Phagocytosis by other cell types 
 
GAS is an extracellular pathogen, although several studies have reported that GAS is 
able to invade a diverse range of cells, including epithelial cells (LaPenta, et al. 1994) and 
cultured endothelial cells (Greco, et al. 1995). Importantly, internalisation into such cells is 
undergone by a tiny minority of bacteria, and the contribution to pathogenicity is unclear 
(Cunningham 2000). Cell invasion has been reported to be of importance in GAS virulence, 
acting as a reservoir for persistent infections, although this has primarily been associated with 
GAS survival within macrophages (Hertzen, et al. 2010). Indeed GAS has been reported to 
be killed very efficiently upon phagocytosis by neutrophils (Sullivan and Mandell 1980).  
There are two conflicting reports regarding the impact that SpyCEP makes on the 
invasion of eukaryotic cells by GAS. One report demonstrated that SpyCEP can act as an 
invasin, its expression allowing enhanced entry of SpyCEP-expressing killed Group B 
Streptococcus and SpyCEP-coated latex beads into endothelial cells (Kaur, et al. 2010). In 
contrast, another group (Andreoni and Zinkernagel, Abstract at XVIII Lancefield Symposium) 
have reported that SpyCEP acts as an anti-invasin, preventing the invasion of epithelial cells 
by GAS. Zinkernagel et al. 2008 also describe SpyCEP as an anti-adhesin. One of the starting 
points for work in this chapter was that the reduced entry of SpyCEP expressing strains into 
neutrophils may represent an example of SpyCEP preventing GAS “invading” neutrophils, 
rather than reducing neutrophil phagocytosis of GAS. 
To examine whether this might explain the observations of this study, and to provide 
support for the hypothesis that SpyCEP prevents phagocytosis by interfering with CXCR 
mediated upregulation of phagocytosis receptors, other phagocytic cells were used for 
SpyCEP interferes with the neutrophil response against Group A Streptococcus 
199 
 
phagocytosis experiments. The HL60 leukocyte cell line can be differentiated to resemble a 
cell with neutrophil like characteristics. HL60 phagocytose opsonised particles and express 
complement receptors and antibody receptors akin to neutrophils (Collins, et al. 1979). 
However, they express low levels of CXCR1 and 2, and are thus poorly responsive to 
neutrophil specific chemokines (Grob, et al. 1990, Zahn, et al. 1997).  
SpyCEP-positive and negative L. lactis strains were phagocytosed equally well by HL60 
cells, although much less well than was observed using freshly extracted human neutrophils 
(Figure 6-1). Phagocytosis by these cells was not affected by the expression of SpyCEP. 
These phagocytic cells express only low levels of CXCR1 and 2, and thus enzymatic activity 
which disrupts this pathway would be much less noticeable using these cells than using 
neutrophils (Grob, et al. 1990, Zahn, et al. 1997). Such a result hence strengthens the 
hypothesis that by cleaving chemokines, SpyCEP inhibits full activation of neutrophils 
mediated by chemokines, preventing the full upregulation of receptors involved in 
phagocytosis. If the mechanism did not depend on chemokine cleavage, rather the presence 
of SpyCEP on the GAS surface, an observed difference in phagocytosis by HL60 cells would 
have been expected.    
The ability of HL60 cells to phagocytose particles was less than that of freshly extracted 
neutrophils. Neutrophils are known to be particularly efficient phagocytes, able to 
phagocytose particles very quickly (Nordenfelt and Tapper 2011). Indeed, a noteworthy 
difference between neutrophils and HL60 cells was the level of extracellular signal that was 
quenched by addition of trypan blue (Figure 6-13). These results show that bacteria were 
bound to the surface of HL60, but were not phagocytosed efficiently. Neutrophils, upon 
binding bacteria to their surface were much more efficient at phagocytosis (Figure 6-13). 
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Figure 6-13 – Comparison of fluorescence quenching between neutrophils and HL60 
Percentage of neutrophils (A) and HL60 cells (B) positive for fluorescence following 
incubation with FITC-stained H292 (wild type GAS) for 15, 30, 45 and 60 minutes. Each 
time point represents 20000 gated events (gating made around neutrophils based on 
morphology). Measurements were taken at each time point without quenching, then trypan 
blue was added to quench extracellular signal. Data representative of three separate 
experiments 
 HL60 cells are a cell line, and thus the experiments were repeated using freshly 
extracted monocytes. These are genuine human phagocytes, which express complement and 
antibody binding receptors, but, like HL60, few CXCR1 and 2 receptors (Shi and Pamer 
2011). It was hypothesised that these cells would give similar results to those obtained using 
B 
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HL60 cells, such that if SpyCEP-mediated its effects on phagocytosis by cleaving 
chemokines, phagocytosis by these cells should be unaffected.  
SpyCEP-positive and negative L. lactis and GAS strains were both equally phagocytosed 
by monocytes (Figure 6-2). Monocyte phagocytosis was slow compared to neutrophils, which 
has been previously reported (Nordenfelt and Tapper 2011). Together, these results show that 
SpyCEP does not act as a broad spectrum anti-invasin on the surface of GAS, as has been 
suggested. Instead, SpyCEP acts to specifically prevent neutrophil specific phagocytosis. As 
SpyCEP is known to have cleavage activity against neutrophil specific chemokines, this 
provides a likely source for the specificity of cell type of which SpyCEP can impair 
phagocytosis.  
Phagocytosis of GAS by macrophages is reportedly a vital feature in successful 
clearance of experimental GAS infections. Indeed macrophage deficient mice had a 
significantly more severe infection and a much higher mortality rate than wild type mice 
(Goldmann, et al. 2004). In this chapter, the contribution of complement and antibody to this 
vital process was examined. It was determined that, similar to neutrophils, depletion of 
antibody had only a small impact on phagocytosis. However, ablation of complement had a 
major impact on phagocytosis. The double depleted serum allowed no phagocytosis, 
demonstrating the effectiveness of the serum depletion methods. The importance of 
complement to phagocytosis of GAS identified complement receptors as a likely basis for 
SpyCEP-mediated inhibition of phagocytosis. 
The main role of antibody in opsonisation of GAS may be to enhance complement 
deposition, thus without complement, antibody can only poorly opsonise GAS. Indeed the 
direct blockade of Fc receptors is known to have no impact on GAS phagocytosis (Nilsson, et 
al. 2005). The GAS strain used throughout this study was an emm/M81 strain. Whilst this M 
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protein type has not been studied extensively, variation between biological activities of M-
types is known. There are broadly two groups of M protein, both of which inhibit 
complement deposition, but using different mechanisms (Carlsson, et al. 2005), thus impact 
of antibody in the sera may be different between these M protein types. 
  
6.3.2 Assessing the impact of chemokines on neutrophil phagocytosis 
 
The results of this chapter suggested that SpyCEP disrupts chemokine-mediated 
neutrophil activation. This was hypothesised to prevent full upregulation of receptors 
involved in phagocytosis. Initially an antagonist of CXCR1 and 2 was used to try to mimic 
the prevention of chemokine signalling that was hypothesised to be mediating the SpyCEP 
effect on phagocytosis. However, this coloured compound made the neutrophils fluorescent 
in all channels available on the FACS Calibur machine used in this study. Furthermore, the 
antagonist was antibacterial, hence was of no use for assays measuring bacterial growth in 
blood. Later, serine protease inhibitors were added to block SpyCEP activity in flow 
cytometry phagocytosis experiments using IVIg-opsonised bacteria. However, these 
inhibitors proved toxic to neutrophils (Results not shown).  Other antagonists of CXCR1 and 
2 exist, but were not used in this study. 
As chemokine receptor antagonists had failed to provide results to validate or 
disprove our hypothesis, we sought to use an alternative approach by determining whether 
any effect of SpyCEP could be overcome using an excess of chemokine. The addition of 
excess exogenous chemokine to the phagocytosis reactions upon the addition of the bacteria 
was hypothesised to increase the phagocytosis of the SpyCEP-positive strains. The 
recombinant CXCL8 used for this experiment has been reported to be cleaved relatively 
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slowly by SpyCEP, but still has biological activity as indicated by chemotaxis assays 
(Goldblatt, personal communication). Hence, despite the presence of proteolytic SpyCEP 
activity, some CXCL8 would remain intact to bind neutrophils, especially when using higher 
concentrations. It is also known that this particular cleaved chemokine does not antagonise 
the binding of intact chemokines to the CXCR1 and 2 receptors (Goldblatt, personal 
communication). 
 Surprisingly, exogenous chemokine had no effect on phagocytosis (Figure 6-5). The 
chemokine used in this experiment however has been reported to be a relatively poor 
substrate for SpyCEP compared to other sources of recombinant CXCL8. Whilst it was used 
for this reason, this may also mean this chemokine has a poor affinity for CXCR1 and 2. 
CXCL8 undergoes extensive processing, and is found in a variety of lengths, with varying 
biological activity (Mortier, et al. 2011, Van Damme, et al. 1990). Indeed, the 77aa acid form 
of CXCL8, used in this experiment, is known to be less chemotactic than the 72aa version 
(Mortier, et al. 2011). It may also be that simply not enough chemokine was added in these 
experiments to overwhelm the cleavage by SpyCEP. 
The inclusion of all the neutrophil specific chemokines also had no effect on 
phagocytosis. Again, processing is known to play an important role in their activity; however, 
these results were still highly unexpected. Indeed, comparable concentrations of a different 
recombinant chemokine of 77aa to those added in these experiments caused a measurable 
increase in CD11b concentration within 30 minutes (Figure 6-9). A unifying explanation for 
these observations is that phagocytosis by neutrophils requires endogenous chemokine. 
If the hypothesis explaining SpyCEP-mediated inhibition of phagocytosis was correct, 
a higher chemokine concentration ought to have been measurable in the phagocytosis 
reaction mixtures between the strains which lack SpyCEP compared to the isogenic SpyCEP-
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positive strains. Initially, CXCL8, the most abundant CXCL chemokine (Mortier, et al. 2011), 
was measured in the freshly extracted serum and supernatant around freshly extracted 
neutrophils alone. No CXCL8 was measurable in either fluid. As the sera used were from 
healthy donors, and the neutrophils had been extracted using sterile technique, this 
inflammatory chemokine would be at only very low concentrations. 
However, soluble CXCL8 was also not detectable in the supernatant taken from 
phagocytosis reactions, including experiments where opsonised SpyCEP-negative bacteria 
were mixed with neutrophils. Addition of bacteria to neutrophils leads to the exocytosis of 
secretory vesicles that are quick to degranulate, and contain CXCL8 (Amulic, et al. 2012), 
hence a measurable level of CXCL8 was expected in the supernatants (Cassatella, et al. 1992). 
A greater amount of CXCL8 could be measured following neutrophil incubation with 
SpyCEP-negative bacteria compared to SpyCEP-positive strains but this difference was only 
detected at the surface of neutrophils. This result suggests that following the release of 
CXCL8 from neutrophil granules, the chemokine is very rapidly or perhaps immediately 
bound by the neutrophils. This was likely an artefact of the reaction conditions used; where 
neutrophils are the only human cell present, the reaction mixture is being agitated, and they 
are at high concentrations. What could not be determined was whether the CXCL8 was 
bound to its receptors or was simply associated with the surface of the neutrophil.   
To confirm that cleavage of chemokines by any form of SpyCEP was responsible for 
the observed differences in phagocytosis between SpyCEP-positive and negative strains, 
bacterial supernatants were included in the phagocytosis reaction mixes (Figure 6-8). GAS 
supernatants were initially added to L. lactis strains, as wild type GAS strain H292 is known 
to produce high concentrations of soluble SpyCEP (Figure 3-6). However, it was found that 
both supernatants from SpyCEP-positive and negative GAS strains were able provide 
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considerable protection for both L. lactis strains. This was presumably due to other soluble 
virulence factors expressed by GAS (Results not shown). 
 Experiments using the supernatants from L. lactis strains demonstrated that soluble 
SpyCEP produced by SpyCEP-positive L. lactis strain H487 offered no protection against 
phagocytosis. These results suggested that surface expression of SpyCEP was essential for its 
observed effect on phagocytosis (Figure 6-8). However, SpyCEP-positive L. lactis strain 
H487 is known to produce only very low levels of soluble SpyCEP (Figure 3-6), and thus the 
SpyCEP concentration may have been too low to mediate any biologically relevant effects.  
 
6.3.3 A mechanism by which SpyCEP inhibits phagocytosis 
 
The only known function of SpyCEP is the cleavage of ELR+ CXCL chemokines 
which are specific for neutrophils. Specificity for neutrophils is due to their binding affinity 
for CXCR1 and CXCR2 which are expressed in high levels on the surface of neutrophils 
(Grob, et al. 1990). It is known that CXCL8, a substrate of SpyCEP which binds with high 
affinity to CXCR1 and CXCR2, upregulates CD11b in a dose responsive manner (Detmers, 
et al. 1990). CD11b is part of the complement receptor 3 (CR3) heterodimer (Hynes 1992). 
This receptor has previously been shown to be vitally important for GAS phagocytosis 
(DeMaster et al. 2002) which coupled with the observations made here that complement is 
required for GAS phagocytosis, provides a mechanism by which SpyCEP was hypothesised 
to act. However, previous work showing CXCR receptor blockade have not reported reduced 
phagocytosis, but have instead focussed on reduced neutrophil recruitment (Stillie, et al. 
2009).  
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CD11b is found preformed in a variety of neutrophil granules, which are released 
upon progressive activation of neutrophils. Neutrophil activation is a gradual continuum, 
whereby different stimuli, including CXCL8, act in concert to gradually increase the state of 
activation (Borregaard, et al. 1994). CD11b is classically used as a measure of neutrophil 
activation. Due to its presence in many classes of granules which are released at various 
stages of activation, its release onto the cell surface continues throughout activation (Amulic, 
et al. 2012). Its upregulation is also accompanied by the upregulation of other phagocytic 
receptors, such as complement receptor 1 and antibody receptors for phagocytosis, 
specifically FcγRIII.   
Figure 6-9 confirmed the earlier work (Detmers, et al. 1990) which showed that 
CXCL8 was able to upregulate CD11b in a dose dependent manner. A CD11b response was 
seen when CXCL8 reached 1nM (approximately 8000pg/ml), a concentration typically 
exceeded in infection (Kurupati, et al. 2010). A similar dose dependent response was 
observed using increasing concentrations of another neutrophil CXCR ligand, CXCL5. Both 
these ligands are substrates of SpyCEP, and their ability to upregulate CD11b was ablated 
following SpyCEP cleavage (Figure 6-10). This result was expected, as work currently 
underway at Imperial College demonstrates that SpyCEP cleavage ablates the binding of the 
chemokines to their receptors (Goldblatt personal communication). CXCL10, known not to 
be a ligand for these receptors, was unable to increase CD11b expression, demonstrating this 
was a specific effect that required CXCR1/2 activation.  
The increase in CD11b was observed thirty minutes subsequent to the addition of 
chemokine. This was also reported by Detmers 1990, and can occur this rapidly as the CD11b 
is pre-formed in granules within the neutrophil. These granules are known to be able to 
exocytose very quickly following detection of a stimulus (Detmers, et al. 1990). 
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The surface levels of CD11b were also measured following incubation with the 
different SpyCEP-positive and negative strains (Figure 6-11). SpyCEP-negative L. lactis was 
found to induce neutrophils to upregulate surface CD11b more strongly than the SpyCEP-
positive strain. The same pattern of results was observed using the GAS strains, although 
with reduced difference between the isogenic GAS strains. The SpyCEP-positive strains 
activated the neutrophils less than the SpyCEP-negative strains. It was confirmed that 
SpyCEP could not directly cleave CD11b using densitometry analysis of Western blots 
(Figure 6-12). 
Neutrophils are activated by a variety of stimuli including exposure to both bacteria 
and chemokine (Amulic, et al. 2012). The bacterial strains used in this experiment were 
isogenic, apart from their expression of SpyCEP. It hence seems unlikely that bacterial 
stimuli being received by the neutrophil are different between the SpyCEP-positive and 
negative strains, and instead differences in chemokine signalling are the more likely source of 
activation differences. As complement is known to be important for opsonisation of L. lactis 
and GAS (Figure 5-12 and Figure 5-13), and CD11b is known to be a component of a 
complement receptor, the reduced CD11b levels seen with SpyCEP positive bacteria also 
provides a mechanism by which SpyCEP inhibits phagocytosis. Furthermore, it is known that 
neutralisation of CD11b using antibody can prevent phagocytosis of GAS by neutrophils, 
indicating its importance in GAS phagocytosis (Nilsson, et al. 2005). Thus, taken together, 
these results provide a mechanism by which SpyCEP could interfere with phagocytosis, 
illustrated in Figure 6-14. 
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Figure 6-14 – Proposed mechanism by which SpyCEP disrupts phagocytosis 
Left of dashed line indicates SpyCEP-negative strain, right of line indicates SpyCEP-positive 
strain. LEFT (moving down diagram): Bacteria (purple) interact with neutrophils causing 
some activation. Neutrophils release CXCL8 (green circles) from their granules. This causes 
further activation, and the upregulation of CD11b. CR3 bind complement opsonised bacteria 
leading to phagocytosis. RIGHT (moving down diagram). Bacteria (purple) interact with 
neutrophils causing some activation. Neutrophils release CXCL8 (green circles) from their 
granules, which is cleaved by SpyCEP (scissors). CD11b is hence not upregulated. 
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Chapter 7 - Results: The effects of localisation of SpyCEP on 
function and immune response to GAS  
 
7.1 Introduction 
 
The C terminus of SpyCEP features an LP(X)TG motif which acts as a substrate for 
the bacterial sortase enzymes. These covalently attach SpyCEP to the cell wall. H292 is 
noteworthy in that it transcribes very high levels of the SpyCEP gene, and releases large 
amounts of this protein into the supernatant, in addition to binding to the cell wall (Turner, et 
al. 2009a). All strains known to express high amounts of SpyCEP release the protein into the 
supernatant. Whether the release of SpyCEP requires active catalysis or simply reflects the 
overwhelming of the sortase system is unclear, although it is known that release is not 
autocatalytic (Zingaretti, et al. 2010). The effect of SpyCEP release on virulence is also 
unknown. The amino acid sequence SpyCEP of H292 differs from other sequenced strains in 
that it has a two amino acid deletion proximal to the LP(X)TG motif. 
 
H292 VKVGDASDSTGDHKVMSKNNSQALTASATPTKTTTS--AKALPSTG 
H305 VKVGDASDSTGDHKVMSKNNSQALTASATPTKSTTSATAKALPSTG 
 
Figure 7-1 – Amino acid sequence of H292 compared to typical SpyCEP sequence 
Amino acid alignment of SpyCEP from GAS strain H292 used throughout this study, and 
from strain H305, which expresses a SpyCEP with a typical C-terminus. Grey indicates 
sortase motif, blue indicates a 2 amino acid difference. Sequences from NCBI. 
1600                1610 
 
N C 
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 Previous work in this study and others (Kurupati, et al. 2010) has demonstrated that 
SpyCEP has both systemic and local effects. SpyCEP released locally can affect neutrophil 
release from the bone marrow, in association with reduced concentrations of systemic 
neutrophil chemokines implying that soluble SpyCEP has a role in virulence distant from the 
focus of infection (Figure 4-1, Figure 4-8). Negative effects on phagocytosis (Figure 5-5) 
however depended upon bacterial surface bound SpyCEP, and could not be reproduced by 
addition of soluble SpyCEP (Figure 6-8). It was thus hypothesised that both surface bound 
and soluble SpyCEP contributed separately to virulence in GAS infection. I postulated that a 
strain constructed without a SpyCEP sortase motif would survive less well at the site of 
infection, but result in otherwise similar effects systemically when compared with an isogenic 
control strain of GAS. 
 I further postulated that loss of surface-expressed SpyCEP might abrogate any 
protective effect of SpyCEP vaccination against invasive GAS infection. However, if the 
mechanism of vaccine efficacy required neutralising anti-SpyCEP activity, rather than 
opsonisation of bacteria, then vaccination would impact similarly on infection caused by 
bacteria expressing SpyCEP on the surface or bacteria that released SpyCEP. 
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7.2 Results 
 
7.2.1 Construction and in vitro characterisation of SpyCEP sortase mutant (H887) 
 
Cell wall extracts and supernatants from H292 and H887 were prepared and analysed 
by immunoblotting using an anti SpyCEP antibody. It was observed that strain H887 had 
more SpyCEP in its supernatant than H292. H887 however had much reduced SpyCEP in the 
cell wall fraction compared to H292, although a small amount was still detectable, likely 
related to the export of SpyCEP through the cell membrane or due to contamination of cell 
wall preparations with large amounts of SpyCEP in the culture supernatant (Figure 7-2). 
Furthermore, non-specific Van der Waals type interactions between SpyCEP and other large 
GAS cell wall proteins may also lead to some carry over during the preparation of the cell 
wall extracts. This was as expected, and confirmed that SpyCEP expression was not 
quantitatively affected following insertion of the plasmid, but the location of expression was 
as predicted. Hence SpyCEP was present wholly in the culture supernatant rather than being 
cell surface anchored.  
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Figure 7-2 – Immunoblots showing SpyCEP localisation is GAS strains H292 and H887 
Supernatants and cell wall extracts were collected from GAS cultures of wild type strain 
H292 and isogenic sortase motif mutant strain H887 at early, mid and late log. SpyCEP levels 
were measured using an antibody raised against an N terminal segment of SpyCEP. 
Equivalent protein amounts were loaded for each strain, as assessed by spectroscopy.  
Supernatants were also tested to ensure that SpyCEP produced by strain H887 
retained its enzymatic activity. Cleavage assays were performed using all the known CXCL 
chemokine substrates of SpyCEP No differences in cleavage activity between H292 and 
H887 were observed, although slightly more cleavage was observed using the supernatants of 
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sortase negative strains, indicative of the greater amount of SpyCEP present in the 
supernatant (Figure 7-3).  
 
Figure 7-3 - Chemokine cleavage by supernatants of GAS strains H292 and H887 
200ng of the chemokine CXCL6 was incubated with 8μl of wild type GAS supernatant 
(H292) or an isogenic SpyCEP sortase mutant (H887), each grown to an OD on 1.0.  These 
were examined by protein electrophoresis and stained with colloidal blue. CXCL6 shown to 
illustrate the slightly increased cleavage by the sortase mutant strain. 
H887 was characterised prior to its use in virulence assays. Initial studies examined its 
growth in TH media to ensure that the disruption of the sortase motif of SpyCEP had no 
indirect effects on GAS growth (Figure 7-4). 
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Figure 7-4 – Growth curve of H292 and H887 
Cultures grown o/n were subcultured 1 in 10 into fresh TH media in triplicate. At 60 minute 
intervals, a sample was taken and the OD600 measured. Results indicate mean and standard 
deviation of three experiments.  
 The two isogenic strains were labelled using FITC and ability to affect phagocytosis 
was compared using purified human neutrophils. No difference was seen between the two 
strains, with 50% of neutrophils containing fluorescent bacteria after sixty minutes (Figure 
7-5). 
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Figure 7-5 – Neutrophil phagocytosis of GAS strains H292 and H887 
(A): Percentage of neutrophils positive for fluorescence following incubation with FITC-
stained H292 (wild type) and H887 (Δsortase) at 15, 30, 45 and 60 minutes. Each time point 
represents 20000 gated events (gating made around neutrophils based on morphology). Data 
representative of three separate experiments using different donors. (B): Phagocytosis from 
the two experiments 30 minutes post addition of bacteria to neutrophils. Values shown are 
phagocytosis levels for sortase-positive strain (H292), relative to values obtained for sortase-
negative strain (H887) in each experiment. Error bars indicate SD. 
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 This finding surprisingly disproved the hypothesis generated in Chapter 6 that surface 
bound SpyCEP was required to prevent phagocytosis, although Figure 7-3 suggests there is 
some SpyCEP on the surface of H887. The tenet that inhibition of phagocytosis required 
surface-bound SpyCEP stemmed from the observation that supernatant from SpyCEP-
positive L. lactis was unable to prevent phagocytosis (Figure 6-8). However, L. lactis 
produces only a small amount of soluble SpyCEP (Figure 3-6), providing a potential 
explanation as to why the L. lactis supernatant could not prevent phagocytosis. Clearly in a 
setting where soluble secreted SpyCEP is abundant, phagocytosis inhibition does occur 
readily. 
 
7.2.2 In vivo studies to determine if soluble SpyCEP has a specific role 
 
In this study, the systemic effects of SpyCEP have been noted to specifically prevent the 
release neutrophils from the bone marrow, while the local effects include impairment of 
neutrophil recruitment (Edwards, et al. 2005) and impairment of phagocytosis (this study). 
To determine if GAS secreting only soluble SpyCEP might differentially affect distant and 
local events following infection compared with wild type GAS, pilot experiments were 
conducted where mice were infected intramuscularly with wild type H292 or sortase motif 
negative H887 GAS strains. At six hours, neutrophils were counted in the peripheral blood.  
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Figure 7-6 - Peripheral neutrophil levels following H292 and H887 infection 
Five female CD1 mice were injected with approximately 10
8 
CFU of GAS strains H292 (wild 
type) or H887 (SpyCEP sortase mutant). Mouse blood was collected at 6 hours and peripheral 
circulating neutrophil counted.  
 We had hypothesised that H887 would release more soluble SpyCEP, which seemed 
to be supported by immunoblotting (Figure 7-2). This would have a greater systemic effect, 
and thus have a greater impact on neutrophil release. It was found that there were more 
circulating neutrophils in mice infected with strain H292 than strain H887. However, this 
difference was not statistically significant. This experiment was necessarily a pilot study, 
designed to power a more substantive experiment. The data shows that 16 mice per group 
would be required to show a 60% reduction in peripheral neutrophil numbers. H292 releases 
large amounts of soluble SpyCEP itself. It would be interesting to compare H887 with a 
strain unable to release SpyCEP from its surface, and with strain H575. 
 GAS strains H292 and H887 were also compared with regard to local and systemic 
bacterial survival: in this instance a third experimental group was included to allow 
comparison with the SpyCEP-negative isogenic strain H575 (Figure 7-7). It was expected 
that by releasing all its SpyCEP from the cell surface, H887 would survive less well at the 
site of infection, with an unpredictable effect on systemic spread. 
SpyCEP interferes with the neutrophil response against Group A Streptococcus 
219 
 
 
Figure 7-7 - Bacterial load 24 hours post infection with GAS strains H292 and H887 
Groups of 12 CD1 female mice were infected intramuscularly with either H292 (wild type 
GAS, SpyCEP+ve), H887 (sortase negative SpyCEP) or six mice with H575 (SpyCEP-ve 
GAS). 24 hours post infection, the mice were euthanized and organs harvested and 
homogenised. Bacterial loads were quantified. Horizontal lines indicate median. P values 
determined by One way ANOVA analysis, * = P<0.05. 
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 Strains H887 and H292 caused very similar levels of infection in the mouse model 
(Figure 7-7). Hence, surface binding of SpyCEP on GAS had little impact on the virulence of 
GAS. H292 is known to readily release large concentrations of SpyCEP into the supernatant, 
thus the difference in SpyCEP release between these two strains may not be sufficient to see 
any differences in bacterial systemic spread. Specifically however, there was no evidence that 
cell surface expression of SpyCEP was essential for local bacterial survival. Mice infected 
with SpyCEP-negative strain H575 were included as an indicator for the role of SpyCEP, and 
did demonstrate a difference in bacterial survival in the thigh, consistent with previous 
reports (Kurupati, et al. 2010). Interestingly the SpyCEP-negative mutant spread as well as 
the SpyCEP positive strains in this experiment, although numbers in this group were only 6, 
in contrast to the earlier report, underlining the subtlety of effect of single virulence factors 
on GAS pathogenesis. None of the other differences in bacterial load measured between 
H292 and H887 infected mice were significant. 
 It is known that the N terminus of SpyCEP can be used as a vaccine to protect against 
GAS and S. equi infection (Turner, et al. 2009b); however the mode of action of this 
protection is unclear. SpyCEP is cell surface-expressed, and antibodies can recognise cell-
surface expressed proteins (Turner, et al. 2009b). However, antibody-mediated protection 
could stem from opsonising antibodies against this surface bound protein, or from 
neutralisation of the action of SpyCEP. H887 was used as a tool to examine this protection. 
As the sortase negative SpyCEP strain H887 has no SpyCEP bound to its surface, only 
neutralising antibodies against SpyCEP would offer protection against this strain. 
 An N terminal fragment of SpyCEP, CEP5, which was previously used for 
vaccination studies (Turner, et al. 2009b) was expressed recombinantly, purified, and injected 
with adjuvant into the thighs of mice. A further group of mice received PBS with adjuvant as 
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a sham vaccine. The mice received an initial prime, followed by two boost vaccinations. 
Immunity was confirmed prior to infection by tail bleeding three mice from each group. 
Serum was collected and used as a primary antibody for immunoblotting against recombinant 
CEP5 spotted onto membrane (Figure 7-8). 
 
 
Figure 7-8 – Dot immunoblot using sera of vaccinated mice 
Balb/C female mice were injected intramuscularly with either recombinant CEP5 with 
Freund’s adjuvant (15 mice), or a sham vaccine of PBS and adjuvant (15 mice). Three days 
following second boost vaccination, three vaccinated and three sham vaccinated mice were 
randomly selected and tail bleeds were performed. The sera was collected and used as 
primary antibody against recombinant CEP5. Upper three panels using vaccinated mice, 
lower three panels, sham vaccinated mice.  
 Having vaccinated the mice successfully, the sham and vaccine group were then 
challenged with either wild type GAS H292 (7 mice) or sortase negative SpyCEP GAS H887 
(8 mice). 24 hours post infection, the mice were euthanized, and the organs harvested to 
allow determination of bacterial load. 
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Figure 7-9 – GAS CFU recovered following challenge of CEP5 or sham vaccinated mice 
with H292 and H887 
Balb/C female mice were injected intramuscularly with either recombinant CEP5 with 
Freund’s adjuvant (15 mice), or a sham vaccine of PBS and adjuvant (15 mice). Seven days 
following second boost vaccination, the mice were challenged with 5x10
7
CFU of either H292 
(wild type) (7 mice per group) or H887 (SpyCEP sortase negative) (8 mice per group) GAS 
strains. 24 hours following infection, mice were euthanized, organs collected and then 
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homogenised to determine bacterial load. Bars indicate median. P values determined using 
Mann Whitney within groups. 
 Previous vaccination studies found little effect of vaccination at the site of infection, 
but a much greater protective effect against distant sites (Turner, et al. 2009b). In this 
experiment, none of the mice developed a measurable invasive infection, hence protective 
effects against dissemination could not be measured – in all cases no bacteria were detected. 
The results are however consistent with previous work showing a reduction in bacterial 
burden in the thigh muscle following vaccination, compared to sham vaccination, which was 
not seen in mice infected with H887. This result suggests that the antibody response to the 
vaccine has a mainly opsonising role in deep tissue infection. Group sizes were small 
however and such an observation would need to be confirmed in a larger study where 
dissemination to distant tissues was seen consistently.  
Interestingly, in this experiment, a difference in local infection was observed between 
mice infected with H292 and mice infected with H887. The GAS strain that did not express 
surface SpyCEP survived less well in the muscle tissue, as was hypothesised previously. The 
difference observed may be related to the different experimental setting, whereby mice had 
been primed for an immune response with sham vaccination, or may simply be the fact that 
in-bred mice were used in vaccination studies, rendering it easier to determine biological 
differences in response to infection between groups using smaller group sizes.  
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7.3 Discussion 
 
SpyCEP is released in large concentrations from the surface of GAS strain H292. It is 
known that SpyCEP is antigenic, and antibodies are raised against SpyCEP following natural 
infection (Fritzer, et al. 2010). Furthermore, it known that vaccination against SpyCEP is 
protective against invasive GAS soft tissue and respiratory infection (Rodriguez-Ortega, et al. 
2006, Turner, et al. 2009b). As GAS largely retains SpyCEP on the cell wall (Edwards, et al. 
2005), it was hypothesised that surface bound SpyCEP must enhance virulence. We earlier 
demonstrated that the addition of soluble SpyCEP from L. lactis was not protective against 
phagocytosis (Figure 6-8). It was thus hypothesised that a strain unable to retain SpyCEP on 
its surface would survive less well at the site of infection, but might exert systemic effects at 
distant sites to the same or greater extent than a wild type GAS strain. 
To test this hypothesis, a strain was constructed where the sortase motif, which acts as a 
substrate for sortase enzyme-mediated attachment to the cell wall, was replaced with a stop 
codon. The method used single cross-over recombination to alter the chromosomal sequence. 
Such a method generates stable integrants in GAS strains, and thus antibiotic is not needed to 
maintain this mutation (Kurupati, et al. 2010). It is also much easier than allelic replacement 
which requires two recombination events to occur. As such, single cross-over recombination 
is useful for in vivo studies, and does not require antibiotic dosing to maintain mutations.  
The amino acids closer to the C terminus of the protein than the sortase motif were also 
lost following insertion of this plasmid. However, these residues are lost following processing 
by the sortase enzyme of wild type SpyCEP, hence protein function was not expected to be 
impaired. Indeed the C-terminal mutant strain was able to cleave the same substrates as the 
wild type SpyCEP (Figure 7-3). The approach appears to have been effective if removing 
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SpyCEP from the cell wall of GAS, although a small amount of SpyCEP remains associated 
with the bacterial wall (Figure 7-3). The sortase-negative SpyCEP strain was also observed to 
have very similar growth in TH media compared to the wild type strain (Figure 7-4). As such, 
the strains could be used for in vitro and in vivo work, without the results being influenced by 
growth defects, alongside the isogenic mutant H575 that lacks functional SpyCEP. Ultimately, 
a strain that could not release SpyCEP from the cell surface would be a desirable 
complimentary tool to develop, however construction of such a strain would require insight 
into the mechanisms permitting release and secretion of SpyCEP. 
Phagocytosis experiments were carried out comparing the sortase motif-negative 
SpyCEP strain with wild type GAS. No difference in neutrophil phagocytosis was observed 
between the two strains (Figure 7-5). This refuted the hypothesis that surface bound SpyCEP 
was required to prevent neutrophil phagocytosis. This hypothesis was based on the results of 
an earlier experiment (Figure 6-8), where soluble SpyCEP from SpyCEP-positive L. lactis 
H487 was unable to inhibit phagocytosis of SpyCEP-negative L. lactis strain H486. However, 
H487 is known to produce only low levels of soluble SpyCEP (Figure 3-6), thus SpyCEP 
may not reach high enough levels in H487 supernatant to provide protection against 
phagocytosis. We were unable to test GAS supernatants in a similar way because GAS 
supernatants contain a range of other reagents capable of interfering with phagocytosis. The 
observations of this chapter also strengthen the hypothesis that SpyCEP prevents 
phagocytosis by cleaving chemokines (Figure 6-14). Soluble SpyCEP is able to cleave 
chemokines, hence soluble SpyCEP ought to be able to prevent neutrophil phagocytosis. 
In vivo studies were also carried out using the sortase negative SpyCEP strain, H887. 
Initially release of neutrophils into the peripheral blood was measured. It was hypothesised 
that by releasing more soluble SpyCEP, H887 would have greater systemic effects, and hence 
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have a more profound effect on neutrophil release from the bone marrow than wild type GAS. 
Although fewer neutrophils were measured in the peripheral blood following intramuscular 
infection with H887 than with wild type H292, this difference was not significant (Figure 
7-6), and the data require confirmation with a larger experiment. Levels of systemic and soft 
tissue chemokines should also be measured to determine if H887 results in greater systemic 
cleavage of KC and MIP-2.  
Wild type GAS strain H292 is known to release large amounts of soluble SpyCEP 
(Figure 3-6). Thus differences in soluble SpyCEP levels between H292 and sortase negative 
SpyCEP strain H887 are likely to be small. Furthermore, KC, which is cleaved by SpyCEP 
and is involved in neutrophil release from the bone marrow, is initially made locally at the 
infection focus. Thus, a locally high level of SpyCEP in the infection site may be more 
important than high levels of circulating SpyCEP and may indeed impact on systemic levels 
of chemokine (Figure 7-10).  
Having not detected any significant differences in neutrophil release, the virulence of the 
wild type GAS strain H292 and the sortase negative SpyCEP stain H887 were compared 
using the intramuscular invasive disease model of mouse infection. Although we 
hypothesised that the sortase negative SpyCEP strain would survive less well at sites of 
infection due to enhanced phagocytosis, the earlier results showing H887 and H292 were 
phagocytosed equally in vitro suggested this hypothesis was incorrect (Figure 7-5), or that 
enough SpyCEP remained associated with the surface of H887 (Figure 7-3). 
The sortase negative SpyCEP strain resulted in a slightly lower bacterial load at the site 
of infection, however the difference was not statistically significant. Furthermore, the 
difference between the median infection loads of these two infections was less than one log, 
hence any biological significance is also doubtful. A small difference in bacterial load was 
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observed when comparing the sham vaccinated mice infected with the two GAS strains in 
Figure 7-9. Any differences between the two strains may be due to the chemokine gradient 
established in infection, as highlighted in Figure 7-10, rather than any direct impairment of 
phagocytosis. The binding of SpyCEP to the surface of GAS serves as a focus for SpyCEP 
concentration, thus reducing chemokine concentration most profoundly around the bacteria, 
disrupting normal chemokine gradients. As phagocytosis between the two strains was 
identical when testing human neutrophils in vitro (Figure 7-5), it would be inconsistent to 
attribute differences in local growth observed in vivo to impairment of phagocytosis. It is 
however important to note that the in vitro and in vivo experiments differed in terms of 
species (human vs. mouse). 
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Figure 7-10 – Putative chemokine gradients around H292 and H887 
GAS strains (purple) express SpyCEP (scissors). Chemokine (green) is cleaved at a faster rate 
close to the bacteria. Graph shows chemokine levels at distances away from the infection 
focus. Left panel, wild type GAS strain H292, right sortase negative SpyCEP strain H887. 
 While the SpyCEP-negative strain, H575, was recovered at a significantly lower level 
from the infected thigh than the wild type GAS strain H292, H575 spread to distant sites was 
surprisingly not impaired (Figure 7-7). This contrast with data obtained previously in our 
laboratory and may reflect simple differences in the timing of samples in relation to bacterial 
growth (Kurupati, et al. 2010), the use of outbred mice, and the subtlety of single virulence 
factor contributions to virulence when considering pathogens such as GAS which produce a 
multitude of factors that can influence virulence. Specifically, the greatest difference seen 
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with regard to SpyCEP impact on neutrophils and bacterial clearance was observed very early 
in infection at 3-6h (Kurupati, et al. 2010). 
 The antibody response raised against SpyCEP following vaccination was also studied 
using the sortase negative SpyCEP strain, H887. If the antibody raised was neutralising 
SpyCEP, it was expected that the burden of infection caused by strain H887, and wild type 
GAS strain H292 would be equally impaired by vaccination. However, if the antibody was 
opsonising, the vaccination would preferentially be protective against H292. Previous work 
using SpyCEP as a vaccine in an invasive model of infection found that the vaccine was 
primarily protective against systemic spread from the focus of infection at the 24 hour time 
point (Turner, et al. 2009b). 
 This study found that the vaccinated mice infected with H292 appeared to have a 
slight, but not significant, protection against GAS infection at the infection focus. This 
protection was not evident using strain H887. In this study, the mice infected with H887 had 
a significantly lower bacterial burden in the infected thigh than those infected with wild type 
GAS strain H292, likely due to the mechanism described in Figure 7-10. The slight protection 
seen using strain H292 but not seen using strain H887 implies that the antibody protection 
raised in the mice was opsonising GAS rather than neutralising SpyCEP. Unfortunately, the 
mice in this experiment did not suffer systemic infection, thus the protective effect of the 
vaccine could not be fully assessed. This is likely due to the inocula used in this experiment 
being lower than used in other experiments, due to unpredictable variations in GAS growth. 
Based on the results obtained, upon repeating this experiment, it would be expected that the 
vaccine was able to protect mice against systemic spread of wild type GAS strain H292, but 
not against the spread of sortase negative SpyCEP GAS strain H887.  
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We considered the possibility that, by shedding SpyCEP in its soluble form, GAS may 
actively inhibit any opsonising action of pre-existing anti-SpyCEP antibody. Although this 
study cannot address this directly, vaccination experiment comparing H292 with a strain that 
did not release SpyCEP at all would be illuminating. The development of tools to 
systematically address the structure function of SpyCEP activity has been hampered by 
difficulties in cloning the full length protein in both E. coli and L. lactis. Indeed, those who 
report success have excluded the LPXTG motif in constructs (Kaur, et al. 2010, Zingaretti, et 
al. 2010, Zinkernagel, et al. 2008). The development of a non-LPXTG SpyCEP construct in 
GAS is an advance in this respect but the in vivo studies reported herein are small and require 
confirmation in future work. 
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Chapter 8 - Discussion and Future Work 
 
8.1 Conclusions 
 
This study has enhanced our understanding of SpyCEP and its effects on neutrophils. 
Prior to this study, the substrate range of SpyCEP was incompletely described, including, 
some but not all, neutrophil specific chemokines (Edwards, et al. 2005, Kurupati, et al. 2010, 
Sumby, et al. 2008). However, a structural basis for specificity could not be described based 
upon this list; some chemokines which could bind CXCR2 were not included, but the range 
was not limited to those chemokine which could bind CXCR1. This work, and subsequent 
work (Zingaretti, et al. 2010), has found that all chemokines which bind CXCR1 and 2 with 
high affinity are cleaved by SpyCEP (Figure 3-3). As these substrates all share regions of 
considerable structural homology, including a pair of acidic residues at the SpyCEP cleavage 
site, and are able to bind the same receptors, the named substrates represent a more rational 
list.  
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Chemokine ELR 
Cleaved by 
SpyCEP 
Sequence 
CXCL4 - - LQAPLYKKIIKKLL 
CXCL9 - - PDSADVKELIKKVE 
CXCL11 - - PKSKQARLIIKKVE 
CXCL12 - - PKLKWIQEYLEKAL 
CXCL1 + + PASPIVKKIIEKML 
CXCL3 + + PASPMVQKIIEKIL 
CXCL5 + + PEAPFLKKVIQKIL 
CXCL6 + + PEAPFLKKVIQKIL 
CXCL8 + + PKENWVQRVVEKFL 
 
Figure 8-1 – Chemokine sequence alignment 
List of chemokines used in this study detailing their aligned C termini. Chemokines 
highlighted blue are cleaved by SpyCEP. The bold residues indicate the acidic residues which 
form the cleavage site of SpyCEP. 
This study also provided rates of reaction for SpyCEP cleavage of each if its substrates. 
CXCL8 was found to be the substrate which is cleaved most rapidly (Figure 3-9). This is the 
most potent, and most abundant neutrophil specific chemokine, hence optimal cleavage of 
this substrate is consistent with optimal disruption of neutrophil function (Mortier, et al. 
2011). The other substrates were cleaved more slowly. Interestingly, the ranking of their 
cleavage rate from fastest to slowest matches the order of discovery of the substrates; the 
faster cleaved substrates were the earlier discovered. The strain used in this study is noted for 
its exceptional SpyCEP expression (Turner, et al. 2009a). The slower cleaved substrates may 
have been overlooked in previous studies which used less prodigious SpyCEP producers. 
The discovery of the substrate range of SpyCEP, and the failure to detect any other 
substrates, demonstrates that SpyCEP is a highly specific protease with consequent 
predictably specific effects on GAS virulence. SpyCEP-chemokines have specificity for 
neutrophils alone, and subsequently this study has found that neutrophils are the only cells 
affected by SpyCEP with regard to effects on mobilisation from bone marrow and 
SpyCEP interferes with the neutrophil response against Group A Streptococcus 
233 
 
phagocytosis. Other studies have shown that GAS expression of SpyCEP is upregulated 
following ablation of the GAS CovR/S virulence regulation axis, a hallmark of invasive GAS 
strains (Turner, et al. 2009a).  
These observations are very different from SpeB, the other protease produced by GAS 
which also reportedly shows chemokine degrading activity (Egesten, et al. 2009). SpeB is 
highly unspecific, cleaving a very broad range of substrates, including the C5a peptidase, 
another large GAS cell surface protease (Berge and Bjorck 1995). It also tends to be 
expressed by non-invasive strains and is markedly down-regulated or switched off in strains 
demonstrating covRS mutations in contrast to SpyCEP (Turner, et al. 2009a). 
Neutrophils are known to play a key early role in the clearance of bacterial infections, 
and indeed SpyCEP is known to be a critical virulence factor for GAS in the mouse model of 
infection (Kurupati, et al. 2010, Sumby, et al. 2008, Zinkernagel, et al. 2008). Chemokines 
are vital in the release of neutrophils from bone marrow reserves (Martin, et al. 2003), their 
trafficking across the endothelial barrier (Baggiolini 1995) and their activation including 
upregulation of phagocytic receptors (Detmers, et al. 1990) (Figure 8-2). Whilst the effects of 
SpyCEP on neutrophil trafficking and also on NETosis, a final attempt at bacterial killing as 
neutrophils apoptose (Brinkmann, et al. 2004, Zinkernagel, et al. 2008), are known, the other 
important functions of chemokines on neutrophils had not been explored prior to this study 
(Edwards, et al. 2005).  
The original description of SpyCEP-mediated cleavage of CXCL8 highlighted the C-
terminal cleavage of the molecule, yielding a roughly 6kD residual protein with intact N 
terminal and di-sulphide bonds. Chemokines such as CXCL8 bind their cognate 7 
transmembrane domain spanning receptors via the N terminal ELR motif, thus an effect of 
cleavage on binding and activation of receptors was not predicted, Indeed, the impact of 
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SpyCEP cleavage on neutrophil recruitment can be solely attributed to loss of the C terminal 
of CXCL8, which is essential for transmigration of chemokine across endothelial cells, and 
presentation at the endothelial or luminal surfaces of blood vessels (Middleton, et al. 1997). 
Notwithstanding uncertainty regarding the impact of C-terminal cleavage of chemokines on 
neutrophil binding and activation, we hypothesised that additional chemokine-dependent 
events could also be disrupted, with unknown functional consequences in vivo. A more 
profound disruption of neutrophil function would also explain the profound impact of 
SpyCEP on bacterial virulence (Kurupati, et al. 2010). 
 
Figure 8-2 – Development of a neutrophil response to infection 
 
Neutrophils are held quiescent in the bone marrow by constitutive production of 
CXCL12 (Shirozu, et al. 1995). The first stage of a developing neutrophil response to 
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bacterial infection is the release of these cells from these stores. This study confirmed that a 
local increase in neutrophil specific murine chemokines was able to increase circulating 
neutrophil levels (Wengner, et al. 2008) (Figure 4-5). It was accordingly also found that 
expression of SpyCEP by GAS or L. lactis was able to reduce the numbers of circulating 
neutrophils early after infection (Figure 4-1; Figure 4-3). This difference was seen despite the 
SpyCEP expressing L. lactis strain causing a significantly more severe infection (Figure 4-7). 
It was concluded that by cleaving the chemokines expressed locally at the site of infection, 
SpyCEP reduced systemic chemokine concentrations, interfering with neutrophil release from 
the bone marrow. The reduced neutrophil release means that fewer neutrophils reach the 
blood and are able to cross the endothelial barrier to reach the infection focus. This, 
combined with the known reduced trafficking of neutrophils across the endothelial barrier, 
also attributable to SpyCEP, provides a double level of protection to the bacteria (Figure 8-3). 
Such effects lead to potentially large impacts on disease severity. 
Throughout the study, the isogenic L. lactis strains provided clearer phenotypes than the 
GAS strains. L. lactis is a non-pathogenic species of bacteria, which expresses few 
extracellular proteins of its own (van de Guchte, et al. 1992). This contrasts with GAS which 
produces a wide range of virulence factors, including many that act on neutrophils. As such 
GAS strains which lack SpyCEP still have a considerable arsenal to bring to bear on the 
neutrophil response. Whilst a phenotype difference between SpyCEP-positive and negative 
GAS strains can still be clearly observed, the difference was inevitably smaller than that 
observed between the L. lactis strains. The L. lactis strains have been previously reported to 
display a clearer phenotype than the GAS strains in vivo (Kurupati, et al. 2010, Zinkernagel, 
et al. 2008). 
SpyCEP interferes with the neutrophil response against Group A Streptococcus 
236 
 
The hypothesis that SpyCEP may interfere with neutrophil release from the bone marrow 
stemmed from clinical observations in patients with very severe GAS disease who have 
frequently demonstrated paradoxically low neutrophils counts at presentation to hospital. 
(Shiranee Sriskandan, personal communication). This has been borne out in non-human 
primate models of invasive GAS disease and strengthened by the data from this study, shown 
in Figure 4-8. These data showed that the mice infected with a SpyCEP-expressing GAS 
strain had reduced systemic levels of the murine neutrophil chemokine KC compared to mice 
infected with an isogenic SpyCEP-negative strain 6 hours post infection. This effect could not 
be reproduced using the L. lactis strains, due to the huge difference in L. lactis infection 
severity; the SpyCEP-negative strain had been completely cleared by six hours (Figure 4-7), 
and thus chemokine levels were returning to normal precluding any comparison with mice 
infected with the SpyCEP-positive strain. All the other chemokines and cytokines measured 
were found to be at similar concentrations between the strains, although TNFα and IL-6 
appeared to be higher in the SpyCEP-positive GAS strains. These are markers of acute 
disease, and high concentrations tend to be associated with poor outcome of infection.  
Importantly, the reduced concentrations of systemic chemokine were specifically 
associated with a reduction in circulating neutrophils. Previously it was reported that CXCL 
chemokines were central to mobilisation of neutrophils from the bone marrow (Wengner, et 
al. 2008), and experiments conducted in this study have confirmed that KC can mobilise 
neutrophils into the peripheral blood in the absence of infection (Figure 4-5). The observed 
reduction in circulating neutrophils in mice infected with SpyCEP-producing bacteria was not 
associated with a change in systemic G-CSF levels (Figure 4-8), suggesting that chemokine 
cleavage by SpyCEP provided the sole reason for the difference. 
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This study has demonstrated that the first stage of the developing neutrophil response - 
release from the bone marrow - is disrupted by SpyCEP. Previous studies have indicated that 
the second stage, extravasation is disrupted (Edwards, et al. 2005, Kurupati, et al. 2010), 
leading to a reduction in tissue neutrophils through reduced recruitment across endothelium 
(Figure 5-1). We next set about to determine if the third stage, activation leading to 
phagocytosis, was also disrupted by SpyCEP.  The classical Lancefield assay was initially 
used to measure phagocytosis. However this method was only useful when examining the L. 
lactis strains (Figure 5-2; Figure 5-3). The donors used had immunity against the GAS strains, 
and thus the bacteria were all killed, illustrating a common limitation of the Lancefield assay. 
As L. lactis is not a human pathogen (van de Guchte, et al. 1992), it was predictable that the 
human donors would  not have immunity against this pathogen.  
Although antibody-mediated immunity against L. lactis was not present in early 
experiments, it did appear to be present in some of the donors used for later experiments. As 
L. lactis is not a human pathogen, presumably an acquired antibody response against it is 
unusual. The donors used in these experiments were laboratory workers, and thus potentially 
occupationally exposed to L. lactis. It was hypothesised that using donors from an external 
source would lead to more consistent results, and a complete lack of antibody mediated 
opsonisation. 
As the Lancefield assay proved unsuccessful at measuring differences in phagocytosis 
between SpyCEP-negative and positive strains, a more quantitative method of measuring 
bacterial phagocytosis by flow cytometry (Bjerknes and Bassoe 1983) which has previously 
been used successfully with GAS (Ji, et al. 1998, Schnitzler, et al. 1997) was employed. The 
method measured the gain of fluorescence by phagocytes incubated with fluorescent bacteria. 
This method clearly and reproducibly showed that SpyCEP expression by both L. lactis and 
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GAS reduced phagocytosis by neutrophils (Figure 5-5; Figure 5-7; Figure 5-8). As such, 
these results confirmed that SpyCEP inhibits all phases of the neutrophil response to infection. 
Indeed, the effects of SpyCEP are additive. SpyCEP reduces circulating neutrophils, so there 
are fewer neutrophils to extravasate; SpyCEP inhibits extravasation, so there are fewer 
neutrophils to phagocytose bacteria; SpyCEP inhibits phagocytosis by those few neutrophils 
which do enter tissue (Figure 8-3).   
 
Figure 8-3 – Progressive impact of SpyCEP on neutrophil function 
SpyCEP-positive bacteria (RIGHT of panel) inhibit progressive stages of neutrophil function, 
leading to profound ablation of neutrophil function, compared to SpyCEP-negative bacteria 
(LEFT of panel). 
 Having determined that SpyCEP acts to inhibit phagocytosis of opsonised bacteria, 
the methodologies were used to further examine phagocytosis of GAS and describe the 
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mechanism by which SpyCEP inhibits phagocytosis by neutrophils. Neutrophil phagocytosis 
of both L. lactis and GAS was found to be dependent on opsonisation (Figure 5-10). L. lactis 
was found to be opsonised equally by whole serum and antibody depleted serum 
(complement positive). Complement depleted serum (antibody positive) was found to only 
occasionally allow phagocytosis (Figure 5-13). This data indicated that complement is the 
required opsonin for L. lactis phagocytosis, and further shows that antibodies against L. lactis 
are uncommon. 
 Neutrophil phagocytosis of GAS was found to be optimal in whole serum containing 
both complement and antibody. Complement depleted serum (antibody positive), was found 
to allow low levels of phagocytosis, whereas antibody depleted serum (complement positive) 
was able to opsonise the bacteria such as to allow good, but sub-optimal phagocytosis. These 
data indicates that complement is very important for opsonisation, but this is enhanced by 
antibody. Antibody alone was only slightly opsonising (Figure 5-12). 
 These results raise interesting questions about the role of antibody in GAS immunity. 
The Lancefield assay was used to determine whether a blood sample was immune to GAS, 
defined as having serotype specific antibodies against the variable M protein, a major GAS 
antigen. The donors used in this study were largely immune to the serotype of the GAS strain 
used in this study (M81), as demonstrated by the Lancefield assays carried out (Figure 5-2). 
Indeed, this immune blood was able to rapidly kill the GAS. Despite this, antibody alone 
from the same group of broadly immune donors was not able to effectively opsonise the 
bacteria and complement was needed, a feature of the innate immune response, present in 
both immune and non-immune blood. The M protein is itself anti-phagocytic, preventing 
proper complement deposition and its interaction with complement receptors (Peterson, et al. 
1979, Weis, et al. 1985). Based on the results obtained in this study, the serotype specific 
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antibody against M protein seems to primarily function not by opsonising the bacteria 
directly, but by overcoming this inhibition, enhancing complement deposition. This 
conclusion is further supported by earlier work. It has been determined that direct blockade of 
Fc receptors which mediate antibody opsonised phagocytosis had no effect on phagocytosis 
of GAS, unlike blockade of complement receptors (Nilsson, et al. 2005). 
 The mechanism by which SpyCEP inhibits neutrophil phagocytosis was hypothesised 
to involve chemokines, as these form the only known substrates of SpyCEP. Chemokines are 
known to have a role in the activation of neutrophils; a process which includes the 
upregulation of CR3 receptors that are involved in the phagocytosis of GAS (DeMaster, et al. 
2002, Detmers, et al. 1990). It was confirmed that neutrophil-specific chemokines increased 
the surface levels of CD11b (Figure 6-9), and it was found that SpyCEP-expressing strains 
induced lower levels of CD11b on the neutrophil surface than their SpyCEP-negative 
counterparts (Figure 6-11). It was confirmed that SpyCEP had no direct cleavage activity 
against CD11b (Figure 6-12), or on opsonisation of bacteria (Figure 5-11). 
 These observations provided a mechanism by which SpyCEP could retard neutrophil 
phagocytosis (Figure 6-14). By cleaving neutrophil specific chemokines, neutrophils fail to 
completely activate and upregulate phagocytosis receptors of known importance in GAS 
phagocytosis. The effects on phagocytosis are seen over very short time periods, suggesting 
that SpyCEP is rapidly cleaving chemokine (Figure 5-5). As such, differences in chemokine 
levels in the phagocytosis reaction mixtures would be detectable. It was indeed found that 
neutrophils incubated with SpyCEP-negative strains had more CXCL8 bound to their surface 
than those incubated with SpyCEP-positive strains (Figure 6-7). 
 Paradoxically however, the addition of excess CXCL8 failed to have any effect on 
phagocytosis. The addition of CXCL8 with the addition of bacteria to the neutrophils was 
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hypothesised to upregulate CD11b, as had been previously demonstrated (Figure 6-9), thus 
increasing phagocytosis. Despite SpyCEP beginning to cleave this chemokine immediately, 
the cleavage rates found in Figure 3-9 suggested that SpyCEP could not cleave all this 
chemokine within the time period of this experiment, especially where high concentrations of 
chemokine were used. The results could also not be explained by cleaved chemokine 
antagonising receptor binding (Goldblatt, personal communication), nor would it seem likely 
that the recombinant chemokine had no biological activity (Figure 6-9). Other experiments to 
examine the hypothesis of Figure 6-14 that chemokine cleavage prevents phagocytosis, 
including the addition of soluble SpyCEP and a chemokine receptor antagonist, also failed to 
provide support for the hypothesis. However, these could be explained by technical problems. 
 Despite being contradicted by the results of where soluble exogenous chemokines 
were added, the hypothesis proposed is supported by work using other cells. It was found that 
other phagocytes, which unlike neutrophils, express low numbers of CXCR1 and 2 receptors 
(Grob, et al. 1990, Zahn, et al. 1997) were unaffected in their ability to phagocytose bacteria 
by the presence of SpyCEP (Figure 6-1; Figure 6-2). These cells express very similar 
phagocytosis receptors to neutrophils (Collins, et al. 1979, Shi and Pamer 2011), and 
accordingly have similar dependence on complement to opsonise both GAS and L. lactis 
(Figure 6-3). Hence any direct effect that SpyCEP might have had on phagocytosis receptors 
or opsonisation would have been seen using all types of phagocytic cell. The effects of 
SpyCEP on phagocytosis are specific for neutrophils; the chemokine substrates of SpyCEP 
are specific for neutrophils, and it is known that the binding of these substrates to neutrophils 
upregulates a receptor known to be important for GAS phagocytosis (DeMaster, et al. 2002).   
 An alternative hypothesis explaining the impairment of phagocytosis has been 
suggested based on observations that SpyCEP inhibits invasion of epithelial cells by GAS, in 
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a chemokine independent manner (Andreoni, personal communication). This observation was 
dependent upon SpyCEP being present on the bacterial surface, and enzyme being 
catalytically active. It could be hypothesised that SpyCEP is acting to prevent “invasion” of 
neutrophils by GAS. However, if this were the case, the impairment would be seen using the 
other phagocytes. Furthermore, a strain of GAS mutated such that it can express only soluble 
SpyCEP would be phagocytosed more efficiently than a wild type strain with surface bound 
SpyCEP. This was not observed to be the case (Figure 7-5). This strain was however found to 
survive slightly less well in the invasive mouse model at the infection focus (Figure 7-9), 
which we hypothesise was due to differences in chemokine gradients in the infection site 
(Figure 7-10). 
 In conclusion, this study has found that SpyCEP specifically cleaves all neutrophil 
specific chemokines. The effects of this on neutrophil function are profound, impacting 
cumulatively on neutrophil release from the bone marrow, and phagocytosis, as well as 
neutrophil trafficking and NETosis which had previously been described (Edwards et al. 
2005, Zinkernagel et al. 2008). These effects specifically target neutrophils due to their high 
expression of chemokine receptors CXCR1 and 2, and as such the effects of SpyCEP on 
neutrophil function are mediated by ablated chemokine signalling.  
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8.2 Future work 
 
Future investigation into the impacts of SpyCEP would be facilitated by being able to 
genetically manipulate and express SpyCEP recombinantly in E. coli.  Attempts to achieve 
this aim were pursued in this study, but ultimately proved unsuccessful. Indeed, attempts to 
obtain a shuttle vector containing the SpyCEP gene, cepA, from collaborators in Switzerland 
were abortive due to cryogenic stocks being non-viable. Many investigators have reported 
difficulties in manipulating cepA through E. coli (Edwards, et al. 2005, Fritzer, et al. 2009, 
Kurupati, et al. 2010, Rodriguez-Ortega, et al. 2006, Sjolinder, et al. 2008, Sumby, et al. 
2008, Zinkernagel, et al. 2008). This has impacted on cloning and expression of SpyCEP in L. 
lactis since all manipulations are generally undertaken in E. coli. However, some recent work 
has included successful manipulation of SpyCEP by expressing sub-domains that appear to 
self-associate and form functional enzyme (Kaur, et al. 2010, Zingaretti, et al. 2010), hence 
there is precedence for such manipulation being performed. Future work would thus include 
trying to genetically manipulate SpyCEP, or establish collaborations to use these successfully 
created strains. 
Recombinant SpyCEP would be used to allow more precise quantification of the rate of 
chemokine cleavage. Current work has allowed quantification of SpyCEP cleavage rates in 
specific reaction mixtures. Using recombinant SpyCEP would allow excess concentrations of 
SpyCEP to be used, finding maximal cleavage rates for each substrate, at a specific substrate 
concentration, providing a constant value for reference. We would also like to determine why 
the cleavage rates of these chemokines are different. Using the recombinant SpyCEP, we 
could determine binding affinities between the enzyme and the ligand. We would also like to 
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crystallise the protein, allowing full structural determination; with improved techniques, this 
may be possible using lower quantities of protein than were previously required. 
Recombinant SpyCEP would also be used to further examine its effects on neutrophil 
release.  Enzyme alone, chemokine alone and enzyme mixed with chemokine could be 
injected intramuscularly into the mouse to confirm that chemokine cleaved by SpyCEP could 
not mobilize chemokines, as this could not be confirmed in the current study using the 
reagents currently available.  
We would also use the recombinant SpyCEP to further confirm the hypothesis 
regarding the mechanism of SpyCEP disruption of phagocytosis. Earlier work using bacterial 
supernatants as sources of recombinant chemokine failed to demonstrate that the introduction 
of soluble SpyCEP could protect SpyCEP-negative strains. The GAS strains contained too 
many other virulence factors, and the L. lactis supernatants contained only very low 
concentrations of SpyCEP. Thus recombinant SpyCEP would be ideal to use to repeat this 
experiment. 
Genetic manipulation of SpyCEP would also allow us to perform structure function 
analysis on SpyCEP. Previous work where SpyCEP has been genetically manipulated has 
revealed information about its structure (Zingaretti, et al. 2010), and the minimal domains 
required for proteolytic activity (Kaur, et al. 2010). We would like to mutate the active site to 
ensure that SpyCEP requires its enzymatic activity for all the phenotypes observed in this 
study, as a means of further proving that chemokine cleavage is mediating the effects 
observed. We would also investigate the C terminus of this protein, which has been indicated 
not to be important for enzymatic activity (Kaur, et al. 2010).  
Being able to genetically manipulate cepA in E. coli would also allow us to better 
investigate the impact of the localisation of SpyCEP. In this study, we could mutate the 
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sortase motif of chromosomally encoded GAS cepA using single cross-over recombination. 
However, as GAS strains typically release large amounts of SpyCEP, such mutagenesis could 
only be expected to produce a limited phenotype. The L. lactis strains do not release much 
soluble SpyCEP, thus a sortase motif negative cepA in this species would be more instructive. 
We would use site directed mutagenesis to alter the cepA encoding plasmid in E. coli before 
re-transforming L. lactis. Using these strains, we would repeat vaccine studies, trying to 
achieve a more systemic infection than achieved in this study. Previous work using this 
vaccine identified that the main protection offered was against systemic infection (Turner, et 
al. 2009b). 
Cloning difficulties were also encountered when trying to manipulate the orthologues 
of SpyCEP found in other organisms. The orthologue found in S. pneumoniae appears 
particularly interesting, as a novel fibrinogen cleavage effect was reported in this study 
(Figure 3-10). As a known function of the SpyCEP orthologue in S. agalactiae is fibrinogen 
cleavage, investigating the S. pneumoniae orthologue PrtA would be interesting. However, 
without genetic manipulation of S. pneumoniae or expressing PrtA in L. lactis such studies 
could not occur. 
Further work which would not require genetic manipulation of SpyCEP could be 
carried out which would also be useful to support the hypotheses from this study. We would 
investigate cytokine and chemokine levels following infection with SpyCEP-positive and 
negative L. lactis strains at shorter time points than those used in this study. By six hours, the 
SpyCEP-negative L. lactis infection had been completely cleared, and thus cytokine and 
chemokines were returning to resting levels. As the L. lactis strains showed greater 
phenotypic differences than GAS strains, these earlier time points may reveal differences in 
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the immune response against these two strains which have been missed, and which could thus 
be further investigated using the GAS strains. 
The impact of neutrophil release from the bone marrow has been described based on 
the increase in circulating neutrophils. Whilst it seems highly unlikely that these neutrophils 
came from anywhere except the bone marrow, future work to confirm their origin would be 
important. Previous work has used canulated murine femurs, adding stimuli in the supportive 
media, and measuring the output (Wengner, et al. 2008). This method provides certainty that 
emerging cells have originated from the bone marrow. Recombinant SpyCEP, chemokine and 
SpyCEP plus chemokine could be used in such a study and the output from the marrow 
measured.  
The contradictory data obtained where soluble chemokine failed to have any impact on 
phagocytosis needs to be investigated further. Further work here would be to use alternate 
forms of recombinant chemokine, including the more bioactive 72aa form (Mortier, et al. 
2011). Other further work would be to activate the neutrophils with chemokines prior to 
adding bacteria, allowing chemokines to bind neutrophils before any SpyCEP activity could 
occur. 
Observations have been made in this study regarding the role of antibody in GAS 
immunity. The results in this study have led us to hypothesise that immunising antibody 
primarily functions to enhance complement deposition. This would be investigated using the 
methods used in this study, using the depleted sera. 
   Chemokine ligands for CXCR1 and 2 have been implicated in a variety of 
autoimmune diseases linked to aberrant neutrophil function, such as chronic obstructive 
pulmonary disorder, asthma (Pease and Sabroe 2002) and Crohn’s disease (Morain, et al. 
1981). Accordingly, small molecule antagonists against these receptors have been the subject 
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of drug investigation. Indeed many of these drugs, such as Repertaxin, are the subject of 
current study determining efficacy (Pease and Horuk 2012). With its exquisite substrate 
specificity, limited to agonists of CXCR1 and 2, SpyCEP may be an alternative to the 
antagonists being studied. 
  A major barrier to SpyCEP being used therapeutically is finding an efficient and safe 
means to deliver the protein to the site where required. L. lactis, which is being studied as a 
potential vector for vaccination due to its avirulence, was transformed into a lethal pathogen 
upon expression of SpyCEP (Kurupati, et al. 2010, van de Guchte, et al. 1992, Zinkernagel, 
et al. 2008). As such, using a live vector would be a dangerous approach.  
As a recombinant protein, SpyCEP would have poor bioavailability, due to action of 
proteases (Shaji and Patole 2008), and would need to be injected directly into the site 
required. Interestingly, SpyCEP expression by bacteria injected directly into the blood stream 
or using a dermonecrotic model of infection was found to reduce inflammation and thus be 
protective to the mouse (Sjolinder, et al. 2008, Sumby, et al. 2008). SpyCEP has repeatedly 
been shown to be difficult to make recombinantly, and needs nearly all of its domains to 
retain chemokine cleaving function (Kaur, et al. 2010), making production of SpyCEP for 
therapeutic use challenging. If recombinant SpyCEP could be made in large amounts in E. 
coli, structural studies may allow functional analogues to be designed, overcoming the issues 
of SpyCEP for therapy, whilst maintaining its specificity and efficacy. 
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